BCMA-targeted CAR-T cell therapy for multiple myeloma
Through chimeric antigen receptor-T cell therapy targets multiple myeloma, combined with lymphatic clearance and IL-6R inhibitors, the problem of difficult-to-control multiple myeloma treatment is solved, significantly improving the response rate and progress-free survival rate , reducing the side effects of treatment.
Patent Information
- Application Number
- CN202380022977.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-02-28
- Filing Date
- 2023-02-27
- Publication Date
- 2024-11-05
AI Technical Summary
The existing treatments for multiple myeloma are difficult to control diseases for a long time, especially for recurrent or refractory patients. Traditional therapies such as proteasome inhibitors, immunomodulators and anti-CD38 monoclonal antibody therapy have limited effects, and patients often have drugs. Refractory or recurrence and faces treatment difficulties.
Chimeric antigen receptor (CAR)-T cell therapy is used to intravenously infusion of T cells containing specific chimeric antigen receptors, including CAR-T cells with BCMA binding moieties, transmembrane domains and intracellular signaling domains. , targeted treatment for multiple myeloma cells, and combined with lymphatic clearance regimen, pre-treatment of IL-6R inhibitors and antihistamines to optimize the therapeutic effect.
It significantly improved the overall response rate and progress-free survival rate of patients with multiple myeloma, shortened the first reaction time, prolonged the maintenance time of trace residual disease (MRD) negative status, and reduced the occurrence of cytokine release syndrome, and improved the treatment Safety and effectiveness.
Smart Images

Figure CN118900698A_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the benefit of priority to U.S. Provisional Patent Application No. 63 / 314,968, filed on February 28, 2022, the disclosure of which is incorporated herein by reference in its entirety.
[0003] Sequence Listing
[0004] This application contains a computer-readable sequence listing, which has been submitted with this application in XML file format, the entire contents of which are incorporated herein by reference in their entirety. The sequence listing XML file submitted with this application is titled "14651-054-228_SEQ_LISTING.xml", created on February 23, 2023, and is 21,916 bytes in size. Background Art
[0005] Multiple myeloma is an aggressive plasma cell neoplasm. Multiple myeloma is considered a B-cell neoplasm that proliferates uncontrollably in the bone marrow. Symptoms include one or more of hypercalcemia, renal insufficiency, anemia, bone lesions, bacterial infection, hyperviscosity, and amyloidosis. Although available new therapies, including proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies, have significantly improved patient outcomes, multiple myeloma is still considered an incurable disease. Because most patients will relapse or become refractory to treatment, there is a continuing need for new therapies for multiple myeloma. Summary of the invention
[0006] In one aspect, a method of treating a subject having multiple myeloma is provided, the method comprising administering to the subject via a single intravenous infusion a composition comprising T cells, the T cells comprising a chimeric antigen receptor (CAR) comprising:
[0007] a) an extracellular antigen binding domain comprising a first anti-BCMA binding moiety and a second BCMA binding moiety;
[0008] b) a transmembrane domain; and
[0009] c) intracellular signaling domain,
[0010] To deliver a dose of CAR-expressing T cells (CAR-T cells) to the subject,
[0011] The first BCMA binding portion comprises the amino acid sequence set forth in SEQ ID NO:2, and the second BCMA binding portion comprises the amino acid sequence set forth in SEQ ID NO:4.
[0012] In some embodiments, the dose comprises 1.0×10 5 Up to 5.0×10 6 CAR-T cells / kg of the subject's mass. In some embodiments, the dose comprises 5.0×10 5 to 1.0×10 6 The CAR-T cells / kg of the subject's mass. In some embodiments, the dose comprises about 0.75×10 6 CAR-T cells / kg of the subject's mass. In some embodiments, the dose comprises less than 1.0×10 8 The CAR-T cells.
[0013] In some embodiments, the single intravenous infusion is administered using a single bag of the CAR-T cells. In some embodiments, the administration of the single bag of the CAR-T cells is completed no later than 3 hours after the single bag of CAR-T cells is thawed.
[0014] In some embodiments, the single intravenous infusion is administered using two bags of the CAR-T cells. In some embodiments, the administration of each of the two bags of the CAR-T cells is completed no later than 3 hours after each bag of the two bags of the CAR-T cells is thawed.
[0015] In some embodiments, the method is effective to obtain in the subject a minimal residual disease (MRD) negative state assessed in the bone marrow after the infusion of the CAR-T cells. In some embodiments, the MRD negative state is obtained at the first follow-up time between about 28 days and about 179 days after the infusion of the CAR-T cells.
[0016] In some embodiments, the lymphodepletion regimen precedes the infusion of the CAR-T cells. In some embodiments, the lymphodepletion regimen comprises administration of cyclophosphamide or administration of fludarabine. In some embodiments, the lymphodepletion regimen is administered intravenously. In some embodiments, the lymphodepletion regimen is administered 5 to 7 days prior to the infusion of the CAR-T cells. In some embodiments, the lymphodepletion regimen comprises intravenous administration of cyclophosphamide and fludarabine 5 to 7 days prior to the infusion of the CAR-T cells. In some embodiments, the cyclophosphamide is administered at 300 mg / m 2 In some embodiments, the fludarabine is administered intravenously at 30 mg / m 2 Intravenous administration.
[0017] In some embodiments, the method further includes treating the subject's cytokine release syndrome (CRS) for more than 3 days after infusion without significantly reducing the in vivo expansion of CAR-T cells. In some embodiments, the treatment of CRS includes administering an IL-6R inhibitor to the subject. In some embodiments, the IL-6R inhibitor is an antibody. In some embodiments, the antibody inhibits IL-6R by binding to the extracellular domain of IL-6R. In some embodiments, the IL-6R inhibitor prevents the binding of IL-6 to IL-6R. In some embodiments, the IL-6R inhibitor is tocilizumab.
[0018] In some embodiments, the subject is treated with a pre-infusion medication comprising an antipyretic and an antihistamine up to 1 hour prior to the infusion comprising CAR-T cells. In some embodiments, the antipyretic comprises paracetamol or acetaminophen. In some embodiments, the antipyretic is administered to the subject orally or intravenously. In some embodiments, the antipyretic is administered to the subject at a dose between 650 mg and 1000 mg. In some embodiments, the antihistamine comprises diphenhydramine. In some embodiments, the antihistamine is administered orally or intravenously to the subject. In some embodiments, the antihistamine is administered at a dose between 25 mg and 50 mg or its equivalent.
[0019] In some embodiments, the infusion comprising CAR-T cells further comprises an excipient selected from dimethyl sulfoxide or dextran-40.
[0020] In some embodiments, the subject receives prior treatment comprising at least three prior lines of therapy. In some embodiments, the at least three prior lines of therapy comprise treatment with at least one drug comprising at least one of a proteasome inhibitor (PI), an immunomodulator (IMiD), or an anti-CD38 antibody.
[0021] In some embodiments, the subject relapses after said at least three prior lines of therapy. In some embodiments, the multiple myeloma is refractory to at least two drugs after said at least three prior lines of therapy. In some embodiments, the at least two drugs for a refractory subject comprise a PI and an IMiD. In some embodiments, the subject is refractory to at least three drugs. In some embodiments, the subject is refractory to at least four drugs. In some embodiments, the subject is refractory to at least five drugs.
[0022] In some embodiments, the method is effective to obtain an overall response rate of greater than 91%. In some embodiments, the method is effective to obtain an overall response rate of greater than 93%. In some embodiments, the method is effective to obtain an overall response rate of greater than 95%. In some embodiments, the method is effective to obtain an overall response rate of greater than 97%. In some embodiments, the method is effective to obtain an overall response rate of greater than 99%. In some embodiments, the overall response rate is assessed at a median follow-up time of at least 12 months after the infusion of the CAR-T cells.
[0023] In some embodiments, the methods are effective to obtain a median time to first response of less than 1.15 months. In some embodiments, the methods are effective to obtain a median time to first response of less than 1.10 months. In some embodiments, the methods are effective to obtain a median time to first response of less than 1.05 months. In some embodiments, the methods are effective to obtain a median time to first response of less than 1.00 months. In some embodiments, the methods are effective to obtain a median time to first response of less than 0.95 months.
[0024] In some embodiments, the methods are effective to obtain a median time to best response of less than 2.96 months. In some embodiments, the methods are effective to obtain a median time to best response of less than 2.86 months. In some embodiments, the methods are effective to obtain a median time to best response of less than 2.76 months. In some embodiments, the methods are effective to obtain a median time to best response of less than 2.66 months. In some embodiments, the methods are effective to obtain a median time to best response of less than 2.56 months.
[0025] In some embodiments, the method is effective to obtain in the subject a minimal residual disease (MRD) negative state assessed in the bone marrow at a follow-up time of about 28 days or longer after the infusion of the CAR-T cells. In some embodiments, the method is effective to maintain in the subject the MRD negative state assessed in the bone marrow at a follow-up time of about 12 months or longer after the infusion of the CAR-T cells.
[0026] In some embodiments, the first BCMA binding moiety and / or the second BCMA binding moiety is an anti-BCMA VHH. In some embodiments, the first BCMA binding moiety is a first anti-BCMA VHH and the second BCMA binding moiety is a second anti-BCMA VHH. In some embodiments, the first BCMA binding moiety comprises a polypeptide encoded by the nucleic acid sequence of SEQ ID NO: 10. In some embodiments, the second BCMA binding moiety comprises a polypeptide encoded by the nucleic acid sequence of SEQ ID NO: 12. In some embodiments, the first BCMA binding moiety and the second BCMA binding moiety are connected to each other via a peptide linker.
[0027] In some embodiments, the peptide linker comprises the amino acid sequence of SEQ ID NO: 3. In some embodiments, the peptide linker comprises a polypeptide encoded by the nucleic acid sequence of SEQ ID NO: 11.
[0028] In some embodiments, the CAR polypeptide further comprises a signal peptide located at the N-terminus of the polypeptide. In some embodiments, the signal peptide is derived from CD8α. In some embodiments, the signal peptide comprises an amino acid sequence of SEQ ID NO: 1. In some embodiments, the signal peptide comprises a polypeptide encoded by a nucleic acid sequence of SEQ ID NO: 9.
[0029] In some embodiments, the transmembrane domain comprises the amino acid sequence of SEQ ID NO: 6. In some embodiments, the transmembrane domain comprises a polypeptide encoded by the nucleic acid sequence of SEQ ID NO:14.
[0030] In some embodiments, the intracellular signaling domain comprises a primary intracellular signaling domain of an immune effector cell. In some embodiments, the intracellular signaling domain is derived from CD3 zeta. In some embodiments, the intracellular signaling domain comprises one or more co-stimulatory signaling domains. In some embodiments, the intracellular signaling domain comprises the amino acid sequence of SEQ ID NO: 8. In some embodiments, the intracellular signaling domain comprises a polypeptide encoded by the nucleic acid sequence of SEQ ID NO: 16. In some embodiments, the intracellular signaling domain comprises the amino acid sequence of SEQ ID NO: 7. In some embodiments, the intracellular signaling domain comprises a polypeptide encoded by the nucleic acid sequence of SEQ ID NO: 15.
[0031] In some embodiments, the CAR polypeptide further comprises a hinge domain located between the C-terminus of the extracellular antigen binding domain and the N-terminus of the transmembrane domain. In some embodiments, the hinge domain comprises an amino acid sequence of SEQ ID NO: 5. In some embodiments, the hinge domain comprises a polypeptide encoded by a nucleic acid sequence of SEQ ID NO: 13.
[0032] In some embodiments, the T cells are autologous T cells. In some embodiments, the T cells are allogeneic T cells.
[0033] In some embodiments, the subject is a human.
[0034] In one aspect, a method of treating a subject having multiple myeloma who has received at least three prior lines of therapy is provided, the method comprising administering to the subject a composition comprising T cells comprising a chimeric antigen receptor (CAR) comprising the amino acid sequence of SEQ ID NO: 17 by a single intravenous infusion to deliver to the subject approximately 0.75×10 6 The invention relates to a method for treating a subject with a CAR-expressing T cell (CAR-T cell) in a humanized, non-human CAR-positive patient. The method further comprises administering to the subject a dose of CAR-expressing T cells (CAR-T cells), wherein the method is effective to obtain a minimal residual disease (MRD) negative status in the subject, the minimal residual disease negative status being assessed in the bone marrow at a follow-up time greater than or equal to 28 days after the infusion of the CAR-T cells.
[0035] In some embodiments, the method comprises a follow-up period of about 12 months after the infusion of the CAR-T cells. -5 The sensitivity threshold level was between about 44% and about 65%, and the follow-up time was about 18 months after the infusion of the CAR-T cells. -4 The sensitivity threshold level was between about 57% and about 76%, and the follow-up time was about 18 months after the infusion of the CAR-T cells. -5 The sensitivity threshold level is between about 47% and about 68%, or about 10% at a follow-up time of about 18 months after the infusion of the CAR-T cells. -6 The sensitivity threshold level is effective in obtaining the MRD-negative status at a rate between about 29% and about 50%.
[0036] In some embodiments, the method is based on a follow-up period of about 12 months after the administration of the CAR-T cells. -5 The sensitivity threshold level was about 55% at a rate of 10 at a follow-up time of about 18 months after the infusion of the CAR-T cells. -4 The sensitivity threshold level was about 67% at a rate of 10 at a follow-up time of about 18 months after the infusion of the CAR-T cells. -5 The sensitivity threshold level is about 58% at a rate of 10 at a follow-up time of about 18 months after the infusion of the CAR-T cells. -6 The sensitivity threshold level of was effective in obtaining the MRD-negative status at a rate of approximately 39%.
[0037] In some embodiments, the method comprises a follow-up period of about 12 months after the infusion of the CAR-T cells. -5 The sensitivity threshold level is between about 83% and about 98% in subjects with evaluable samples, or between about 10% and 18% at a follow-up time of about 18 months after the infusion of the CAR-T cells. -5 The sensitivity threshold level is effective in obtaining the minimal residual disease (MRD) negative status at a rate of between about 82% and about 97% in subjects with evaluable samples.
[0038] In some embodiments, the method comprises a follow-up period of about 12 months after the infusion of the CAR-T cells. -5 The sensitivity threshold level was about 93% in subjects with evaluable samples, or about 10% at a follow-up time of about 18 months after the infusion of the CAR-T cells. -5 The sensitivity threshold level of was effective in obtaining the minimal residual disease (MRD) negative status at a rate of approximately 92% in subjects with evaluable samples.
[0039] In some embodiments, the method is effective to obtain at least one response in the subject following said infusion of said CAR-T cells, wherein said at least one response comprises, in order from best to worst, a stringent complete response, a complete response, a very good partial response, a partial response, or a minimal response.
[0040] In some embodiments, the method is effective to obtain the first response before a time between about 27 days and about 321 days after the infusion of the CAR-T cells. In some embodiments, the method is effective to obtain the first response before a time between about 27 days and about 89 days after the infusion of the CAR-T cells. In some embodiments, the method is effective to obtain the first response before about 42 days after the infusion of the CAR-T cells. In some embodiments, the method is effective to obtain the first response before about 29 days after the infusion of the CAR-T cells.
[0041] In some embodiments, the method is effective to obtain the best response of any one of a minimal response, a partial response, a very good partial response, a complete response, or a strict complete response. In some embodiments, the method is effective to obtain the best response of any one of a minimal response, a partial response, a very good partial response, a complete response, or a strict complete response at a rate of between about 91% and about 99% at a follow-up time of about 12 months after the infusion of the CAR-T cells or at a rate of between about 93% and about 100% at a follow-up time of about 18 months after the infusion of the CAR-T cells. In some embodiments, the method is effective to obtain the best response of any one of a minimal response, a partial response, a very good partial response, a complete response, or a strict complete response at a rate of about 97% at a follow-up time of about 12 months after the infusion of the CAR-T cells or at a rate of about 98% at a follow-up time of about 18 months after the infusion of the CAR-T cells.
[0042] In some embodiments, the method is effective to obtain a partial response, a very good partial response, a complete response, or a strict complete response as the best response of any one of them. In some embodiments, the method is effective to obtain a partial response, a very good partial response, a complete response, or a strict complete response as the best response of any one of them at a rate of between about 91% and about 99% at a follow-up time of about 12 months after the infusion of the CAR-T cells or at a rate of between about 93% and about 100% at a follow-up time of about 18 months after the infusion of the CAR-T cells. In some embodiments, the method is effective to obtain a partial response, a very good partial response, a complete response, or a strict complete response as the best response of any one of them at a rate of about 97% at a follow-up time of about 12 months after the infusion of the CAR-T cells or at a rate of about 97% at a follow-up time of about 18 months after the infusion of the CAR-T cells.
[0043] In some embodiments, the method is effective to obtain the best response of any one of a very good partial response, a complete response, or a strict complete response. In some embodiments, the method is effective to obtain the best response of any one of a very good partial response, a complete response, or a strict complete response at a rate of between about 86% and about 97% at a follow-up time of about 12 months after the infusion of the CAR-T cells or at a rate of between about 88% and about 98% at a follow-up time of about 18 months after the infusion of the CAR-T cells. In some embodiments, the method is effective to obtain the best response of any one of a very good partial response, a complete response, or a strict complete response at a rate of about 93% at a follow-up time of about 12 months after the infusion of the CAR-T cells or at a rate of about 95% at a follow-up time of about 18 months after the infusion of the CAR-T cells.
[0044] In some embodiments, the method is effective to obtain a complete response or a strict complete response as the best response. In some embodiments, the method is effective to obtain a complete response or a strict complete response as the best response at a rate of between about 57% and about 76% at a follow-up time of about 12 months after the infusion of the CAR-T cells or at a rate of between about 73% and about 89% at a follow-up time of about 18 months after the infusion of the CAR-T cells. In some embodiments, the method is effective to obtain a complete response or a strict complete response as the best response at a rate of about 67% at a follow-up time of about 12 months after the infusion of the CAR-T cells or at a rate of about 83% at a follow-up time of about 18 months after the infusion of the CAR-T cells.
[0045] In some embodiments, the method is effective to obtain a strict complete response as the best response. In some embodiments, the method is effective to obtain a strict complete response as the best response at a rate of between about 57% and about 76% at a follow-up time of about 12 months after the infusion of the CAR-T cells or at a rate of between about 73% and about 89% at a follow-up time of about 18 months after the infusion of the CAR-T cells. In some embodiments, the method is effective to obtain a strict complete response as the best response at a rate of about 67% at a follow-up time of about 12 months after the infusion of the CAR-T cells or at a rate of about 83% at a follow-up time of about 18 months after the infusion of the CAR-T cells.
[0046] In some embodiments, the method is effective to obtain progression-free survival of the subject. In some embodiments, the method is effective to obtain progression-free survival of the subject between the infusion of the CAR-T cells and about 209 days after the infusion of the CAR-T cells, about 386 days after the infusion of the CAR-T cells, about 632 days after the infusion of the CAR-T cells, or about 684 days after the infusion of the CAR-T cells.
[0047] In some embodiments, the method is effective in obtaining said progression-free survival at a rate between about 79% and about 93% at a follow-up time of about 6 months after said infusion of said CAR-T cells, at a rate between about 67% and about 84% at a follow-up time of about 12 months after said infusion of said CAR-T cells, at a rate between about 57% and about 75% at a follow-up time of about 18 months after said infusion of said CAR-T cells, at a rate between about 57% and about 75% at a follow-up time of about 21 months after said infusion of said CAR-T cells, or at a rate between about 49% and about 70% at a follow-up time of about 24 months after said infusion of said CAR-T cells.
[0048] In some embodiments, the method is effective in obtaining said progression-free survival at a rate of about 88% at a follow-up time of about 6 months after said infusion of said CAR-T cells, at a rate of about 76% at a follow-up time of about 12 months after said infusion of said CAR-T cells, at a rate of about 67% at a follow-up time of about 18 months after said infusion of said CAR-T cells, at a rate of about 67% at a follow-up time of about 21 months after said infusion of said CAR-T cells, or at a rate of about 61% at a follow-up time of about 24 months after said infusion of said CAR-T cells.
[0049] In some embodiments, the method further comprises treating the subject for cytokine release syndrome more than about 1 day after the infusion of the CAR-T cells. In some embodiments, the method is effective to obtain a recovery rate of between about 1% and about 99% of the cytokine release syndrome at a time of about 1, 3, 4, 6, 16, or 97 days after the cytokine release syndrome is first observed.
[0050] In some embodiments, the method further comprises treating the subject for immune effector cell-related neurotoxicity for more than about 3 days after the infusion of the CAR-T cells. In some embodiments, the method is effective to obtain a recovery rate of between about 1% and about 17% of the immune effector cell-related neurotoxicity at a time of about 1, 4, 5, 8, 12, or 16 days after the immune effector cell-related neurotoxicity is first observed.
[0051] In some embodiments, the method is effective to obtain the optimal response before a time between about 27 days and about 534 days after the infusion of the CAR-T cells. In some embodiments, the method is effective to obtain the optimal response before a time between about 27 days and about 293 days after the infusion of the CAR-T cells. In some embodiments, the method is effective to obtain the optimal response before about 153 days after the infusion of the CAR-T cells. In some embodiments, the method is effective to obtain the optimal response before about 78 days after the infusion of the CAR-T cells.
[0052] In some embodiments, the method is effective in maintaining the subject's response at a follow-up time between the time of the first response and about 180 days after the infusion of the CAR-T cells, about 357 days after the infusion of the CAR-T cells, about 606 days after the infusion of the CAR-T cells, or about 654 days after the infusion of the CAR-T cells. In some embodiments, the method is effective in maintaining the response at a follow-up time of about 77% to about 91% at a rate of about 12 months after the infusion of the CAR-T cells, at a rate of about 56% to about 75% at a follow-up time of about 18 months after the infusion of the CAR-T cells, at a rate of about 52% to about 72% at a follow-up time of about 21 months after the infusion of the CAR-T cells, or at a rate of about 48% to about 70% at a follow-up time of about 24 months after the infusion of the CAR-T cells. In some embodiments, the method is effective in maintaining a response at a rate of about 85% at a follow-up time of about 6 months after the infusion of the CAR-T cells, at a rate of about 74% at a follow-up time of about 12 months after the infusion of the CAR-T cells, at a rate of about 67% at a follow-up time of about 18 months after the infusion of the CAR-T cells, at a rate of about 63% at a follow-up time of about 21 months after the infusion of the CAR-T cells, or at a rate of about 60% at a follow-up time of about 24 months after the infusion of the CAR-T cells.
[0053] In some embodiments, the method is effective to obtain in said subject between the time of said administration of said CAR-T cells and about 3 months after said administration of said CAR-T cells, with a mean age of 10 years or more. -5The sensitivity threshold level of the minimal residual disease (MRD) negative status assessed in the bone marrow. In some embodiments, the method is effective to obtain a minimal residual disease (MRD) negative complete response or a minimal residual disease (MRD) negative strict complete response at a rate of between about 25% and about 44% at a follow-up time of about 12 months after the infusion of the CAR-T cells or at a rate of between about 33% and about 54% at a follow-up time of about 18 months after the infusion of the CAR-T cells. In some embodiments, the method is effective to obtain a minimal residual disease (MRD) negative complete response or a minimal residual disease (MRD) negative strict complete response at a rate of about 34% at a follow-up time of about 12 months after the infusion of the CAR-T cells or at a rate of about 43% at a follow-up time of about 18 months after the infusion of the CAR-T cells.
[0054] The present disclosure further relates to a drug product comprising a cedakinumab suspension for intravenous infusion, wherein the drug product is packaged, and wherein the package includes a label identifying the cedakinumab suspension as an approved drug product for the treatment of adult patients with relapsed or refractory multiple myeloma after receiving four or more prior lines of therapy including a proteasome inhibitor, an immunomodulator, and an anti-CD38 monoclonal antibody.
[0055] The present disclosure provides methods of treating relapsed or refractory multiple myeloma in an adult patient in need thereof, comprising administering an approved drug product comprising a cedakinumab suspension in an amount and in a manner described in the drug product labeling for the approved drug product and / or in the treatment regimen described herein.
[0056] The present disclosure also provides a method of marketing an approved drug product comprising a cedakinumab suspension, the method comprising marketing such a drug product, wherein the drug product labeling of a reference product for such drug product comprises instructions for use in treating patients with relapsed or refractory multiple myeloma after receiving four or more prior lines of therapy comprising a proteasome inhibitor, an immunomodulator, and an anti-CD38 monoclonal antibody.
[0057] The present disclosure also provides a method of offering for sale a drug product comprising a cedakinumab suspension, the method comprising offering for sale such a drug product, wherein the drug product labeling of a reference product for such a drug product comprises instructions for treating patients with relapsed or refractory multiple myeloma after receiving four or more prior lines of therapy comprising a proteasome inhibitor, an immunomodulator, and an anti-CD38 monoclonal antibody. BRIEF DESCRIPTION OF THE DRAWINGS
[0058] Figure 1The expression of BCMA antigen on the surface of GC, memory and plasmablasts in lymph nodes, long-lived plasma cells in bone marrow LN and MALT, and multiple myeloma cells is shown. BAFF-R antigen is not expressed on plasmablasts, long-lived plasma cells, or multiple myeloma cells. TACI is expressed on memory and plasmablasts, long-lived plasma cells, and multiple myeloma cells. CD138 is only expressed on long-lived plasma cells and multiple myeloma cells.
[0059] Figure 2 The design of the Cedaciolinsel CAR is shown. Cedaciolinsel contains two VHH domains, as opposed to the single VL domain and single VH domain found on various other CARs. Cedaciolinsel contains intracellular CD137 and human CD3ζ domains.
[0060] Figure 3 A schematic diagram is shown for preparing a virus encoding the Sidaquioren CAR, transducing the virus into the patient's T cells, and then preparing CAR T cells expressing the Sidaquioren CAR.
[0061] Figure 4 A schematic diagram of the study design of the cedaciolencel CAR T cells is shown. The patient population includes those with relapsed or refractory multiple myeloma, who have been treated with 3 prior lines or are double refractory to PI / IMiD, and have been previously exposed to PI, IMiD, and anti-CD38. The primary objectives are safety and the establishment of RP2D, such as studying the incidence and severity of adverse events (Phase 1b). Another primary objective is efficacy: ORR-PR or better, as defined by IMWG (Phase 2). The following are secondary objectives: the incidence and severity of adverse events (Phase 2) and any further efficacy characterization.
[0062] Figure 5A is a graph showing response and duration of response (DOR) for the 50 responders with the greatest number of follow-up based on independent review committee (IRC) assessment in the all-treatment analysis set at a median follow-up of 12.4 months, arranged along the vertical axis in order of the duration of follow-up of the responders. Figure 5B is a graph showing response and duration of response (DOR) for the 44 responders with the fewest follow-up based on independent review committee (IRC) assessment in the all-treated analysis set at a median follow-up of 12.4 months, arranged in order of the duration of follow-up of the responders along the vertical axis.
[0063] Figure 6Kaplan-Meier plots of duration of response (DOR) for responders in the all-treatment analysis set based on independent review committee (IRC) assessment at a median follow-up of 12.4 months are shown, showing that the probability of a responder maintaining a response at 9 and 12 months was approximately 80.2% and 68.2%, respectively.
[0064] Figure 7 A Kaplan-Meier plot of overall survival (OS) for all subjects in the all-treatment analysis set with a median follow-up of 12.4 months is shown, showing 9-month and 12-month survival rates of approximately 90.7% and 88.5%, respectively.
[0065] Figure 8 , Fig. 9 , Fig.10 , Fig.11 , Fig.12 , Fig.13 , Fig.14 and Fig.15 A description of the protocol and data obtained in the Phase 1b-2 clinical trial described herein in which patients with relapsed, refractory multiple myeloma were treated with cedakinumab, with a median follow-up of 12.4 months, is shown.
[0066] Fig.16 , Fig.17 , Fig.18 and Fig.19 A description of the evaluation and assessment of cytokine release syndrome (CRS) in the Phase 1b-2 clinical trial described herein in which patients with relapsed, refractory multiple myeloma were treated with cedaciclib.
[0067] Fig. 20 is a graph showing responses and duration of response (DOR) in responders based on independent review committee (IRC) assessment in the all-treatment analysis set with a median follow-up of 18 months.
[0068] Fig.21 Shown are Kaplan-Meier plots of duration of response (DOR) for responders in the all-treatment analysis set based on independent review committee (IRC) assessment at a median follow-up of 18 months.
[0069] Fig. 22 Shown are Kaplan-Meier plots of progression-free survival (PFS) for responders in the all-treatment analysis set based on independent review committee (IRC) assessment at a median follow-up of 18 months.
[0070] Fig.23Shown are Kaplan-Meier plots of overall survival (OS) for all subjects in the all-treatment analysis set at a median follow-up of 18 months.
[0071] Fig.24A , Fig. 24B and Fig.24C Forest plots are shown for subgroup analyses of overall response rate (ORR) in the all-treatment analysis set based on independent review committee (IRC) assessment at a median follow-up of 18 months.
[0072] Fig.25A , Fig.25B and Fig.25C Forest plots are shown for subgroup analyses of duration of response (DOR) in the all-treatment analysis set based on independent review committee (IRC) assessment at a median follow-up of 18 months.
[0073] Fig.26A , Fig.26B and Fig.26C The results showed that at a median follow-up of 18 months, 10 -5 Forest plot of subgroup analysis of overall MRD-negative rate.
[0074] Fig.27A , Fig.27B and Fig.27C Figure 10 Bone marrow 10-year survival in all subjects with evaluable samples in the treatment analysis set at a median follow-up of 18 months. -5 Forest plot of subgroup analysis of overall MRD-negative rate.
[0075] Fig.28 The selection of comparator groups for indirect treatment comparison (ITC) analyses is summarized.
[0076] Fig.29A and Fig.29B A meta-analysis comparison of overall survival of patients treated with cedakinumab and those treated with physician's choice of treatment using all index dates is shown.
[0077] Fig.30 A meta-analysis comparison of progression-free survival between patients treated with cedakinumab and those treated with physician's choice of treatment using all index dates is shown.
[0078] Fig.31 A meta-analysis comparison of overall survival of patients treated with cedakinumab and those treated with physician's choice of treatment using the first index date is shown.
[0079] Fig.32A meta-analysis comparison of progression-free survival between patients treated with cedakinumab and those treated with physician's choice of treatment using the first index date is shown. DETAILED DESCRIPTION
[0080] The present disclosure also provides related nucleic acids, recombinant expression vectors, host cells, cell populations, antibodies or antigen-binding portions thereof, and pharmaceutical compositions involving immune cells and CAR-expressing T cells of the present disclosure. Also provided are dosing regimens, dosage forms, and methods for using CAR-T cell therapy.
[0081] Several aspects of the present disclosure are described below with reference to examples only for illustrative purposes. It should be appreciated that, in order to provide a comprehensive understanding of the present disclosure, many special details, relationships and methods are proposed. However, those of ordinary skill in the relevant art will readily recognize that the present disclosure can be put into practice without one or more special details, or can be put into practice with other methods, schemes, reagents, cell lines and animals. The present disclosure is not limited by the behavior or sequence of events shown, because some behaviors can occur in different orders and / or simultaneously with other behaviors or events. In addition, it is not necessary for all actions, steps or events shown to realize the method according to the present disclosure.
[0082] Unless otherwise defined, all field terms, symbols and other scientific terms or technical terms used herein are intended to have the meanings commonly understood by those skilled in the art to which the present disclosure belongs. In some cases, for clarity and / or for ease of reference, terms with commonly understood meanings are defined herein, and the inclusion of such definitions herein should not necessarily be interpreted as indicating that there are significant differences from the meanings commonly understood in the art. It will be further understood that terms (such as those defined in commonly used dictionaries) should be interpreted as having meanings consistent with their meanings in the context of the relevant art and / or as otherwise defined herein.
[0083] The term "about" or "approximately" includes within a statistically significant range of values. Such a range may be within an order of magnitude of a given value or range, preferably within 50%, more preferably within 20%, still more preferably within 10%, and even more preferably within 5%. The permissible variation encompassed by the term "about" or "approximately" depends on the specific system under study and can be readily understood by one of ordinary skill in the art.
[0084] The term "antibody" includes monoclonal antibodies (including full-length 4-chain antibodies or only full-length heavy chain antibodies with immunoglobulin Fc regions), antibody compositions with multi-epitope specificity, multispecific antibodies (e.g., bispecific antibodies, diabodies, and single-chain molecules), and antibody fragments (e.g., Fab, F(ab')2, and Fv). The terms "immunoglobulin" (Ig) and "antibody" are used interchangeably herein. Antibodies contemplated herein include single domain antibodies, such as heavy chain antibodies only.
[0085] The term "heavy chain only antibody" or "HCAb" refers to a functional antibody comprising a heavy chain but lacking the light chain typically found in a 4-chain antibody. Camelids (such as camels, llamas or alpacas) are known to produce HCAbs.
[0086] The term "single domain antibody" or "sdAb" refers to a single antigen-binding polypeptide with three complementary determining regions (CDRs). A single sdAb is able to bind to an antigen without pairing with a corresponding polypeptide containing CDRs. In some cases, single domain antibodies are engineered from camelid HCAbs, and their heavy chain variable domains are referred to herein as "VHHs". Some VHHs may also be referred to as "nanoantibodies". Camelid sdAbs are one of the smallest known antigen-binding antibody fragments (see, e.g., Hamers-Casterman et al., Nature 363:446-8 (1993); Greenberg et al., Nature 374:168-73 (1995); Hassanzadeh-Ghassabeh et al., Nanomedicine (Lond), 8:1013-26 (2013)). The basic VHH has the following structure from N-terminus to C-terminus: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4, wherein FR1 to FR4 refer to framework regions 1 to 4, respectively, and wherein CDR1 to CDR3 refer to complementarity determining regions 1 to 3.
[0087] The "variable region" or "variable domain" of an antibody refers to the amino terminal domain of the heavy or light chain of that antibody. The variable domains of the heavy and light chains may be referred to as "VH" and "VL", respectively. These domains are usually the most variable parts of an antibody (relative to other antibodies of the same class) and contain the antigen binding site. Heavy chain-only antibodies from camelid species have a single heavy chain variable region, referred to as a "VHH" domain. Thus, VHH is a special type of variable region.
[0088] The term "variable" refers to the fact that some segments of the variable domains have very different sequences between antibodies. The V domain (i.e., variable domain) mediates antigen binding and defines the specificity of a particular antibody to its specific antigen. However, variability is not evenly distributed over the entire span of the variable domain. Instead, it is concentrated in three segments called hypervariable regions (HVRs) in the light and heavy chain variable domains. The more conservative part of the variable domain is called the framework region (FR). The variable domains of native heavy and light chains each include four FR regions that mainly adopt a β sheet configuration, which are connected by three HVRs, which are connected to form a loop connecting a β sheet structure, and in some cases form a part of a β sheet structure. The HVR in each chain is tightly bound together by the FR region and contributes to the formation of the antigen binding site of the antibody (if the antibody is not sdAb or HCAb, then together with the HVR from another chain) (see Kabat et al., Sequences of Immunological Interest, Fifth Edition, National Institute of Health, Bethesda, Md. (1991)). The constant domains are not directly involved in the binding of antibodies to antigens, but exhibit various effector functions, such as participation of antibodies in antibody-dependent cellular cytotoxicity.
[0089] The terms "antibody fragment", "antibody fragment", "functional fragment of an antibody" and "antigen binding portion" are used interchangeably herein to refer to one or more fragments or portions of an antibody that retain the ability to specifically bind to an antigen (see generally Holliger et al., Nat. Biotech., 23 (9): 1 126-1129 (2005)). The antigen recognition portion of the CAR encoded by the nucleic acid sequence disclosed herein may contain any BCMA binding antibody fragment. Antibody fragments desirably include, for example, one or more CDRs, variable regions (or portions thereof), constant regions (or portions thereof), or combinations thereof. Examples of antibody fragments include, but are not limited to, (i) a Fab fragment, which is a monovalent fragment consisting of the VL, VH, CL and CHI domains; (ii) a F(ab')2 fragment, which is a bivalent fragment comprising two Fab fragments linked by a disulfide bond at the hinge region; (iii) an Fv fragment, which consists of the VL and VH domains of a single arm of an antibody; (iv) a single-chain Fv (scFv), which is a monovalent molecule consisting of the two domains of the Fv fragment (i.e., VL and VH) linked by a synthetic linker that enables the two domains to be synthesized as a single polypeptide chain (see, e.g., Bird et al., Science, 242:44). 23-426 (1988); Huston et al., Proc. Natl. Acad. Sci. USA, 85: 5879-5883 (1988); and Osbourn et al., Nat. Biotechnol, 16: 778 (1998)) and (v) diabodies, which are dimers of polypeptide chains, each of which comprises a VH connected to a VL by a peptide linker that is too short to allow pairing between VH and VL on the same polypeptide chain, thereby driving pairing between complementary domains on different VH-VL polypeptide chains to produce a dimeric molecule with two functional antigen binding sites. Antibody fragments are known in the art and are described in more detail, for example, in U.S. Patent Application Publication 2009 / 0093024A1.
[0090] As used herein, the terms "specifically bind," "specifically recognize," or "are specific for" refer to a measurable and reproducible interaction, such as binding between a target and an antigen binding protein (such as a CAR or VHH), that determines the presence of the target in the presence of a heterogeneous population of molecules including biological molecules.
[0091] The term "specificity" refers to the selective recognition of a specific epitope of an antigen by an antigen binding protein (such as a CAR or VHH). For example, natural antibodies are monospecific.
[0092] "Chimeric antigen receptor" or "CAR" is an artificially constructed hybrid protein or polypeptide containing an antigen binding domain of an antibody (or antibody fragment) connected to a T cell signaling domain. The characteristics of CAR may include the ability to redirect T cell specificity and reactivity to a selected target in a non-MHC restricted manner (using the antigen binding properties of monoclonal antibodies). Non-MHC restricted antigen recognition gives CAR-expressing T cells the ability to recognize antigens (independent of antigen processing), thus bypassing the main mechanism of tumor escape. In addition, when expressed in T cells, CAR advantageously does not dimerize with endogenous T cell receptor (TCR) α and β chains. T cells expressing CAR are referred to herein as CAR T cells, CAR-T cells, or CAR-modified T cells, and these terms are used interchangeably herein. The cell can be genetically modified to stably express the antibody binding domain on its surface, thereby conferring a novel antigen specificity that is independent of MHC. "BCMA CAR" refers to a CAR having an extracellular binding domain specific for BCMA. A "dual-epitope CAR" refers to a CAR that has extracellular binding domains specific for two different epitopes on BCMA.
[0093] "Cilta-cel" is a chimeric antigen receptor T cell (CAR-T) therapy that contains two VHH domains designed to confer affinity for B cell maturation antigen (BCMA) targeting BCMA. Cilta-cel may comprise T lymphocytes transduced by a cilta-cel CAR (CAR encoded by a lentiviral vector). The CAR targets human B cell maturation antigen (BCMA CAR). A schematic diagram of a lentiviral vector encoding a cilta-cel CAR is shown in FIG. Figure 2 The amino acid sequence of Sidaquiorunsai CAR is the amino acid sequence of SEQ ID NO: 17.
[0094] The term "express" means allowing or causing the information in a gene or DNA sequence to be produced. For example, expression can take the form of producing a protein by activating cellular functions involved in the transcription and translation of the corresponding gene or DNA sequence. A DNA sequence is expressed in or by a cell to form an "expression product" such as a protein. The expression product itself, such as the resulting protein, may also be referred to as being "expressed" by a cell. An expression product may be characterized as being intracellular, extracellular, or transmembrane.
[0095] The term "treatment" refers to therapeutic treatment, wherein the purpose is to slow down or alleviate undesirable physiological changes or diseases, or to provide beneficial or desired clinical results during treatment. Beneficial or desired clinical results include alleviation of symptoms, reduction of disease extent, stabilization of disease state (i.e., no deterioration), delay or slowing of disease progression, improvement or alleviation of disease state, and / or relief (whether partial relief or complete relief), whether detectable or undetectable. "Treatment" can also mean prolonged survival compared to the expected survival of the subject without treatment. Those subjects in need of treatment include those subjects who have already suffered from undesirable physiological changes or diseases and those subjects who tend to suffer from physiological changes or diseases. Treatment may involve a therapeutic agent, also referred to herein as a "medicament or medication", which may be intended to help achieve the beneficial or desired clinical results of interest through its action. The therapeutic agent or drug can be administered to the subject by many routes, including at least intravenous and oral routes. The term "intravenous" related to the administration of a therapeutic agent or drug refers to administering the therapeutic agent or drug in one or more veins. The term "oral" in relation to the administration of a therapeutic agent or drug refers to administration of the therapeutic agent or drug via the oral passage, such as the mouth.
[0096] As used herein, the term "subject" refers to an animal. The terms "subject" and "patient" are used interchangeably herein when referring to a subject. Therefore, "subject" includes a person who is being treated for a disease or preventing a disease as a patient. The methods described herein can be used to treat animal subjects belonging to any classification. Examples of such animals include mammals. Mammals include, but are not limited to, rodents (order Rodentia) mammals, such as mice and hamsters, and lagomorpha (order Logomorpha) mammals, such as rabbits. Mammals can be carnivores (order Carnivora), including felines (cats) and canines (dogs). Mammals can be even-toed ungulates, including bovines (cows) and suids (pigs) or odd-toed ungulates, including equines (horses). Mammals can be primates (order Primate), four-legged monkeys (order Ceboid) or monkeys (order Simoid) (monkeys) or anthropoids (order Anthropoid) (humans and apes). In some embodiments, mammals are humans.
[0097] The term "effective" as applied to dosage or amount refers to an amount of a compound or pharmaceutical composition sufficient to produce the desired activity upon administration to a subject in need thereof. Note that when a combination of active ingredients is administered, the effective amount of the combination may or may not include the amount of each ingredient that would be effective if administered alone. The exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the condition being treated, the specific drug or drugs employed, the mode of administration, and the like.
[0098] The phrase "pharmaceutically acceptable" used in conjunction with the compositions described herein refers to molecular entities and other ingredients of such compositions that are physiologically tolerable and typically do not produce adverse reactions when administered to mammals (e.g., humans). Preferably, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or state governments or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in mammals, and more particularly in humans.
[0099] The term "line of therapy" used in conjunction with the treatment methods herein refers to one or more cycles of a planned treatment program, which may consist of one or more planned cycles of a single agent therapy or a combination therapy and a sequence of treatments administered in a planned manner. For example, a planned treatment approach of induction therapy followed by autologous stem cell transplantation and then maintenance is a line of therapy. When the planned course of treatment is modified to include other therapeutic agents or drugs (alone or in combination) due to disease progression, relapse, or toxicity, a new line of therapy is considered to have been started. When a planned post-therapy observation period is interrupted due to the need for additional treatment of the disease, a new line of therapy is also considered to have been started.
[0100] The term "refractory" used in conjunction with treatment with a particular therapeutic agent or drug herein refers to a disease or disease subject that does not respond to the therapeutic agent or drug. The phrase "refractory myeloma" refers to a disease that does not respond to primary or salvage therapy or progresses within 60 days of the last therapy.
[0101] The phrase "unresponsive disease" refers to the failure to achieve a minimal response to therapy or the development of disease progression.
[0102] The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting. As used herein, the indefinite articles "a / an" and "the" should be understood to include plural references unless the context clearly indicates otherwise.
[0103] Throughout the disclosure, the various aspects of the disclosure can be presented in the form of ranges. It should be understood that the description of the range form is only for convenience and brevity, and should not be interpreted as an inflexible limitation to the scope of the disclosure. Therefore, the description of the range should be considered to have all possible sub-ranges with exact disclosure and the individual numerical values within the range. For example, the description of the range such as from 1 to 6 should be considered to have a sub-range with exact disclosure, such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6, etc., and the individual numbers within the range, such as 1, 2, 2.7, 3, 4, 5, 5.3 and 6. As another example, the range such as 95%-99% homogeneity includes 95%, 96%, 97%, 98% or 99% homogeneity, and includes the sub-ranges such as 96%-99%, 96%-98%, 96%-97%, 97%-99%, 97%-98% and 98%-99% homogeneity. This applies regardless of the width of the range.
[0104] Carrier
[0105] Standard recombinant techniques can be used to obtain the polynucleotide sequences encoding the CAR described in this application. The desired polynucleotide sequences can be isolated and sequenced from antibody-producing cells such as hybridoma cells. Alternatively, a nucleotide synthesizer or PCR technique can be used to synthesize polynucleotides.
[0106] The disclosure also provides a vector comprising a nucleic acid sequence encoding the CAR disclosed herein. The vector can be, for example, a plasmid, a cosmid, a viral vector (eg, a retrovirus or adenovirus) or a phage. Suitable vectors and vector preparation methods are well known in the art (see, for example, Sambrook et al. and Ausubel et al.).
[0107] In addition to the nucleic acid sequence encoding the CAR disclosed herein, the vector preferably includes expression control sequences, such as promoters, enhancers, polyadenylation signals, transcription terminators, internal ribosome entry sites (IRES), etc., which provide expression of the nucleic acid sequence in a host cell. Exemplary expression control sequences are known in the art and are described in, for example, Goeddel, Gene Expression Technology: Methods in Enzymology, Vol. 185, Academic Press, San Diego, Calif. (1990).
[0108] In some embodiments, the vector comprises a promoter. A large number of promoters recognized by a variety of potential host cells are well known. The selected promoter can be operably connected to the cistron DNA encoding the CAR disclosed herein by removing the promoter from the source DNA via restriction enzyme digestion and inserting the separated promoter sequence into the vector of the present application. A large number of promoters from a variety of different sources, including constitutive, inducible and repressible promoters are well known in the art. Representative promoter sources include, for example, viruses, mammals, insects, plants, yeast and bacteria, and suitable promoters from these sources are easily available, or can be prepared based on publicly available sequences from, for example, collection centers such as ATCC and other commercial or separate sources. The promoter can be unidirectional (ie, transcription is initiated in one direction) or bidirectional (ie, transcription is initiated in the 3' or 5' direction). Non-limiting examples of promoters include, for example, T7 bacterial expression systems, pBAD (araA) bacterial expression systems, cytomegalovirus (CMV) promoters, SV40 promoters and RSV promoters. Inducible promoters include, for example, the Tet system (U.S. Pat. Nos. 5,464,758 and 5,814,618), the ecdysone inducible system (No et al., Proc. Natl. Acad. Sci., 93:3346-3351 (1996)), T-REX TM System (Invitrogen, Carlsbad, CA), LACSWITCH TM system (Stratagene, San Diego, CA) and the Cre-ERT tamoxifen-inducible recombinase system (Indra et al., Nuc. Acid. Res., 27:4324-4327 (1999); Nuc. Acid. Res., 28:e99 (2000); U.S. Patent 7,112,715; and Kramer & Fussenegger, Methods Mol. Biol, 308:123-144 (2005)).
[0109] In some embodiments, the vector comprises an "enhancer". As used herein, the term "enhancer" refers to a DNA sequence that increases, for example, the transcription of a nucleic acid sequence operably connected thereto. The enhancer can be located many kilobases away from the coding region of the nucleic acid sequence and can mediate the binding of regulatory factors, changes in DNA methylation patterns, or DNA structure. A large number of enhancers from various sources are well known in the art and can be obtained as cloned polynucleotides or in cloned polynucleotides (e.g., from collections such as ATCC and other commercial or personal sources). Many polynucleotides comprising promoters (such as the commonly used CMV promoter) also comprise enhancer sequences. The enhancer can be located upstream, internal, or downstream of the coding sequence. The term "Ig enhancer" refers to an enhancer element derived from an enhancer region that is located in an immunoglobulin (Ig) locus. Such Ig enhancers include, for example, the heavy chain (μ) 5' enhancer, the light chain (κ) 5' enhancer, the κ and μ intronic enhancers, and the 3' enhancer (see generally Paul WE (ed.), Fundamental Immunology, 3rd Edition, Raven Press, New York (1993), pp. 353-363; and U.S. Pat. No. 5,885,827).
[0110] In some embodiments, the vector comprises a "selectable marker gene". As used herein, the term "selectable marker gene" refers to a nucleic acid sequence that allows cells expressing a nucleic acid sequence to be specifically selected or targeted in the presence of a corresponding selection agent. Suitable selective marker genes are known in the art and are disclosed in, for example, International Patent Application Publications WO 1992 / 08796 and WO 1994 / 28143; Wigler et al., Proc. Natl. Acad. Sci. USA, 77: 3567 (1980); O'Hare et al., Proc. Natl. Acad. Sci. USA, 78: 1527 (1981); Mulligan & Berg, Proc. Natl. Acad. Sci. USA, 78: 2072 (1981); Colberre-Garapin et al., J. Mol. Biol., 150: 1 (1981); Sanford et al., J. Mol. Biol., 150: 1 (1981); Terre et al., Gene, 30:147 (1984); Kent et al., Science, 237:901-903 (1987); Wigler et al., Cell, IP.223 (1977); Szybalska & Szybalski, Proc. Natl. Acad. Sci. USA, 48:2026 (1962); Lowy et al., Cell, 22:817 (1980); and described in U.S. Patents 5,122,464 and 5,770,359.
[0111] In some embodiments, the vector is an "episomal expression vector" or "episome" that can replicate in a host cell and persist as an extrachromosomal segment of DNA in a host cell under appropriate selection pressure (see, e.g., Conese et al., Gene Therapy, 11: 1735-1742 (2004)). Representative commercially available episomal expression vectors include, but are not limited to, episomal plasmids utilizing Epstein Barr nuclear antigen 1 (EBNA1) and Epstein-Barr virus (EBV) replication origin (oriP). Vectors pREP4, pCEP4, pREP7, and pcDNA3.1 from Invitrogen (Carlsbad, California) and pB-CMV from Stratagene (La Jolla, California) represent non-limiting examples of episomal vectors that use T antigen and SV40 replication origin instead of EBNA1 and oriP.
[0112] In some embodiments, the vector is an "integrating expression vector" that can be randomly integrated into the DNA of the host cell or can include recombination sites to enable recombination between the expression vector and a specific site in the chromosomal DNA of the host cell. Such an integrating expression vector can utilize endogenous expression control sequences of the host cell chromosome to achieve expression of the desired protein. Examples of vectors that integrate in a site-specific manner include, for example, components of the flp-in system from Invitrogen (Carlsbad, CA) (e.g., pcDNA TM 5 / FRT), or cre-lox system, such as can be found in the pExchange-6 core vector from Stratagene (La Jolla, CA). Examples of vectors that are randomly integrated into the host cell chromosome include, for example, pcDNA3.1 from Invitrogen (Carlsbad, CA) (when introduced in the absence of T antigen), and pCI or pFNIOA (ACT) FLEXI from Promega (Madison, WI). TM .
[0113] In some embodiments, the vector is a viral vector. Representative viral expression vectors include, but are not limited to, adenovirus-based vectors (e.g., adenovirus-based Per.C6 systems available from Crucell, Inc. (Leiden, The Netherlands)), lentivirus-based vectors (e.g., lentivirus-based pLP1 from Life Technologies (Carlsbad, CA)), and retroviral vectors (e.g., pFB-ERV plus pCFB-EGSH from Stratagene (La Jolla, CA)). In a preferred embodiment, the viral vector is a lentiviral vector.
[0114] The vector comprising the nucleic acid of the present invention encoding CAR can be introduced into a host cell, which can express the CAR encoded thereby, including any suitable prokaryotic or eukaryotic cells. Preferred host cells are those that can be easily and reliably grown, have a reasonably fast growth rate, have a well-characterized expression system, and can be easily and efficiently transformed or transfected.
[0115] As used herein, the term "host cell" refers to any type of cell that may contain an expression vector. The host cell may be a eukaryotic cell, such as a plant, an animal, a fungus or an alga, or may be a prokaryotic cell, such as a bacterium or a protozoan. The host cell may be a cultured cell or a primary cell, i.e., directly isolated from an organism such as a human. The host cell may be an adherent cell or a suspension cell, i.e., a cell grown in a suspension. Suitable host cells are known in the art, including, for example, DH5α Escherichia coli cells, Chinese hamster ovary cells, monkey VERO cells, COS cells, HEK 293 cells, etc. In a preferred embodiment, the host cell is a HEK 293 cell. In some embodiments, HEK 293 cells are derived from ATCC SD-3515. In some embodiments, HEK 293 cells are derived from IU-VPF MCB. In some embodiments, HEK 293 cells are derived from IU-VPF MWCB. In some embodiments, the host cell may be a peripheral blood lymphocyte (PBL), a peripheral blood mononuclear cell (PBMC), or a natural killer cell (NK). Preferably, the host cell is a natural killer (NK) cell. More preferably, the host cell is a T cell.
[0116] In order to amplify or replicate the recombinant expression vector, the host cell can be a prokaryotic cell, such as a DH5α cell. In order to produce a virus from a viral expression vector, the host cell can be a eukaryotic cell, such as a HEK 293 cell. In order to produce a recombinant CAR, the host cell can be a mammalian cell. The host cell is preferably a human cell. The host cell can be any cell type, can be derived from any type of tissue, and can be at any developmental stage. Methods for selecting suitable mammalian host cells and methods for transforming, culturing, amplifying, screening and purifying cells are known in the art.
[0117] In some embodiments, the present disclosure provides an isolated host cell expressing a nucleic acid sequence encoding a CAR described herein.
[0118] In some embodiments, host cells are T cells. The T cells disclosed herein can be any T cells, such as cultured T cells, such as primary T cells, or T cells from cultured T cell lines, or T cells obtained from mammals. If obtained from mammals, T cells can be obtained from a variety of sources, including but not limited to blood, bone marrow, lymph nodes, thymus or other tissues or fluids. T cells can also be enriched or purified. T cells are preferably human T cells (e.g., separated from humans). T cells can be any developmental stage, including but not limited to CD4+ / CD8+ double positive T cells, CD4+ helper T cells, such as Th and Th2 cells, CD8+ T cells (e.g., cytotoxic T cells), tumor infiltrating cells, memory T cells, initial T cells, etc. In one embodiment, T cells are CD8+ T cells or CD4+ T cells. T cell lines are available from, for example, the American Type Culture Collection (ATCC, Manassas, VA) and the German Collection of Microorganisms and Cell Cultures (DSMZ), and include, for example, Jurkat cells (ATCC TIB-152), Sup-T1 cells (ATCC CRL-1942), RPMI 8402 cells (DSMZ ACC-290), Karpas45 cells (DSMZ ACC-545), and derivatives thereof.
[0119] In certain embodiments, host cell is natural killer (NK) cell.NK cell is a kind of cytotoxic lymphocyte that works in the innate immune system.NK cell is defined as large granular lymphocyte and constitutes the third type of cell differentiated from common lymphocyte progenitor cell, and this common lymphocyte progenitor cell also produces B lymphocyte and T lymphocyte (referring to, for example, Immunobiology, the 5th edition, Janeway et al., editor, Garland Publishing, New York, NY (2001)). NK cell is differentiated and matured in bone marrow, lymph node, spleen, tonsil and thymus. After maturation, NK cell enters circulation as large lymphocyte with unique cytotoxic granules.NK cell can recognize and kill some abnormal cells, such as some tumor cells and virus-infected cells, and is considered to be important in the innate immune defense against intracellular pathogens. As described above with respect to T cell, NK cell can be any NK cell, such as cultured NK cell, such as primary NK cell, or NK cell from cultured NK cell line, or NK cell obtained from mammal. If obtained from a mammal, NK cells can be obtained from a variety of sources, including but not limited to blood, bone marrow, lymph nodes, thymus or other tissues or fluids. NK cells can also be enriched or purified. NK cells are preferably human NK cells (e.g., separated from humans). NK cell lines can be obtained from, for example, the American Type Culture Collection (ATCC, Manassas, VA), and include, for example, NK-92 cells (ATCC CRL-2407), NK92MI cells (ATCC CRL-2408) and derivatives thereof.
[0120] In some embodiments, the nucleic acid sequence encoding CAR can be introduced into cells by "transfection", "conversion" or "transduction". As used herein, "transfection", "conversion" or "transduction" refers to the introduction of one or more exogenous polynucleotides into host cells by using physical or chemical methods.
[0121] Many transfection techniques are known in the art and include, for example, calcium phosphate DNA coprecipitation (see, e.g., Murray EJ (ed.), Methods in Molecular Biology, Vol. 7, Gene Transfer and Expression Protocols, Humana Press (1991)); DEAE-dextran; electroporation; cationic liposome-mediated transfection; microprojectile bombardment facilitated by tungsten particles (Johnston, Nature, 346:776-777 (1990)); and strontium phosphate DNA coprecipitation (Brash et al., Mol. Cell Biol., 7:2031-2034 (1987)). Phage or viral vectors can be introduced into host cells after the infectious particles have been grown in appropriate packaging cells, many of which are commercially available.
[0122] Chimeric Antigen Receptor
[0123] International Patent Publication No. WO 2018 / 028647 is incorporated herein by reference in its entirety. U.S. Patent Publication No. 2018 / 0230225 is incorporated herein by reference in its entirety.
[0124] The present disclosure provides a method for treating a subject with a cell expressing a chimeric antigen receptor (CAR). CAR comprises an extracellular antigen binding domain containing one or more single-domain antibodies. In various embodiments, a CAR targeting BCMA (also referred to herein as "BCMA CAR") is provided, which comprises a polypeptide comprising: (a) an extracellular antigen binding domain comprising an anti-BCMA binding portion; (b) a transmembrane domain; and (c) an intracellular signaling domain. In some embodiments, the anti-BCMA binding portion is camelid, chimeric, human or humanized. In some embodiments, the intracellular signaling domain comprises a primary intracellular signaling domain of an immune effector cell (such as a T cell). In some embodiments, the primary intracellular signaling domain is derived from CD4. In some embodiments, the primary intracellular signaling domain is derived from CD3ζ. In some embodiments, the intracellular signaling domain comprises a costimulatory signaling domain. In some embodiments, the costimulatory signaling domain is derived from a costimulatory molecule selected from the group consisting of a ligand of CD27, CD28, CD137, OX40, CD30, CD40, CD3, LFA-1, ICOS, CD2, CD7, LIGHT, NKG2C, B7-H3, CD83, and combinations thereof. In certain embodiments, the transmembrane domain is derived from CD137.
[0125] In some embodiments, BCMA CAR further comprises a hinge domain (such as a CD8α hinge domain) located between the C-terminus of the extracellular antigen binding domain and the N-terminus of the transmembrane domain. In some embodiments, BCMA CAR further comprises a signal peptide (such as a CD8α signal peptide) located at the N-terminus of the polypeptide. In some embodiments, the polypeptide comprises from N-terminus to C-terminus: a CD8α signal peptide, an extracellular antigen binding domain, a CD8α hinge domain, a CD28 transmembrane domain, a first co-stimulatory signaling domain derived from CD28, a second co-stimulatory signaling domain derived from CD137, and a primary intracellular signaling domain derived from CD4. In some embodiments, the polypeptide comprises from N-terminus to C-terminus: a CD8α signal peptide, an extracellular antigen binding domain, a CD8α hinge domain, a CD8α transmembrane domain, a second co-stimulatory signaling domain derived from CD137, and a primary intracellular signaling domain derived from CD3ζ. In some embodiments, BCMA CAR is monospecific. In some embodiments, BCMA CAR is monovalent.
[0126] The present application also provides a CAR having two or more (including but not limited to any one of 2, 3, 4, 5, 6 or more) binding moieties that specifically bind to an antigen such as BCMA. In some embodiments, one or more binding moieties are antigen binding fragments. In some embodiments, one or more binding moieties comprise a single domain antibody. In some embodiments, one or more binding moieties comprise a VHH.
[0127] In some embodiments, the CAR is a multivalent (e.g., bivalent, trivalent or higher valent) CAR comprising a polypeptide comprising: (a) an extracellular antigen binding domain comprising a plurality (e.g., at least about any one of 2, 3, 4, 5, 6 or more) of binding moieties that specifically bind to an antigen (e.g., a tumor antigen); (b) a transmembrane domain; and (c) an intracellular signaling domain.
[0128] In some embodiments, the binding moiety, such as VHH (including multiple VHHs, or a first VHH and / or a second VHH) is camelid, chimeric, human or humanized. In some embodiments, the binding moiety or VHH is connected to each other via a peptide bond or a peptide linker. In some embodiments, each peptide linker is no more than about 50 (e.g., no more than about any of 35, 25, 20, 15, 10, or 5) amino acids in length.
[0129] In some embodiments, the first BCMA binding moiety and / or the second BCMA binding moiety is an anti-BCMA VHH. In some embodiments, the first BCMA binding moiety is a first anti-BCMA VHH and the second BCMA binding moiety is a second anti-BCMA VHH.
[0130] In some embodiments, the first BCMA binding moiety and the second BCMA binding moiety are connected to each other via a peptide linker. In some embodiments, the peptide linker comprises the amino acid sequence of SEQ ID NO: 3. In some embodiments, the peptide linker comprises a polypeptide encoded by the nucleic acid sequence of SEQ ID NO: 11.
[0131] In some embodiments, CAR further comprises a hinge domain (such as a CD8α hinge domain) between the C-terminus of the extracellular antigen binding domain and the N-terminus of the transmembrane domain. In some embodiments, CAR further comprises a signal peptide (such as a CD8α signal peptide) at the N-terminus of the polypeptide.
[0132] Without wishing to be bound by theory, multivalent CARs or those comprising an extracellular antigen binding domain containing a first BCMA binding portion and a second BCMA binding portion may be particularly suitable for targeting multimeric antigens via cooperative binding of different antigen binding sites, or for enhancing binding affinity or avidity to antigens. The increased affinity may allow a significant reduction in the dose of CAR-T cells required to achieve a therapeutic effect, such as a dose range of 4.0×104 to 1.0×106 CAR-T cells / kg subject mass, or 3.0×106 to 1.0×108 total CAR-T expressing cells. Monovalent CARs, such as bb2121, may need to be administered at 5 to 10 times these amounts to achieve comparable effects. In various embodiments, the reduced dose range may provide a significant reduction in other potentially dangerous side effects of cytokine release syndrome (CRS) and CAR-T therapy.
[0133] Various binding moieties in the CAR described herein (e.g., an extracellular antigen binding domain comprising a first BCMA binding moiety and a second BCMA binding moiety) can be connected to each other via a peptide linker. The peptide linkers connecting different binding moieties (such as VHH) can be the same or different. The different domains of CAR can also be connected to each other via a peptide linker. In some embodiments, the binding moieties (e.g., VHH) are directly connected to each other without any peptide linker.
[0134] The peptide linker in the CAR described herein can have any suitable length. In some embodiments, the length of the peptide linker is at least about any one of the following: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 50, 75, 100 or more amino acids. In some embodiments, the length of the peptide linker is no more than about any one of the following: 100, 75, 50, 40, 35, 30, 25, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5 or less amino acids. In some embodiments, the length of the peptide linker is any one of: about 1 amino acid to about 10 amino acids, about 1 amino acid to about 20 amino acids, about 1 amino acid to about 30 amino acids, about 5 amino acids to about 15 amino acids, about 10 amino acids to about 25 amino acids, about 5 amino acids to about 30 amino acids, about 10 amino acids to about 30 amino acids long, about 30 amino acids to about 50 amino acids, about 50 amino acids to about 100 amino acids, or about 1 amino acid to about 100 amino acids.
[0135] The CAR of the present application comprises a transmembrane domain that can be directly or indirectly connected to an extracellular antigen binding domain.
[0136] CAR may include a T cell activation portion. The T cell activation portion may be any suitable portion derived from or obtained from any suitable molecule. In one embodiment, for example, the T cell activation portion includes a transmembrane domain. The transmembrane domain may be any transmembrane domain derived from or obtained from any molecule known in the art. For example, the transmembrane domain may be obtained from or derived from a CD8a molecule or a CD28 molecule. Without wishing to be bound by theory, CD8 is a transmembrane glycoprotein that serves as a co-receptor for a T cell receptor (TCR) and is primarily expressed on the surface of cytotoxic T cells. The most common form of CD8 exists as a dimer consisting of CD8α and CD8β chains. CD28 is expressed on T cells and provides co-stimulatory signals required for T cell activation. CD28 is a receptor for CD80 (B7.1) and CD86 (B7.2). In a preferred embodiment, CD8α and CD28 are human.
[0137] In addition to the transmembrane domain, the T cell activation portion may further include an intracellular (i.e., cytoplasmic) T cell signaling domain. The intercellular T cell signaling domain may be obtained from or derived from CD28 molecules, CD3ζ molecules or modified forms thereof, human Fc receptor γ (FcRγ) chains, CD27 molecules, OX40 molecules, 4-1BB molecules, or other intracellular signaling molecules known in the art. It is not desirable to be bound by theory: (1) CD28 is an important T cell marker in T cell costimulation; (2) CD3ζ associates with TCR to generate signals and contains an immunoreceptor tyrosine-based activation motif (ITAM); and (3) 4-1BB, also referred to as CD137, delivers potent costimulatory signals to T cells, thereby promoting T lymphocyte differentiation and enhancing the long-term survival of T lymphocytes. In a preferred embodiment, CD28, CD3ζ, 4-1BB, OX40, and CD27 are human.
[0138] The T cell activation domain of the CAR encoded by the nucleic acid sequence disclosed herein may include any of the aforementioned transmembrane domains and any one or more of the aforementioned intercellular T cell signaling domains in any combination. For example, the nucleic acid sequence disclosed herein may encode a CAR comprising a CD28 transmembrane domain and an intracellular T cell signaling domain of CD28 and CD3ζ. Alternatively, for example, the nucleic acid sequence disclosed herein may encode a CAR comprising a CD8α transmembrane domain and an intracellular T cell signaling domain of CD28, CD3ζ, Fc receptor γ (FcRγ) chain and / or 4-1BB.
[0139] In some embodiments, the CAR polypeptide further comprises a signal peptide located at the N-terminus of the polypeptide. In some embodiments, the signal peptide is derived from CD8α. In some embodiments, the signal peptide comprises an amino acid sequence of SEQ ID NO: 1. In some embodiments, the signal peptide comprises a polypeptide encoded by a nucleic acid sequence of SEQ ID NO: 9.
[0140] In certain embodiments, the transmembrane domain comprises the amino acid sequence of SEQ ID NO: 6. In certain embodiments, the transmembrane domain comprises a polypeptide encoded by the nucleic acid sequence of SEQ ID NO:14.
[0141] In some embodiments, the intracellular signaling domain comprises a primary intracellular signaling domain of an immune effector cell. In some embodiments, the intracellular signaling domain is derived from CD3 zeta. In some embodiments, the intracellular signaling domain comprises at least one co-stimulatory signaling domain. In some embodiments, the intracellular signaling domain comprises the amino acid sequence of SEQ ID NO: 8. In some embodiments, the intracellular signaling domain comprises a polypeptide encoded by the nucleic acid sequence of SEQ ID NO: 16. In some embodiments, the intracellular signaling domain comprises the amino acid sequence of SEQ ID NO: 7. In some embodiments, the intracellular signaling domain comprises a polypeptide encoded by the nucleic acid sequence of SEQ ID NO: 15.
[0142] In some embodiments, the CAR polypeptide further comprises a hinge domain located between the C-terminus of the extracellular antigen binding domain and the N-terminus of the transmembrane domain. In some embodiments, the hinge domain comprises an amino acid sequence of SEQ ID NO: 5. In some embodiments, the hinge domain comprises a polypeptide encoded by a nucleic acid sequence of SEQ ID NO: 13.
[0143] In some embodiments, the CAR comprises one or more or all of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8. In one embodiment, the CAR comprises SEQ ID NO: 17. In some embodiments, the CAR comprises a polypeptide encoded by a nucleic acid sequence of one or more or all of SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, and SEQ ID NO: 16.
[0144] Immune effector cell composition
[0145] "Immune effector cell" refers to an immune cell that can play an immune effector function. In some embodiments, the immune effector cell expresses at least FcγRIII and plays an ADCC effector function. Examples of immune effector cells that mediate ADCC include peripheral blood mononuclear cells (PBMC), natural killer (NK) cells, monocytes, cytotoxic T cells, neutrophils, and eosinophils. In some embodiments, the immune effector cell is a T cell. In some embodiments, the T cell is an autologous T cell. In some embodiments, the T cell is an allogeneic T cell. In some embodiments, the T cell is CD4+ / CD8-, CD4- / CD8+, CD4+ / CD8+, CD4- / CD8-, or a combination thereof. In some embodiments, T cells produce IL-2, TFN and / or TNF after expressing CAR and binding to target cells (such as CD20+ or CD19+ tumor cells). In some embodiments, CD8+T cells lyse antigen-specific target cells after expressing CAR and binding to target cells.
[0146] The biological method of introducing carrier into immune effector cell includes using DNA and RNA carrier.Viral vector has become the most widely used method for inserting gene into mammal, for example, human cell.Chemical method for introducing carrier into immune effector cell includes colloidal dispersion system, such as macromolecular complex, nanocapsule, microsphere, pearl and lipid-based system, including water-in-oil emulsion, micelle, mixed micelle and liposome.The exemplary colloidal system used as in vitro delivery vehicle is liposome (for example, artificial membrane vesicle).
[0147] The dosage forms provided herein comprise 3.0×107 to 1.0×108 CAR-T cells, the CAR-T cells comprising a CAR containing a polypeptide, the polypeptide comprising: (a) an extracellular antigen binding domain comprising a first BCMA binding portion that specifically binds to a first epitope of BCMA and a second BCMA binding portion that specifically binds to a second epitope of BCMA; (b) a transmembrane domain; and (c) an intracellular signaling domain, wherein the first epitope and the second epitope are different. In certain embodiments, the dosage form comprises 3.0×107 to 4.0×107 CAR-T cells. In certain embodiments, the dosage form comprises 3.5×107 to 4.5×107 CAR-T cells. In certain embodiments, the dosage form comprises 4.0×107 to 5.0×107 CAR-T cells. In certain embodiments, the dosage form comprises 4.5×107 to 5.5×107 CAR-T cells. In certain embodiments, the dosage form comprises 5.0×107 to 6.0×107 CAR-T cells. In certain embodiments, the dosage form comprises 5.5×107 to 6.5×107 CAR-T cells. In certain embodiments, the dosage form comprises 6.0×107 to 7.0×107 CAR-T cells. In certain embodiments, the dosage form comprises 6.5×107 to 7.5×107 CAR-T cells. In certain embodiments, the dosage form comprises 7.0×107 to 8.0×107 CAR-T cells. In certain embodiments, the dosage form comprises 7.5×107 to 8.5×107 CAR-T cells. In certain embodiments, the dosage form comprises 8.0×107 to 9.0×107 CAR-T cells. In certain embodiments, the dosage form comprises 8.5×107 to 9.5×107 CAR-T cells. In certain embodiments, the dosage form comprises 9.0×107 to 1.0×108 CAR-T cells.
[0148] In some embodiments, the dosage form provided comprises 3.0×107 to 1.0×108 engineered immune effector cells (such as T cells), the engineered immune effector cells comprising a CAR containing a polypeptide, the polypeptide comprising: (a) an extracellular antigen binding domain comprising a first anti-BCMA VHH that specifically binds to a first epitope of BCMA, and a second anti-BCMA VHH that specifically binds to a second epitope of BCMA; (b) a transmembrane domain; and (c) an intracellular signaling domain, wherein the first epitope and the second epitope are different. In certain embodiments, the dosage form comprises 3.0×107 to 4.0×107 CAR-T cells. In certain embodiments, the dosage form comprises 3.5×107 to 4.5×107 CAR-T cells. In certain embodiments, the dosage form comprises 4.0×107 to 5.0×107 CAR-T cells. In certain embodiments, the dosage form comprises 4.5×107 to 5.5×107 CAR-T cells. In certain embodiments, the dosage form comprises 5.0×107 to 6.0×107 CAR-T cells. In certain embodiments, the dosage form comprises 5.5×107 to 6.5×107 CAR-T cells. In certain embodiments, the dosage form comprises 6.0×107 to 7.0×107 CAR-T cells. In certain embodiments, the dosage form comprises 6.5×107 to 7.5×107 CAR-T cells. In certain embodiments, the dosage form comprises 7.0×107 to 8.0×107 CAR-T cells. In certain embodiments, the dosage form comprises 7.5×107 to 8.5×107 CAR-T cells. In certain embodiments, the dosage form comprises 8.0×107 to 9.0×107 CAR-T cells. In certain embodiments, the dosage form comprises 8.5×107 to 9.5×107 CAR-T cells. In certain embodiments, the dosage form comprises 9.0×107 to 1.0×108 CAR-T cells.
[0149] In some embodiments, the cell population of the CAR-T dosage form described herein comprises T cells or T cell populations, for example, at different stages of differentiation. The stage of T cell differentiation includes initial T cells, stem central memory T cells, central memory T cells, effector memory T cells, and terminal effector T cells from the lowest degree of differentiation to the highest degree of differentiation. After antigen exposure, the initial T cells proliferate and differentiate into memory T cells, such as stem central memory T cells and central memory T cells, which then differentiate into effector memory T cells. After receiving appropriate T cell receptors, costimulatory signals, and inflammatory signals, memory T cells further differentiate into terminal effector T cells. See, for example, Restifo.Blood.124.4(2014):476-77; and Joshi et al. J.Immunol.180.3(2008):1309-15.
[0150] Initial T cells may have the following expression pattern of cell surface markers: CCR7+, CD62L+, CD45RO-, CD95-. Stem central memory T cells (Tscm) may have the following expression pattern of cell surface markers: CCR7+, CD62L+, CD45RO-, CD95+. Central memory T cells (Tcm) may have the following expression pattern of cell surface markers: CCR7+, CD62L+, CD45RO+, CD95+. Effector memory T cells (Tem) may have the following expression pattern of cell surface markers: CCR7-, CD62L-, CD45RO+, CD95+. Terminal effector T cells (Teff) may have the following expression pattern of cell surface markers: CCR7-, CD62L-, CD45RO-, CD95+. See, e.g., Gattinoni et al. Nat. Med. 17 (2011): 1290-7; and Flynn et al. Clin. Translat. Immunol. 3 (2014): e20.
[0151] Pharmaceutical compositions and preparations
[0152] The application further provides a pharmaceutical composition, which includes any anti-BCMA antibody disclosed herein, or any engineered immune effector cell including any CAR (e.g., BCMA CAR) as described herein, and a pharmaceutically acceptable carrier. The pharmaceutical composition can be prepared by mixing any immune effector cell with a desired purity as described herein with an optional pharmaceutically acceptable carrier, excipient or stabilizer (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Editor (1980)) in the form of a lyophilized preparation or an aqueous solution. In certain embodiments, the pharmaceutical composition of CAR-T cells further includes an excipient selected from dimethyl sulfoxide or dextran-40.
[0153] The compositions described herein can be administered as part of a pharmaceutical composition comprising one or more vectors. The selection of the vector will be determined in part by the specific nucleic acid sequence, vector or host cell expressing the CAR disclosed herein, and the specific method for administering the nucleic acid sequence, vector or host cell expressing the CAR disclosed herein. Therefore, there are a variety of suitable preparations of the pharmaceutical composition disclosed herein.
[0154] For example, the pharmaceutical composition may contain a preservative. Suitable preservatives may include, for example, methylparaben, propylparaben, sodium benzoate, and benzalkonium chloride. A mixture of two or more preservatives may optionally be used. The preservative or mixture thereof is typically present in an amount of about 0.0001% to about 2% by weight of the total composition.
[0155] In addition, a buffer can be used in the composition. Suitable buffers include, for example, citric acid, sodium citrate, phosphoric acid, potassium phosphate, and various other acids and salts. A mixture of two or more buffers can be optionally used. The buffer or its mixture is typically present in an amount of about 0.001% to about 4% by weight of the total composition.
[0156] Compositions comprising nucleic acid sequences encoding CAR disclosed herein or host cells expressing CAR disclosed herein can be formulated as inclusion complexes, such as cyclodextrin inclusion complexes, or liposomes. Liposomes can be used to target host cells (such as T cells or NK cells) or nucleic acid sequences disclosed herein to specific tissues. Liposomes can also be used to increase the half-life of nucleic acid sequences disclosed herein. Many methods can be used to prepare liposomes, such as in, for example, Szoka et al., Ann.Rev.Biophys.Bioeng., 9:467 (1980), and those described in U.S. Patents 4,235,871; 4,501,728; 4,837,028; and 5,019,369. Compositions can use timed release delivery systems, delayed release delivery systems, and sustained release delivery systems so that the delivery of the composition disclosed herein occurs before the sensitization of the site to be treated, and there is enough time to cause sensitization of the site to be treated. Many types of release delivery systems are available and known to those of ordinary skill in the art. Such a system can avoid repeated administration of the composition, thereby increasing convenience to the subject and the physician, and may be particularly suitable for certain composition embodiments of the present disclosure.
[0157] In certain embodiments, the CAR-T cells are administered at about 1.0×105 to 2.0×105 cells / kg, 1.5×105 to 2.5×105 cells / kg, 2.0×105 to 3.0×105 cells / kg, 2.5×105 to 3.5×105 cells / kg, 3.0×105 to 4.0×105 cells / kg, 3.5×105 to 4.5×105 cells / kg, 4.0×105 to 5.0×105 cells / kg, 4.5×105 to 5.5×105 cells / kg, 5 cells / kg, 5.0×10 5 Up to 6.0×10 5 cells / kg, 5.5×10 5 to 6.5×10 5 cells / kg, 6.0×10 5 to 7.0×10 5 cells / kg, 6.5×10 5 to 7.5×10 5 cells / kg, 7.0×10 5 Up to 8.0×105 cells / kg, 7.5×10 5 Up to 8.5×10 5 cells / kg, 8.0×10 5 to 9.0×10 5 cells / kg, 8.5×10 5 to 9.5×10 5 cells / kg, 9.0×10 5 to 1.0×10 6 In a preferred embodiment, the dose is about 0.75×10 6 In certain embodiments, the CAR-T cells are formulated at less than 1.0×10 8 The dose was formulated to contain 1 cell / subject.
[0158] Treatment
[0159] The present application further relates to methods and compositions for use in cellular immunotherapy. In some embodiments, cellular immunotherapy is used to treat cancer in a subject, including but not limited to hematological malignancies and solid tumors. In some embodiments, the subject is a human. In some embodiments, the method is suitable for treating adult and pediatric populations, including all age subgroups, and can be used as any line of therapy, including the first line or subsequent line.
[0160] Any anti-BCMA VHH, CAR and engineered immune effector cells (e.g., CAR-T cells) described herein can be used in methods for treating cancer. In some embodiments, the immune effector cells are autologous. In some embodiments, the immune effector cells are allogeneic.
[0161] In certain embodiments, the CAR-T cells are administered at about 1.0×105 to 2.0×105 cells / kg, 1.5×105 to 2.5×105 cells / kg, 2.0×105 to 3.0×105 cells / kg, 2.5×105 to 3.5×105 cells / kg, 3.0×105 to 4.0×105 cells / kg, 3.5×105 to 4.5×105 cells / kg , 4.0×105 to 5.0×105 cells / kg, 4.5×105 to 5.5×105 cells / kg, 5.0×105 to 6.0×105 cells / kg, 5.5×105 to 6.5×105 cells / kg, 6.0×105 to 7.0×105 cells / kg, 6.5×105 to 7.5×105 cells / kg, 7.0×105 to 8.0×105 cells / kg cells / kg, 7.5×105 to 8.5×105 cells / kg, 8.0×105 to 9.0×105 cells / kg, 8.5×105 to 9.5×105 cells / kg, 9.0×105 to 1.0×106 cells / kg, 1.0×106 to 2.0×106 cells / kg, 1.5×106 to 2.5×106 cells / kg, 2.0×106 to 3. 0×106 cells / kg, 2.5×106 to 3.5×106 cells / kg, 3.0×106 to 4.0×106 cells / kg, 3.5×106 to 4.5×106 cells / kg, 4.0×106 to 5.0×106 cells / kg, 4.5×106 to 5.5×106 cells / kg or 5.0×106 to 6.0×106 cells / kg. In a preferred embodiment, the dose includes about 0.75×106 cells / kg. In certain embodiments, CAR-T cells are administered at a dose of about 1.0×108 cells per subject.
[0162] In certain embodiments, the CAR-T cells are administered at a dose of less than 1.0×108 cells per subject. In certain embodiments, the CAR-T cells are administered at a dose of about 3.0 to 4.0×107 cells. In certain embodiments, the CAR-T cells are administered at a dose of about 3.5 to 4.5×107 cells. In certain embodiments, the CAR-T cells are administered at a dose of about 4.0 to 5.0×107 cells. In certain embodiments, the CAR-T cells are administered at a dose of about 4.5 to 5.5×107 cells. In certain embodiments, the CAR-T cells are administered at a dose of about 5.0 to 6.0×107 cells. In certain embodiments, the CAR-T cells are administered at a dose of about 5.5 to 6.5×107 cells. In certain embodiments, the CAR-T cells are administered at a dose of about 6.0 to 7.0×107 cells. In certain embodiments, the CAR-T cells are administered at a dose of about 6.5 to 7.5×107 cells. In certain embodiments, the CAR-T cells are administered at a dose of about 7.0 to 8.0×107 cells. In certain embodiments, the CAR-T cells are administered at a dose of about 7.5 to 8.5×107 cells. In certain embodiments, the CAR-T cells are administered at a dose of about 8.0 to 9.0×107 cells. In certain embodiments, the CAR-T cells are administered at a dose of about 8.5 to 9.5×107 cells. In certain embodiments, the CAR-T cells are administered at a dose of about 9.0×107 to 1.0×108 cells.
[0163] In certain embodiments, the CAR-T cells are administered at a dose of about 0.693×106 CAR-positive live T cells / kg. In certain embodiments, the CAR-T cells are administered at a dose of about 0.52×106 CAR-positive live T cells / kg. In certain embodiments, the CAR-T cells are administered at a dose of about 0.94×106 CAR-positive live T cells / kg. In certain embodiments, the CAR-T cells are administered at a dose of about 0.709×106 CAR-positive live T cells / kg. In certain embodiments, the CAR-T cells are administered at a dose of about 0.51×106 CAR-positive live T cells / kg. In certain embodiments, the CAR-T cells are administered at a dose of about 0.95×106 CAR-positive live T cells / kg. In certain embodiments, the CAR-T cells are administered in an outpatient setting.
[0164] In some embodiments, the composition comprising CAR-T cells administered to a subject further comprises an excipient selected from dimethyl sulfoxide or dextran-40.
[0165] In certain embodiments, CAR-T cells are administered in one or more intravenous infusions (e.g., at any of the aforementioned doses). In certain embodiments, the administration of the CAR-T cells is via a single intravenous infusion. In certain embodiments, a single intravenous infusion is administered using a single bag of CAR-T cells. In certain embodiments, the administration of the CAR-T cells of the single bag is completed between the time when the single bag of CAR-T cells is thawed and 3 hours after the single bag of CAR-T cells is thawed. In certain embodiments, a single intravenous administration is administered using two bags of CAR-T cells. In certain embodiments, the administration of each bag of the two bags of CAR-T cells is completed between the time when the first bag of the two bags of CAR-T cells is thawed and 3 hours after the first bag of CAR-T cells is thawed.
[0166] In certain embodiments, the time from initial apheresis to administration of CAR-T cells is less than 41, 47, 54, 61, 68, 75, 82, 89, 96, 103, 110, 117, 124, 131, 138, 145, 152, 159, 166, or 167 days. In certain embodiments, the time from initial apheresis to administration of CAR-T cells is greater than 41, 47, 54, 61, 68, 75, 82, 89, 96, 103, 110, 117, 124, 131, 138, 145, 152, 159, 166, or 167 days.
[0167] In certain embodiments, the lymphodepletion regimen precedes the administration of CAR-T cells. In certain embodiments, the lymphodepletion regimen includes the administration of cyclophosphamide and / or the administration of fludarabine. In certain embodiments, the lymphodepletion regimen is administered intravenously. In certain embodiments, the lymphodepletion regimen is 5 to 7 days before the administration of CAR-T cells. In certain embodiments, the lymphodepletion regimen is 2 to 4 days before the administration of CAR-T cells. In certain embodiments, the lymphodepletion regimen includes the intravenous administration of cyclophosphamide and fludarabine 5 to 7 days before the administration of CAR-T cells. In certain embodiments, the lymphodepletion regimen includes the intravenous administration of cyclophosphamide and fludarabine 2 to 4 days before the administration of CAR-T cells. In certain embodiments, the lymphodepletion regimen includes the intravenous administration of cyclophosphamide at 300mg / m2. In certain embodiments, the lymphodepletion regimen includes the intravenous administration of fludarabine at 30mg / m2. In certain embodiments, the lymphodepletion regimen is performed daily for 3 days. In the case where the administration of CAR-T cells is delayed for more than 14 days, the lymphodepletion regimen can be repeated.
[0168] In certain embodiments, the method of treating with CAR-T cells further includes treating the subject's cytokine release syndrome (CRS) within 3 days of CAR-T cell administration without significantly reducing the expansion of CAR-T cells in vivo. In certain embodiments, the treatment of CRS includes administering an IL-6R inhibitor to the subject. In certain embodiments, the IL-6R inhibitor is an antibody. In certain embodiments, the IL-6 inhibitor inhibits IL-6R by binding to the extracellular domain of IL-6R. In certain embodiments, the IL-6R inhibitor prevents the binding of IL-6 to IL-6R. In certain embodiments, the IL-6R inhibitor is tocilizumab. CRS can be identified based on clinical manifestations [see the approved label provided herein]. In certain embodiments, other causes of fever, hypoxia and hypotension are evaluated and treated. Laboratory tests can be used to monitor disseminated intravascular coagulation, hematological parameters, and lung, heart, kidney and liver function. CRS can be managed according to the recommendations in Table 1 of the approved label disclosed herein. These methods may include administering levetiracetam to patients experiencing CRS for anti-epileptic prevention. In some embodiments, these methods include monitoring patients experiencing grade 2 or higher CRS (e.g., hypotension that is unresponsive to fluids, or hypoxia requiring supplemental oxygenation) with continuous cardiac telemetry and pulse oximetry. In some embodiments, intensive care unit level monitoring and supportive therapy may be used for severe or life-threatening CRS. For CRS refractory to first-line interventions (such as tocilizumab or tocilizumab and corticosteroids), these methods include alternative treatment options (i.e., higher corticosteroid doses, alternative anti-cytokine agents, such as anti-IL1 and / or anti-TNFα, anti-T cell therapy). Refractory CRS is characterized by fever, end-organ toxicity (e.g., hypoxia, hypotension) that does not improve within 12 hours after first-line intervention or the occurrence of HLH / MAS.
[0169] In certain embodiments, the method of treating with CAR-T cells further includes treating the subject with a pre-infusion drug comprising an antipyretic and an antihistamine up to 1 hour before administering the CAR-T cells. In certain embodiments, the antipyretic comprises paracetamol or acetaminophen. In certain embodiments, the antipyretic is administered orally or intravenously to the subject. In certain embodiments, the antipyretic is administered to the subject at a dose between 650mg and 1000mg. In certain embodiments, the antihistamine comprises diphenhydramine. In certain embodiments, the antihistamine is administered orally or intravenously to the subject. In certain embodiments, the antihistamine is administered at a dose between 25mg and 50mg or its equivalent dose. Standard administration techniques can be used to administer a composition to a mammal, the composition comprising a host cell expressing a CAR encoding nucleic acid sequence disclosed herein or a vector comprising a CAR encoding nucleic acid sequence disclosed herein, the standard administration techniques including oral, intravenous, intraperitoneal, subcutaneous, pulmonary, transdermal, intramuscular, intranasal, buccal, sublingual or suppository administration. The composition is preferably suitable for parenteral administration. As used herein, the term "parenteral" includes intravenous, intramuscular, subcutaneous, rectal, vaginal and intraperitoneal administration. More preferably, the composition is administered to a mammal using peripheral systemic delivery by intravenous, intraperitoneal or subcutaneous injection. Most preferably, the composition is administered by intravenous infusion.
[0170] A composition comprising a host cell expressing a CAR encoding nucleic acid sequence disclosed herein or a vector comprising a CAR encoding nucleic acid sequence disclosed herein can be administered together with one or more additional therapeutic agents, which can be co-administered to a mammal."Co-administration" means administering one or more additional therapeutic agents and a composition comprising a host cell disclosed herein or a vector disclosed herein at a sufficiently close time so that the CAR disclosed herein can enhance the effect of one or more additional therapeutic agents, or vice versa. In this regard, a composition comprising a host cell disclosed herein or a vector disclosed herein can be administered first, and one or more additional therapeutic agents can be administered secondarily, or vice versa.
[0171] The cells expressing CAR described herein and at least one other therapeutic agent can be administered simultaneously (with the same or separate compositions), or sequentially. For sequential administration, the cells expressing CAR described herein can be administered first and other agents can be administered secondly, or the order of administration can be reversed.
[0172] In certain embodiments, the lymphodepletion regimen precedes the administration of the CAR-T cells. In certain embodiments, the lymphodepletion regimen is about 2 to about 7 days before the administration of the CAR-T cells. In certain embodiments, the lymphodepletion regimen is administered intravenously. In certain embodiments, the lymphodepletion regimen includes the administration of cyclophosphamide or the administration of fludarabine. In certain embodiments, the cyclophosphamide is administered intravenously at 300 mg / m2. In certain embodiments, the fludarabine is administered intravenously at 30 mg / m2.
[0173] In certain embodiments, a lymphodepleting regimen comprising intravenous administration of cyclophosphamide at 300 mg / m2 and intravenous administration of fludarabine at 30 mg / m2 is administered about 2 to about 7 days prior to administration of the CAR-T cells.
[0174] In certain embodiments, the subject is further treated with bridging therapy, wherein the bridging therapy comprises short-term treatment with at least one bridging drug between apheresis and the lymphodepletion regimen, and wherein the at least one bridging drug has previously obtained a result of stable disease, minimal response, partial response, very good partial response, complete response, or stringent complete response for the subject. In certain embodiments, despite the bridging therapy, the subject's tumor burden increases. In certain embodiments, despite the bridging therapy, the subject's tumor burden increases by about 25% or more. Suitable bridging therapies include, for example, dexamethasone, bortezomib, cyclophosphamide, and pomalidomide. In some embodiments, bridging therapy includes dexamethasone. In some embodiments, bridging therapy includes bortezomib. In some embodiments, bridging therapy includes cyclophosphamide. In some embodiments, bridging therapy includes pomalidomide.
[0175] In certain embodiments, the subject is treated with a pre-administration drug comprising an antipyretic and an antihistamine up to about 1 hour before the administration of the CAR-T cells. In certain embodiments, the antipyretic comprises paracetamol or acetaminophen. In certain embodiments, the antipyretic is administered orally or intravenously to the subject. In certain embodiments, the antipyretic is administered to the subject at a dose between 650mg and 1000mg. In certain embodiments, the antihistamine comprises diphenhydramine. In certain embodiments, the antihistamine is administered orally or intravenously to the subject. In certain embodiments, the antihistamine is administered at a dose between 25mg and 50mg or its equivalent. In certain embodiments, the antipyretic comprises paracetamol or acetaminophen, the antipyretic is administered orally or intravenously to the subject at a dose between 650mg and 1000mg, and wherein the antihistamine comprises diphenhydramine, the antihistamine is administered orally or intravenously to the subject at a dose between 25mg and 50mg or its equivalent.
[0176] In some embodiments, the method comprises administering a lymphodepleting chemotherapy regimen comprising cyclophosphamide 300 mg / m2 intravenous (IV) and fludarabine 30 mg / m2 IV daily for 3 days prior to administering the CAR-T cells, and administering a pre-infusion medication comprising an antipyretic (such as oral or intravenous acetaminophen 650 to 1000 mg) and an antihistamine (such as oral or intravenous diphenhydramine 25 to 50 mg or equivalent), wherein:
[0177] CAR-T cells are administered 2-4 days after completion of lymphodepleting chemotherapy, and
[0178] CAR-T cells were administered 30-60 minutes after pre-infusion drug administration.
[0179] In some embodiments, CAR-T cells are not administered, or administration of CAR-T cells is delayed, if the patient has any of the following: clinically significant active infection or inflammatory disorder; or ≥ grade 3 non-hematologic toxicity from cyclophosphamide and fludarabine conditioning, excluding grade 3 nausea, vomiting, diarrhea, or constipation. Administration of CAR-T cells should be delayed until these events resolve to ≤ grade 1. In some embodiments, prophylactic systemic corticosteroids are not administered.
[0180] In some embodiments, the method further includes diagnosing cytokine release syndrome (CRS) of the subject. In a preferred embodiment, according to the American Society for Transplantation and Cellular Therapy (ASTCT), the American Society for Blood and Marrow Transplantation (ASBMT) consensus grading was previously used for diagnosis. Table 13 provides a non-limiting summary of the ASTCT consensus grading for CRS diagnosis. In some embodiments, CRS is assessed by assessing one or more or all of the levels of IL-6, IL-10, IFN-□, C-reactive protein (CRP) and ferritin.
[0181] In some embodiments, the method further includes treating cytokine release syndrome (CRS) of the subject. In some embodiments, CRS is treated with antipyretics. In some instances, CRS is treated with anti-cytokine therapy. In some embodiments, the treatment of CRS occurs more than about 3 days after infusion. In some embodiments, the treatment of CRS is performed without significantly reducing the amplification of CAR-T cells in vivo. In certain embodiments, the method further includes treating the cytokine release syndrome of the subject for more than about 3 days after the administration of the CAR-T cells, without significantly reducing the amplification of the CAR-T cells in vivo. In some embodiments, the treatment of CRS includes administering an IL-6R inhibitor to the subject. In some embodiments, the IL-6R inhibitor is an antibody. In some embodiments, the antibody inhibits IL-6R by binding to the extracellular domain of IL-6R. In some embodiments, the IL-6R inhibitor prevents the binding of IL-6 to IL-6R. In some embodiments, the IL-6R inhibitor is tocilizumab. In some embodiments, anti-cytokine therapy includes administering tocilizumab. In some embodiments, anti-cytokine therapy includes administering steroids. In some embodiments, the treatment of CRS includes treatment with a monoclonal antibody other than tocilizumab. In some embodiments, antibodies other than tocilizumab target cytokines. In some embodiments, the cytokine targeted by antibodies other than tocilizumab is IL-1. In some embodiments, the antibody targeting IL-1 is anakinra. In some embodiments, the cytokine targeted by antibodies other than tocilizumab is TNFα. In some embodiments, the treatment of CRS includes administering corticosteroids to the subject. In some embodiments, the treatment of CRS includes the use of vasopressors. In some embodiments, the treatment of CRS includes intubation or mechanical ventilation. In some embodiments, the treatment of CRS includes administering cyclophosphamide to the subject. In some embodiments, the treatment of CRS includes administering etanercept to the subject. In some embodiments, the treatment of CRS includes administering levetiracetam to the subject. In some embodiments, the treatment of CRS includes supportive care.
[0182] In some embodiments, the method further comprises diagnosing immune cell effector-associated neurotoxicity (ICANS) of the subject. In some embodiments, the diagnosis is made according to the criteria of the National Cancer Institute Common Terminology Criteria for Adverse Events (NCICTCAE). In some embodiments, the diagnosis is made according to the NCI CTCAE Standard Version 5.0. In some embodiments, the diagnosis is made according to the American Society for Transplantation and Cellular Therapy (ASTCT) consensus grading system. In some embodiments, the embodiment has neurotoxicity consistent with ICAN. A non-limiting summary of the ASTCT consensus grading system for ICANS diagnosis is provided in Table 14. In some embodiments, the treatment of ICANS comprises administering an IL-6R inhibitor to the subject. In some embodiments, the IL-6R inhibitor is an antibody. In some embodiments, the antibody inhibits IL-6R by binding to the extracellular domain of IL-6R. In some embodiments, the IL-6R inhibitor prevents the binding of IL-6 to IL-6R. In some embodiments, the IL-6R inhibitor is tocilizumab. In some embodiments, the treatment of ICANS comprises administering an IL-1 inhibitor to the subject. In some embodiments, the IL-1 inhibitor is an antibody. In a preferred embodiment, the IL-1 inhibitory antibody is anakinra. In some embodiments, the treatment of ICANS includes administering corticosteroids to the subject. In some embodiments, the treatment of ICANS includes administering levetiracetam to the subject. In some embodiments, the treatment of ICANS includes administering dexamethasone to the subject. In some embodiments, the treatment of ICANS includes administering methylprednisolone sodium succinate to the subject. In some embodiments, the treatment of ICANS includes administering meperidine to the subject. In some embodiments, the treatment of ICANS includes administering one or more or all of tocilizumab, anakinra, corticosteroids, levetiracetam, dexamethasone, methylprednisolone sodium succinate or meperidine to the subject.
[0183] If concurrent neurotoxicity is suspected during CRS, or vice versa, the method may include administering:
[0184] Corticosteroids for more aggressive interventions based on the CRS and neurotoxicity grades in Tables 1 and 2 based on the approved labeling disclosed herein
[0185] Tocilizumab with CRS grades in Table 1 according to the approved labeling disclosed herein
[0186] Neurotoxic anti-epileptic drugs in Table 2 according to the approved labeling disclosed herein
[0187] In some embodiments, the method further comprises diagnosing cytopenia in the subject. In some embodiments, cytopenia includes one or more or all of lymphopenia, neutropenia, and thrombocytopenia. Without being bound by theory, grade 3 or 4 but not grade 2 or lower lymphopenia is characterized by a lymphocyte count of less than 0.5×109 cells / liter of subject blood sample, grade 3 or 4 but not grade 2 or lower neutropenia is characterized by a neutrophil count of less than 1000 cells / microliter of subject blood sample, and grade 3 or 4 but not grade 2 or lower thrombocytopenia is characterized by a platelet count of less than 50,000 cells / microliter of subject blood sample. In some embodiments, more than 75% of subjects with grade 3 or 4 lymphopenia after CAR-T cell administration recover to grade 2 or lower lymphopenia 60 days after CAR-T cell administration. In some embodiments, more than 80% of subjects with grade 3 or 4 lymphopenia after CAR-T cell administration recover to grade 2 or lower lymphopenia 60 days after CAR-T cell administration. In some embodiments, more than 85% of subjects with grade 3 or 4 lymphopenia after CAR-T cell administration recover to grade 2 or lower lymphopenia 60 days after CAR-T cell administration. In some embodiments, more than 90% of subjects with grade 3 or 4 lymphopenia after CAR-T cell administration recover to grade 2 or lower lymphopenia 60 days after CAR-T cell administration. In some embodiments, more than 70% of subjects with grade 3 or 4 neutropenia after CAR-T cell administration recover to grade 2 or lower neutropenia 60 days after CAR-T cell administration. In some embodiments, more than 75% of subjects with grade 3 or 4 neutropenia after CAR-T cell administration recover to grade 2 or lower neutropenia 60 days after CAR-T cell administration. In some embodiments, more than 80% of subjects with Grade 3 or 4 neutropenia after CAR-T cell administration recover to Grade 2 or lower neutropenia 60 days after CAR-T cell administration. In some embodiments, more than 85% of subjects with Grade 3 or 4 neutropenia after CAR-T cell administration recover to Grade 2 or lower neutropenia 60 days after CAR-T cell administration. In some embodiments, more than 30% of subjects with Grade 3 or 4 thrombocytopenia after CAR-T cell administration recover to Grade 2 or lower thrombocytopenia 60 days after CAR-T cell administration. In some embodiments, more than 34% of subjects with Grade 3 or 4 thrombocytopenia after CAR-T cell administration recover to Grade 2 or lower thrombocytopenia 60 days after CAR-T cell administration.In some embodiments, more than 38% of subjects with grade 3 or 4 thrombocytopenia after CAR-T cell administration recover to grade 2 or lower thrombocytopenia 60 days after CAR-T cell administration. In some embodiments, more than 42% of subjects with grade 3 or 4 thrombocytopenia after CAR-T cell administration recover to grade 2 or lower thrombocytopenia 60 days after CAR-T cell administration.
[0188] Once a host cell expressing a CAR encoding nucleic acid sequence disclosed herein or a composition of a vector comprising a CAR encoding nucleic acid sequence disclosed herein is applied to a mammal (eg, human), the biological activity of CAR can be measured by any suitable method known in the art. According to the method disclosed herein, CAR binds to BCMA on multiple myeloma cells, and these multiple myeloma cells are destroyed. The binding of CAR to BCMA on the surface of multiple myeloma cells can be measured using any suitable method known in the art, including, for example, ELISA and flow cytometry. The ability of CAR to destroy multiple myeloma cells can be measured using any suitable method known in the art, such as in, for example, Kochenderfer et al., J. Immunotherapy, 32 (7): 689-702 (2009), and Herman et al. J. Immunological Methods, 285 (1): 25-40 (2004) described in the cytotoxicity assay. The biological activity of CAR can also be measured by measuring the expression of certain cytokines such as CD 107a, IFNγ, IL-2, and TNF.
[0189] The methods described herein can be used to treat various cancers, including solid cancers and liquid cancers. In certain embodiments, these methods are used to treat multiple myeloma. The methods described herein can be used as the first therapy, the second therapy, the third therapy, or a combination therapy with other types of cancer therapy known in the art (such as, chemotherapy, surgery, radiation, gene therapy, immunotherapy, bone marrow transplantation, stem cell transplantation, targeted therapy, cryotherapy, ultrasound therapy, photodynamic therapy, radiofrequency ablation, etc.) in adjuvant therapy or neoadjuvant therapy.
[0190] In certain embodiments, the cancer is multiple myeloma. In certain embodiments, the cancer is Phase I, Phase II, or Phase III, and / or Phase A or Phase B multiple myeloma based on the Durie-Salmon staging system. In certain embodiments, the cancer is Phase I, Phase II, or Phase III multiple myeloma based on the international staging system published by the International Myeloma Working Group (IMWG). In certain embodiments, the multiple myeloma is progressive.
[0191] In certain embodiments, the subject has received a prior treatment comprising at least three prior therapy lines. In certain embodiments, the median number of prior therapy lines is 6. In certain embodiments, prior therapy lines include surgery, radiotherapy, or autologous transplantation or allogeneic transplantation, or any combination of these treatments. In certain embodiments, at least three prior therapy lines include treatment with a drug, which is a proteasome inhibitor (PI). Non-limiting examples of PI include bortezomib, carfilzomib, and ixazomib. In certain embodiments, at least three prior therapy lines include treatment with a drug, which is an immunomodulatory drug (IMiD). Non-limiting examples of IMiD include lenalidomide, pomalidomide, and thalidomide. In certain embodiments, at least three prior therapy lines include treatment with a drug, which is a corticosteroid. Non-limiting examples of corticosteroids include dexamethasone and prednisone. In certain embodiments, at least three prior therapy lines include treatment with a drug, which is an alkylating agent. In certain embodiments, at least three prior therapy lines include treatment with a drug, which is an anthracycline. In certain embodiments, at least three prior lines of therapy include treatment with a drug that is an anti-CD38 antibody. Non-limiting examples of anti-CD38 antibodies include daratumumab, isatuximab, and research antibody TAK-079. In certain embodiments, at least three prior lines of therapy include treatment with a drug that is elotuzumab. In certain embodiments, at least three prior lines of therapy include treatment with a drug that is panobinostat. In certain embodiments, at least three prior lines of therapy include treatment with at least one drug that includes at least one of a PI, an IMiD, and an anti-CD38 antibody. In certain embodiments, at least three prior lines of therapy include treatment with at least one drug that includes at least one of a PI, an IMiD, and an alkylating agent. In certain embodiments, the subject relapses after the at least three prior lines of therapy. In certain embodiments, multiple myeloma is refractory to one or more or all of bortezomib, carfilzomib, ixazomib, lenalidomide, pomalidomide, thalidomide, dexamethasone, prednisone, alkylating agents, daratumumab, isatuximab, TAK-079, elotuzumab and panobinostat. In certain embodiments, multiple myeloma is refractory to at least two drugs after at least three previous therapy lines. In certain embodiments, at least two drugs of refractory multiple myeloma include PI and IMiD. In certain embodiments, multiple myeloma is refractory to at least three drugs after at least three previous therapy lines. In certain embodiments, multiple myeloma is refractory to at least four drugs after at least three previous therapy lines. In certain embodiments, at least four previous therapy lines include treatment with at least one drug, and the at least one drug includes at least one of PI, IMiD, anti-CD38 antibody and alkylating agent.In certain embodiments, the multiple myeloma is refractory to at least five drugs after said at least three prior lines of therapy.
[0192] In some embodiments, the subject has between about 10% and about 30% bone marrow plasma cells prior to said administration of said CAR-T cells.
[0193] In certain embodiments, bone marrow aspiration or biopsy can be performed for clinical evaluation, or bone marrow aspiration can be performed for biomarker assessment. In certain embodiments, clinical staging (morphology, cytogenetics and immunohistochemistry or immunofluorescence or flow cytometry) can be performed. In certain embodiments, immunophenotyping can be performed on a portion of a bone marrow aspirate and the expression of checkpoint ligands in BCMA, CD138 positive multiple myeloma cells and the expression of checkpoints on T cells can be monitored. In certain embodiments, the next generation sequencing (NGS) of a bone marrow aspirate DNA can be used to monitor trace residual disease (MRD) in a subject. The NGS of a bone marrow aspirate DNA is known to those of ordinary skill in the art. In certain embodiments, NGS is performed via clonoSeq. In certain embodiments, a baseline bone marrow aspirate can be used to define myeloma clones, and samples after treatment can be used to evaluate MRD negative. In certain embodiments, MRD negative status can be based on evaluable samples. In certain embodiments, evaluable samples are those by one or more or all of the following: correction, quality control, and evaluable cell adequacy at a specific sensitivity level. In certain embodiments, the sensitivity level is 10-6. In some embodiments, the sensitivity level is 10-6, the sensitivity level is 10-5. In some embodiments, the sensitivity level is 10-4. In some embodiments, the sensitivity level is 10-3.
[0194] In certain embodiments, the response of the subject to the treatment method is assessed using the response criteria based on the International Myeloma Working Group (IMWG), which are summarized in Table 6. In certain embodiments, the response can be classified as a strict complete response (sCR). In certain embodiments, the response can be classified as a complete response (CR), which is worse than a strict complete response (sCR). In certain embodiments, the response can be classified as a very good partial response (VGPR), which is worse than a complete response (CR). In certain embodiments, the response can be classified as a partial response (PR), which is worse than a very good partial response (VGPR). In certain embodiments, the response can be classified as a minimal response (MR), which is worse than a partial response (PR). In certain embodiments, the response can be classified as a stable disease (SD), which is worse than a minimal response (MR). In certain embodiments, the response can be classified as progressive disease (PD), which is worse than stable disease.
[0195] In certain embodiments, the tests used to assess response criteria based on the International Myeloma Working Group (IMWG) are measurement of myeloma protein (M-protein) in serum and urine, serum calcium corrected for albumin, bone marrow examination, skeletal survey, and documentation of extramedullary plasmacytoma.
[0196] Non-limiting examples of tests for measurement of M-protein in blood and urine are known to those of ordinary skill in the art and include serum quantitative Ig, serum protein electrophoresis (SPEP), serum immunofixation electrophoresis, serum FLC assay, 24-hour urine M-protein electrophoresis quantitative (UPEP), urine immunofixation electrophoresis, and serum β2-microglobulin.
[0197] Calculation of serum calcium corrected for albumin in a blood sample for detection of hypercalcemia is known to those of ordinary skill in the art. Without wishing to be bound by theory, calcium binds to albumin and only unbound (free) calcium is biologically active; therefore, serum calcium levels must be adjusted for abnormal albumin levels ("corrected serum calcium").
[0198] In certain embodiments, a skeletal survey of any or all of the skull, entire spine, pelvis, chest, humerus, femur, and any other bones may be performed and evaluated by radiography ("X-ray") or low-dose computed tomography (CT) diagnostic quality scans without IV contrast, both of which are known to those of ordinary skill in the art. In certain embodiments, after administration of T cells and before confirming disease progression, an X-ray or CT scan may be performed locally to record the response or progression, regardless of whether there is a symptom-based clinical indication. In certain embodiments, magnetic resonance imaging (MRI) may be used to evaluate bone disease, but does not replace skeletal surveys. MRI is known to those of ordinary skill in the art. In certain embodiments, if a radionuclide bone scan is used during screening in addition to a complete skeletal survey, two methods may be used to record the disease state. Radionuclide bone scans are known to those of ordinary skill in the art. In certain embodiments, a radionuclide bone scan and a complete skeletal survey may be performed simultaneously. In certain embodiments, a radionuclide bone scan may not replace a complete skeletal survey. In certain embodiments, if a subject has disease progression manifested by painful symptoms due to bone changes, disease progression may be documented by skeletal surveys or other radiographs based on the symptoms experienced by the subject.
[0199] In certain embodiments, extramedullary plasmacytoma can be recorded by clinical examination or MRI. In certain embodiments, if there is no contraindication to IV contrast, extramedullary plasmacytoma can be recorded by CT scan. In certain embodiments, if the CT part has enough diagnostic quality, extramedullary plasmacytoma can be recorded by fusion of positron emission tomography (PET) scan and CT scan. In certain embodiments, local assessment, measurement or evaluation of the measurable part of extramedullary disease can be performed on the subject once every 4 weeks until a confirmed CR or confirmed disease progression is developed. In certain embodiments, the evaluation of extramedullary plasmacytoma can be performed once every 12 weeks.
[0200] In certain embodiments, to qualify for VGPR or PR or MR, the sum of the products of the perpendicular diameters of existing extramedullary plasmacytomas may decrease by more than 90% or at least 50%, respectively. In certain embodiments, to qualify for disease progression, the sum of the products of the perpendicular diameters of existing extramedullary plasmacytomas must have increased by at least 50%, or the longest diameter of a prior lesion >1 cm in the short axis must have increased by at least 50%, or a new plasmacytoma must have developed. In certain embodiments, when not all existing extramedullary plasmacytomas are reported, to qualify for disease progression, the sum of the products of the perpendicular diameters of the reported plasmacytomas has increased by at least 50%. In certain embodiments, if the study treatment interferes with the immunofixation assay, a CR may be defined as the disappearance of the original M protein associated with multiple myeloma upon immunofixation.
[0201] In certain embodiments, the subject's response to the treatment method is assessed according to changes in disease load or tumor load. Disease load or tumor load represents the type of measurable disease in the subject. In some embodiments, changes in tumor load can be assessed according to changes in paraprotein levels after treatment. In some embodiments, the paraprotein is an M-protein in serum. In some embodiments, the paraprotein is an M-protein in serum. In some embodiments, changes in tumor load are assessed according to the difference between affected and unaffected free light chains (dFLC). In some embodiments, changes in tumor load are assessed according to the maximum paraprotein reduction relative to baseline, i.e., relative to before CAR-T cell administration. In some embodiments, changes in tumor load are assessed at a median follow-up time of greater than or equal to 28 days after administration of CAR-T cells. In some embodiments, changes in tumor load are assessed at a median follow-up time of greater than or equal to 1 month after administration of CAR-T cells. In some embodiments, changes in tumor load are assessed at a median follow-up time of greater than or equal to 3 months after administration of CAR-T cells. In some embodiments, changes in tumor load are assessed at a median follow-up time of greater than or equal to 6 months after administration of CAR-T cells. In some embodiments, changes in tumor burden are assessed at a median follow-up time of greater than or equal to 9 months after administration of the CAR-T cells. In some embodiments, changes in tumor burden are assessed at a median follow-up time of greater than or equal to 12 months after administration of the CAR-T cells.
[0202] In certain embodiments, the subject is treated again by administration of a second intravenous infusion of a second dose of CAR-T cells. In certain embodiments, the retreatment dose comprises 1.0×105 to 5.0×106 CAR-T cells / kg of subject mass. In certain embodiments, the retreatment dose comprises about 0.75×105 CAR-T cells / kg of subject mass. In certain embodiments, the subject is retreated when disease progression is exhibited after the best response of a minimal response or a better response after the first infusion of CAR-T cells. In certain embodiments, the time between the first infusion of CAR-T cells and the detection of disease progression comprises at least six months.
[0203] In one aspect, a method of treating a subject having multiple myeloma is provided, the method comprising administering to the subject a composition comprising a therapeutically effective number of T cells comprising a chimeric antigen receptor (CAR) via a single intravenous infusion to deliver a dose of CAR-expressing T cells (CAR-T cells) to the subject.
[0204] In some embodiments, the subject has received prior treatment comprising at least three prior lines of therapy. In some embodiments, the at least three prior lines of therapy include treatment with at least one drug comprising at least one of a PI, an IMiD, and an anti-CD38 antibody. In some embodiments, the subject relapses after the at least three prior lines of therapy.
[0205] In some embodiments, the multiple myeloma is refractory to at least two drugs after the at least three prior lines of therapy. In some embodiments, the at least two drugs for refractory subjects comprise a PI and an IMiD. In some embodiments, the multiple myeloma is refractory to at least three drugs after the at least three prior lines of therapy. In some embodiments, the multiple myeloma is refractory to at least four drugs after the at least three prior lines of therapy. In some embodiments, the multiple myeloma is refractory to at least five drugs after the at least three prior lines of therapy.
[0206] In some embodiments, the subject is older than 65 years old. In some embodiments, the subject is black or African American. In some embodiments, the subject has received 3 previous lines of therapy. In some embodiments, the subject has received at least 4 previous lines of therapy. In some embodiments, multiple myeloma or the subject is refractory to three classes of drugs, i.e., multiple myeloma or the subject is refractory to three classes of drugs. In some embodiments, multiple myeloma or the subject is refractory to five classes of drugs (medicaments or drug), i.e., multiple myeloma or the subject is refractory to five classes of drugs. In some embodiments, the subject has standard risk cytogenetics. In some embodiments, the subject has high-risk cytogenetics. In some embodiments, the subject or multiple myeloma has been characterized as stage III according to the international staging system. In some embodiments, the subject has bone marrow plasma cells between about 10% and about 30% before the administration of the CAR-T cells. In some embodiments, the subject has bone marrow plasma cells between about 31% and about 59% before the administration of the CAR-T cells. In some embodiments, the subject has bone marrow plasma cells between about 60% and about 100% before the administration of the CAR-T cells. In some embodiments, the subject has BCMA expression in the tumor that is lower than the median in a population of multiple myeloma patients or any randomly selected population. In some embodiments, the subject has BCMA expression in the tumor that is greater than or equal to the median in a population of multiple myeloma patients or any randomly selected population. In some embodiments, a plasmacytoma is present in the subject. In some embodiments, the plasmacytoma is bone-based. In some embodiments, the plasmacytoma is extramedullary. In some embodiments, the plasmacytoma is bone-based and extramedullary.
[0207] In certain embodiments, the method of treatment is effective in obtaining a reduced tumor load in a subject. In certain embodiments, the method of treatment is effective in obtaining a reduction in a subject of between about 1% and about 100%, between about 60% and about 100%, between about 65% and about 100%, between about 70% and about 100%, between about 75% and about 100%, between about 80% and about 100%, between about 85% and about 100%, between about 90% and about 100%, between about 92% and about 100%, between about 95% and about 100%, between about 96% and about 100%, between about 97% and about 100%, between about 98% and about 100%, or between about 99% and about 100%. In certain embodiments, the method of treatment is effective in obtaining a reduction in tumor load of about 100% in a subject. In certain embodiments, the method of treatment is effective to obtain a reduction of between about 1% and about 100% of the tumor load in a subject at a rate between about 1% and about 100%. In certain embodiments, the method of treatment is effective to obtain a reduction of between about 60% and about 100% of the tumor load in a subject at a rate between about 1% and about 100%. In certain embodiments, the method of treatment is effective to obtain a reduction of between about 65% and about 100% of the tumor load in a subject at a rate between about 1% and about 92%. In certain embodiments, the method of treatment is effective to obtain a reduction of between about 70% and about 100% of the tumor load in a subject at a rate between about 1% and about 88%. In certain embodiments, the method of treatment is effective to obtain a reduction of between about 90% and about 100% of the tumor load in a subject at a rate between about 1% and about 88%. In certain embodiments, the method of treatment is effective to obtain a reduction of between about 95% and about 100% of the tumor load in a subject at a rate between about 1% and about 88%. In certain embodiments, the treatment method is effective to obtain a reduction of between about 99% and about 100% in tumor burden in a subject at a rate between about 1% and about 88%. In certain embodiments, the treatment method is effective to obtain a reduction of about 100% in tumor burden in a subject at a rate between about 1% and about 83%.
[0208] In certain embodiments, the treatment method is effective in obtaining a minimal residual disease (MRD) negative state or maintaining the minimal residual disease (MRD) state in the subject. In certain embodiments, the treatment method is effective in obtaining a minimal residual disease (MRD) negative state in the subject at a sensitivity level of 10-6. In certain embodiments, the treatment method is effective in obtaining a minimal residual disease (MRD) negative state in the subject at a sensitivity level of 10-5. In certain embodiments, the treatment method is effective in obtaining a minimal residual disease (MRD) negative state in the subject at a sensitivity level of 10-4. In certain embodiments, the treatment method is effective in obtaining a minimal residual disease (MRD) negative state in the subject at a sensitivity level of 10-3. In certain embodiments, when assessed in the bone marrow, the treatment method is effective in obtaining an MRD negative state. In certain embodiments, when assessed using an evaluable bone marrow sample, the treatment method is effective in maintaining an MRD negative state. In certain embodiments, when assessed using bone marrow DNA, the treatment method is effective in obtaining an MRD negative state. In some embodiments, the method is effective to obtain in the subject a minimal residual disease (MRD) negative state assessed in the bone marrow at a follow-up time of about 28 days or more after the administration of the CAR-T cells, about 2 months or more after the administration of the CAR-T cells, about 3 months or more after the administration of the CAR-T cells, about 6 months or more after the administration of the CAR-T cells, about 9 months or more after the administration of the CAR-T cells, or about 12 months or more after the administration of the CAR-T cells. In some embodiments, the minimal residual disease (MRD) negative state is obtained at the first follow-up time between about 28 days and about 179 days after the infusion of the CAR-T cells.
[0209] In certain embodiments, the treatment method effectively maintains the first obtained minimal residual disease (MRD) negative state in the subject. In certain embodiments, the treatment method effectively maintains the MRD negative state at a sensitivity level of 10-5. In certain embodiments, the treatment method effectively obtains a minimal residual disease (MRD) negative state in the subject at a sensitivity level of 10-6. In certain embodiments, the treatment method effectively maintains the MRD negative state at a sensitivity level of 10-4. In certain embodiments, the treatment method effectively maintains the MRD negative state at a sensitivity level of 10-3. In certain embodiments, when a bone marrow sample is used for evaluation, the treatment method effectively maintains the MRD negative state. In certain embodiments, when an evaluable bone marrow sample is used for evaluation, the treatment method effectively maintains the MRD negative state. In certain embodiments, when bone marrow DNA is used for evaluation, the treatment method effectively maintains the MRD negative state. In some embodiments, the method is effective in maintaining in the subject between about 29 days and about 359 days after the administration of the CAR-T cells, between about 29 days and about 9 months after the administration of the CAR-T cells, between about 29 days and about 6 months after the administration of the CAR-T cells, between about 29 days and about 3 months after the administration of the CAR-T cells, or between about 29 days and about 2 months after the administration of the CAR-T cells. The second follow-up time is between about 29 days and about 2 months. The micro-residual disease (MRD) negative state assessed in the bone marrow. In some embodiments, the method is effective in maintaining in the subject the micro-residual disease (MRD) negative state assessed in the bone marrow at a second follow-up time between about 180 days and about 359 days after the infusion of the CAR-T cells. In some embodiments, the method is effective in maintaining in the subject the micro-residual disease (MRD) negative state assessed in the bone marrow at a second follow-up time between about 360 days and about 539 days after the infusion of the CAR-T cells.
[0210] In certain embodiments, the efficacy of the treatment method is evaluated by evaluating the proportion of subjects with MRD negative status. In certain embodiments, the efficacy of the treatment method is evaluated by evaluating the proportion of subjects with MRD negative status at a sensitivity level of 10-6. In certain embodiments, the efficacy of the treatment method is evaluated by evaluating the proportion of subjects with MRD negative status at a sensitivity level of 10-5. In certain embodiments, the efficacy of the treatment method is evaluated by evaluating the proportion of subjects with MRD negative status at a sensitivity level of 10-4. In certain embodiments, the efficacy of the treatment method is evaluated by evaluating the proportion of subjects with MRD negative status at a sensitivity level of 10-3. In certain embodiments, the efficacy of the treatment method is assessed by evaluating the proportion of subjects with MRD negative status at a median follow-up time between administration of CAR-T cells and about 359 days after administration of CAR-T cells, between administration of CAR-T cells and about 9 months after administration of CAR-T cells, between administration of CAR-T cells and about 6 months after administration of CAR-T cells, between administration of CAR-T cells and about 3 months after administration of CAR-T cells, between administration of CAR-T cells and about 2 months after administration of CAR-T cells, or between administration of CAR-T cells and about 29 days after administration of CAR-T cells.In some embodiments, the method comprises a rate of about 44% or less at a sensitivity threshold level of 10-5 at a follow-up time of about 12 months after said infusion of said CAR-T cells, a rate of about 55% at a sensitivity threshold level of 10-5 at a follow-up time of about 12 months after said infusion of said CAR-T cells, a rate of about 65% or less at a sensitivity threshold level of 10-5 at a follow-up time of about 12 months after said infusion of said CAR-T cells, a rate of about 57% or less at a sensitivity threshold level of 10-4 at a follow-up time of about 18 months after said infusion of said CAR-T cells, a rate of about 67% at a sensitivity threshold level of 10-4 at a follow-up time of about 18 months after said infusion of said CAR-T cells, a rate of about 76% or less at a sensitivity threshold level of 10-4 at a follow-up time of about 18 months after said infusion of said CAR-T cells, The minimal residual disease (MRD) negative status is effectively obtained at a rate of about 47% or less at a sensitivity threshold level of 10-5 at a follow-up time of about 18 months after the infusion of AR-T cells, at a rate of about 58% at a sensitivity threshold level of 10-5 at a follow-up time of about 18 months after the infusion of CAR-T cells, at a rate of about 68% or less at a sensitivity threshold level of 10-5 at a follow-up time of about 18 months after the infusion of CAR-T cells, at a rate of about 29% or less at a sensitivity threshold level of 10-6 at a follow-up time of about 18 months after the infusion of CAR-T cells, at a rate of about 39% at a sensitivity threshold level of 10-6 at a follow-up time of about 18 months after the infusion of CAR-T cells, or at a rate of about 50% or less at a sensitivity threshold level of 10-6 at a follow-up time of about 18 months after the infusion of CAR-T cells. In some embodiments, the method is effective in obtaining the minimal residual disease (MRD) negative status at a rate between about 44% and about 65% at a sensitivity threshold level of 10-5 at a follow-up time of about 12 months after the infusion of the CAR-T cells, at a rate between about 57% and about 76% at a sensitivity threshold level of 10-4 at a follow-up time of about 18 months after the infusion of the CAR-T cells, at a rate between about 47% and about 68% at a sensitivity threshold level of 10-5 at a follow-up time of about 18 months after the infusion of the CAR-T cells, or at a rate between about 29% and about 50% at a sensitivity threshold level of 10-6 at a follow-up time of about 18 months after the infusion of the CAR-T cells.In some embodiments, the method is effective in obtaining the minimal residual disease (MRD) negative status at a rate of about 55% at a sensitivity threshold level of 10-5 at a follow-up time of about 12 months after the administration of the CAR-T cells, at a rate of about 67% at a sensitivity threshold level of 10-4 at a follow-up time of about 18 months after the infusion of the CAR-T cells, at a rate of about 58% at a sensitivity threshold level of 10-5 at a follow-up time of about 18 months after the infusion of the CAR-T cells, or at a rate of about 39% at a sensitivity threshold level of 10-6 at a follow-up time of about 18 months after the infusion of the CAR-T cells.
[0211] In certain embodiments, the efficacy of the treatment method is evaluated by evaluating the proportion of subjects with evaluable bone marrow and MRD negative status. In certain embodiments, the efficacy of the treatment method is evaluated by evaluating the proportion of subjects with evaluable bone marrow and MRD negative status at a sensitivity level of 10-6. In certain embodiments, the efficacy of the treatment method is evaluated by evaluating the proportion of subjects with evaluable bone marrow and MRD negative status at a sensitivity level of 10-5. In certain embodiments, the efficacy of the treatment method is evaluated by evaluating the proportion of subjects with evaluable bone marrow and MRD negative status at a sensitivity level of 10-4. In certain embodiments, the efficacy of the treatment method is evaluated by evaluating the proportion of subjects with evaluable bone marrow and MRD negative status at a sensitivity level of 10-3. In certain embodiments, the efficacy of the treatment method is assessed by evaluating the proportion of subjects with evaluable bone marrow and MRD negative status at a median follow-up time between administration of CAR-T cells and about 359 days after administration of CAR-T cells, between administration of CAR-T cells and about 9 months after administration of CAR-T cells, between administration of CAR-T cells and about 6 months after administration of CAR-T cells, between administration of CAR-T cells and about 3 months after administration of CAR-T cells, between administration of CAR-T cells and about 2 months after administration of CAR-T cells, or between administration of CAR-T cells and about 29 days after administration of CAR-T cells. In some embodiments, the method detects the presence of a CAR-T cell at a rate of about 83% or less at a sensitivity threshold level of 10-5 in subjects with evaluable samples at a follow-up time of about 12 months after the infusion of the CAR-T cells, at a rate of about 93% at a sensitivity threshold level of 10-5 in subjects with evaluable samples at a follow-up time of about 12 months after the infusion of the CAR-T cells, at a rate of about 98% at a sensitivity threshold level of 10-5 in subjects with evaluable samples at a follow-up time of about 12 months after the infusion of the CAR-T cells, -T cells at a follow-up time of about 18 months after the infusion of the CAR-T cells at a sensitivity threshold level of 10-5 in subjects with evaluable samples at a rate of about 82% or less, at a follow-up time of about 18 months after the infusion of the CAR-T cells at a sensitivity threshold level of 10-5 in subjects with evaluable samples at a rate of about 92%, or at a follow-up time of about 18 months after the infusion of the CAR-T cells at a sensitivity threshold level of 10-5 in subjects with evaluable samples at a rate of about 97% or less.In some embodiments, the method is effective in obtaining the minimal residual disease (MRD) negative state at a rate of between about 83% and about 98% at a sensitivity threshold level of 10-5 in subjects with evaluable samples at a follow-up time of about 12 months after the infusion of the CAR-T cells, or at a rate of between about 82% and about 97% at a sensitivity threshold level of 10-5 in subjects with evaluable samples at a follow-up time of about 18 months after the infusion of the CAR-T cells. In some embodiments, the method is effective in obtaining the minimal residual disease (MRD) negative state at a rate of about 93% at a sensitivity threshold level of 10-5 in subjects with evaluable samples at a follow-up time of about 12 months after the infusion of the CAR-T cells, or at a rate of about 92% at a sensitivity threshold level of 10-5 in subjects with evaluable samples at a follow-up time of about 18 months after the infusion of the CAR-T cells.
[0212] In some embodiments, the method is effective to obtain at least one response in the subject following said infusion of said CAR-T cells, wherein said at least one response comprises, in order from best to worst, a stringent complete response, a complete response, a very good partial response, a partial response, or a minimal response.
[0213] In some embodiments, the method is effective to obtain the first response within about 27 days or more, about 29 days or more, about 42 days or more, about 89 days or more, or about 321 days or more after the infusion of the CAR-T cells. In some embodiments, the method is effective to obtain the first response before the time between about 27 days and about 321 days after the infusion of the CAR-T cells. In some embodiments, the method is effective to obtain the first response before the time between about 27 days and about 89 days after the infusion of the CAR-T cells. In some embodiments, the method is effective to obtain the first response before about 42 days after the infusion of the CAR-T cells. In some embodiments, the method is effective to obtain the first response before about 29 days after the infusion of the CAR-T cells.
[0214] In certain embodiments, the efficacy of a treatment method is evaluated by evaluating the proportion of subjects with a stringent complete response. In certain embodiments, the efficacy of a treatment method is evaluated by evaluating the proportion of subjects with a complete response or better. In certain embodiments, the efficacy of a treatment method is evaluated by evaluating the proportion of subjects with a very good partial response or better. In certain embodiments, the efficacy of a treatment method is evaluated by evaluating the proportion of subjects with a partial response or better. In certain embodiments, the efficacy of a treatment method is evaluated by evaluating the proportion of subjects with a minimal response or better.
[0215] In some embodiments, the method effectively obtains the best response of any of a minimal response, a partial response, a very good partial response, a complete response, or a strict complete response, i.e., the best response of a minimal response or a better response. In some embodiments, the ratio of the best response of the method effectively obtaining a minimal response or a better response is referred to as a clinical benefit rate. In some embodiments, the method is about 91% or less at a follow-up time of about 12 months after the infusion of the CAR-T cells, about 97% or less at a follow-up time of about 12 months after the infusion of the CAR-T cells, about 99% or less at a follow-up time of about 12 months after the infusion of the CAR-T cells, about 93% or less at a follow-up time of about 18 months after the infusion of the CAR-T cells, about 98% or less at a follow-up time of about 18 months after the infusion of the CAR-T cells, or about 100% or less at a follow-up time of about 18 months after the infusion of the CAR-T cells. Effectively obtain the best response of a minimal response or a better response. In some embodiments, the method is effective at obtaining the best response of any one of a minimal response, a partial response, a very good partial response, a complete response, or a strict complete response at a rate of between about 91% and about 99% at a follow-up time of about 12 months after the infusion of the CAR-T cells, or at a rate of between about 93% and about 100% at a follow-up time of about 18 months after the infusion of the CAR-T cells. In some embodiments, the method is effective at obtaining the best response of any one of a minimal response, a partial response, a very good partial response, a complete response, or a strict complete response at a rate of about 97% at a follow-up time of about 12 months after the infusion of the CAR-T cells, or at a rate of about 98% at a follow-up time of about 18 months after the infusion of the CAR-T cells.
[0216] In some embodiments, the method effectively obtains the best response of any of a partial response, a very good partial response, a complete response, or a strict complete response, i.e., the best response of a partial response or a better response. In some embodiments, the ratio of the best response of the method effectively obtaining a partial response or a better response is referred to as the overall survival rate or the overall response rate. In some embodiments, the method is about 91% or less at a follow-up time of about 12 months after the infusion of the CAR-T cells, about 97% or less at a follow-up time of about 12 months after the infusion of the CAR-T cells, about 99% or less at a follow-up time of about 12 months after the infusion of the CAR-T cells, about 93% or less at a follow-up time of about 18 months after the infusion of the CAR-T cells, about 97% or less at a follow-up time of about 18 months after the infusion of the CAR-T cells, or about 100% or less at a follow-up time of about 18 months after the infusion of the CAR-T cells. Effectively obtain the best response of partial response or better response. In some embodiments, the method is effective at obtaining the best response of any one of a partial response, a very good partial response, a complete response, or a strict complete response at a rate of between about 91% and about 99% at a follow-up time of about 12 months after the infusion of the CAR-T cells, or at a rate of between about 93% and about 100% at a follow-up time of about 18 months after the infusion of the CAR-T cells. In some embodiments, the method is effective at obtaining the best response of any one of a partial response, a very good partial response, a complete response, or a strict complete response at a rate of about 97% at a follow-up time of about 12 months after the infusion of the CAR-T cells, or at a rate of about 97% at a follow-up time of about 18 months after the infusion of the CAR-T cells.
[0217] In some embodiments, the method is effective to obtain the best response of any of a very good partial response, a complete response, or a strict complete response, i.e., a very good partial response or a better response. In some embodiments, the method is effective to obtain the best response of a very good partial response or a better response at a rate of about 86% or less at a follow-up time of about 12 months after the infusion of the CAR-T cells, at a rate of about 93% or less at a follow-up time of about 12 months after the infusion of the CAR-T cells, at a rate of about 97% or less at a follow-up time of about 12 months after the infusion of the CAR-T cells, at a rate of about 88% or less at a follow-up time of about 18 months after the infusion of the CAR-T cells, at a rate of about 95% or less at a follow-up time of about 18 months after the infusion of the CAR-T cells, or at a rate of about 98% or less at a follow-up time of about 18 months after the infusion of the CAR-T cells. In some embodiments, the method is effective at a rate of between about 86% and about 97% at a follow-up time of about 12 months after the infusion of the CAR-T cells, or at a rate of between about 88% and about 98% at a follow-up time of about 18 months after the infusion of the CAR-T cells to obtain the best response of any one of a very good partial response, a complete response, or a strict complete response. In some embodiments, the method is effective at a rate of about 93% at a follow-up time of about 12 months after the infusion of the CAR-T cells, or at a rate of about 95% at a follow-up time of about 18 months after the infusion of the CAR-T cells to obtain the best response of any one of a very good partial response, a complete response, or a strict complete response.
[0218] In some embodiments, the method is effective in obtaining a complete response or a strict complete response as the best response, i.e., a complete response or a better response as the best response. In some embodiments, the method is effective in obtaining a complete response or a better response as the best response at a rate of about 57% or less at a follow-up time of about 12 months after the infusion of the CAR-T cells, at a rate of about 67% or less at a follow-up time of about 12 months after the infusion of the CAR-T cells, at a rate of about 76% or less at a follow-up time of about 12 months after the infusion of the CAR-T cells, at a rate of about 73% or less at a follow-up time of about 18 months after the infusion of the CAR-T cells, at a rate of about 83% or less at a follow-up time of about 18 months after the infusion of the CAR-T cells, or at a rate of about 89% or less at a follow-up time of about 18 months after the infusion of the CAR-T cells. In some embodiments, the method is effective at obtaining the best response of a complete response or a strict complete response at a rate of between about 57% and about 76% at a follow-up time of about 12 months after the infusion of the CAR-T cells or at a rate of between about 73% and about 89% at a follow-up time of about 18 months after the infusion of the CAR-T cells. In some embodiments, the method is effective at obtaining the best response of a complete response or a strict complete response at a rate of about 67% at a follow-up time of about 12 months after the infusion of the CAR-T cells or at a rate of about 83% at a follow-up time of about 18 months after the infusion of the CAR-T cells.
[0219] In some embodiments, the method is effective to obtain a best response of a stringent complete response. In some embodiments, the method is effective to obtain a best response of a stringent complete response at a rate of about 57% or less at a follow-up time of about 12 months after the infusion of the CAR-T cells, at a rate of about 67% or less at a follow-up time of about 12 months after the infusion of the CAR-T cells, at a rate of about 76% or less at a follow-up time of about 12 months after the infusion of the CAR-T cells, at a rate of about 73% or less at a follow-up time of about 18 months after the infusion of the CAR-T cells, at a rate of about 83% or less at a follow-up time of about 18 months after the infusion of the CAR-T cells, or at a rate of about 89% or less at a follow-up time of about 18 months after the infusion of the CAR-T cells. In some embodiments, the method is effective at obtaining the best response of a stringent complete response at a rate of between about 57% and about 76% at a follow-up time of about 12 months after the infusion of the CAR-T cells or at a rate of between about 73% and about 89% at a follow-up time of about 18 months after the infusion of the CAR-T cells. In some embodiments, the method is effective at obtaining the best response of a stringent complete response at a rate of about 67% at a follow-up time of about 12 months after the infusion of the CAR-T cells or at a rate of about 83% at a follow-up time of about 18 months after the infusion of the CAR-T cells.
[0220] In some embodiments, the method is effective to obtain the optimal response within about 27 days or more, 78 days or more, 153 days or more, 293 days or more, or about 534 days or more after the infusion of the CAR-T cells. In some embodiments, the method is effective to obtain the optimal response before a time between about 27 days and about 534 days after the infusion of the CAR-T cells. In some embodiments, the method is effective to obtain the optimal response before a time between about 27 days and about 293 days after the infusion of the CAR-T cells. In some embodiments, the method is effective to obtain the optimal response before about 153 days after the infusion of the CAR-T cells. In some embodiments, the method is effective to obtain the optimal response before about 78 days after the infusion of the CAR-T cells.
[0221] In some embodiments, the method is effective in maintaining the subject's response at a follow-up period between the time of the first response and about 180 days after the infusion of the CAR-T cells, between the time of the first response and about 357 days after the infusion of the CAR-T cells, between the time of the first response and about 606 days after the infusion of the CAR-T cells, or between the time of the first response and about 654 days after the infusion of the CAR-T cells. In some embodiments, the method achieves a rate of about 77% or less at a follow-up time of about 6 months after the infusion of the CAR-T cells, a rate of about 85% or less at a follow-up time of about 6 months after the infusion of the CAR-T cells, a rate of about 91% or less at a follow-up time of about 6 months after the infusion of the CAR-T cells, a rate of about 63% or less at a follow-up time of about 12 months after the infusion of the CAR-T cells, a rate of about 74% or less at a follow-up time of about 12 months after the infusion of the CAR-T cells, a rate of about 81% or less at a follow-up time of about 12 months after the infusion of the CAR-T cells, a rate of about 56% or less at a follow-up time of about 18 months after the infusion of the CAR-T cells, a rate of about 1 A response is effectively maintained at a rate of about 67% or less at 8 months of follow-up, at a rate of about 75% or less at a rate of about 18 months of follow-up after said infusion of said CAR-T cells, at a rate of about 52% or less at a rate of about 21 months of follow-up after said infusion of said CAR-T cells, at a rate of about 63% or less at a rate of about 21 months of follow-up after said infusion of said CAR-T cells, at a rate of about 72% or less at a rate of about 48% or less at a rate of about 24 months of follow-up after said infusion of said CAR-T cells, at a rate of about 60% or less at a rate of about 24 months of follow-up after said infusion of said CAR-T cells, or at a rate of about 70% or less at a rate of about 24 months of follow-up after said infusion of said CAR-T cells. In some embodiments, the method is effective in maintaining a response at a rate between about 77% and about 91% at a follow-up time of about 6 months after the infusion of the CAR-T cells, at a rate between about 63% and about 81% at a follow-up time of about 12 months after the infusion of the CAR-T cells, at a rate between about 56% and about 75% at a follow-up time of about 18 months after the infusion of the CAR-T cells, at a rate between about 52% and about 72% at a follow-up time of about 21 months after the infusion of the CAR-T cells, or at a rate between about 48% and about 70% at a follow-up time of about 24 months after the infusion of the CAR-T cells.In some embodiments, the method is effective in maintaining a response at a rate of about 85% at a follow-up time of about 6 months after the infusion of the CAR-T cells, at a rate of about 74% at a follow-up time of about 12 months after the infusion of the CAR-T cells, at a rate of about 67% at a follow-up time of about 18 months after the infusion of the CAR-T cells, at a rate of about 63% at a follow-up time of about 21 months after the infusion of the CAR-T cells, or at a rate of about 60% at a follow-up time of about 24 months after the infusion of the CAR-T cells.
[0222] In some embodiments, wherein the method is effective to obtain in said subject between the time of said administration of said CAR-T cells and about 3 months after said administration of said CAR-T cells, with a rate of 10 -5 The sensitivity threshold level of minimal residual disease (MRD) negative status assessed in the bone marrow. In some embodiments, the method is effective in obtaining a minimal residual disease (MRD) negative complete response or a minimal residual disease (MRD) negative strict complete response at a rate of about 25% or less at a follow-up time of about 12 months after the infusion of the CAR-T cells, at a rate of about 34% or less at a follow-up time of about 12 months after the infusion of the CAR-T cells, at a rate of about 44% or less at a follow-up time of about 12 months after the infusion of the CAR-T cells, at a rate of about 33% or less at a follow-up time of about 18 months after the infusion of the CAR-T cells, at a rate of about 43% or less at a follow-up time of about 18 months after the infusion of the CAR-T cells, or at a rate of about 54% or less at a follow-up time of about 18 months after the infusion of the CAR-T cells. In some embodiments, the method is effective in obtaining a minimal residual disease (MRD) negative complete response or a minimal residual disease (MRD) negative stringent complete response at a rate of between about 25% and about 44% at a follow-up time of about 12 months after the infusion of the CAR-T cells or at a rate of between about 33% and about 54% at a follow-up time of about 18 months after the infusion of the CAR-T cells. In some embodiments, the method is effective in obtaining a minimal residual disease (MRD) negative complete response or a minimal residual disease (MRD) negative stringent complete response at a rate of about 34% at a follow-up time of about 12 months after the infusion of the CAR-T cells or at a rate of about 43% at a follow-up time of about 18 months after the infusion of the CAR-T cells.
[0223] In some embodiments, the method is effective to obtain progression-free survival of the subject. In some embodiments, the method is effective to obtain progression-free survival of the subject between about 209 days after the infusion of the CAR-T cells and the infusion of the CAR-T cells, between about 386 days after the infusion of the CAR-T cells and the infusion of the CAR-T cells, between about 632 days after the infusion of the CAR-T cells and the infusion of the CAR-T cells, or between about 684 days after the infusion of the CAR-T cells and the infusion of the CAR-T cells. In some embodiments, the method provides for a rate of about 79% or less at a follow-up time of about 6 months after the infusion of the CAR-T cells, a rate of about 88% or less at a follow-up time of about 6 months after the infusion of the CAR-T cells, a rate of about 93% or less at a follow-up time of about 6 months after the infusion of the CAR-T cells, a rate of about 67% or less at a follow-up time of about 12 months after the infusion of the CAR-T cells, a rate of about 76% or less at a follow-up time of about 12 months after the infusion of the CAR-T cells, a rate of about 84% or less at a follow-up time of about 12 months after the infusion of the CAR-T cells, a rate of about 57% or less at a follow-up time of about 18 months after the infusion of the CAR-T cells, and a rate of about 64% or less at a follow-up time of about 18 months after the infusion of the CAR-T cells. The invention further provides that the progression-free survival is effectively obtained at a rate of about 67% or less at a follow-up time of about 18 months after the infusion of the CAR-T cells, at a rate of about 75% or less at a follow-up time of about 21 months after the infusion of the CAR-T cells, at a rate of about 57% or less at a follow-up time of about 21 months after the infusion of the CAR-T cells, at a rate of about 67% or less at a follow-up time of about 21 months after the infusion of the CAR-T cells, at a rate of about 75% or less at a follow-up time of about 21 months after the infusion of the CAR-T cells, at a rate of about 49% or less at a follow-up time of about 24 months after the infusion of the CAR-T cells, at a rate of about 61% or less at a follow-up time of about 24 months after the infusion of the CAR-T cells, or at a rate of about 70% or less at a follow-up time of about 24 months after the infusion of the CAR-T cells.In some embodiments, the method is effective in obtaining said progression-free survival at a rate between about 79% and about 93% at a follow-up time of about 6 months after said infusion of said CAR-T cells, at a rate between about 67% and about 84% at a follow-up time of about 12 months after said infusion of said CAR-T cells, at a rate between about 57% and about 75% at a follow-up time of about 18 months after said infusion of said CAR-T cells, at a rate between about 57% and about 75% at a follow-up time of about 21 months after said infusion of said CAR-T cells, or at a rate between about 49% and about 70% at a follow-up time of about 24 months after said infusion of said CAR-T cells. In some embodiments, the method is effective in obtaining said progression-free survival at a rate of about 88% at a follow-up time of about 6 months after said infusion of said CAR-T cells, at a rate of about 76% at a follow-up time of about 12 months after said infusion of said CAR-T cells, at a rate of about 67% at a follow-up time of about 18 months after said infusion of said CAR-T cells, at a rate of about 67% at a follow-up time of about 21 months after said infusion of said CAR-T cells, or at a rate of about 61% at a follow-up time of about 24 months after said infusion of said CAR-T cells.
[0224] In some embodiments, the method further comprises treating the subject for cytokine release syndrome more than about 1 day after the infusion of the CAR-T cells. In some embodiments, the method is effective to obtain a recovery rate of between about 1% and about 99% of the cytokine release syndrome at a time of about 1, 3, 4, 6, 16, or 97 days after the cytokine release syndrome is first observed.
[0225] In some embodiments, the method further comprises treating the subject for immune effector cell-related neurotoxicity for more than about 3 days after the infusion of the CAR-T cells. In some embodiments, the method is effective to obtain a recovery rate of between about 1% and about 17% of the immune effector cell-related neurotoxicity at a time of about 1, 4, 5, 8, 12, or 16 days after the immune effector cell-related neurotoxicity is first observed.
[0226] In certain embodiments, the method of treatment is effective in obtaining a reduced tumor burden in a subject. In certain embodiments, the method of treatment is effective in obtaining a reduced tumor burden in greater than 90% of the subjects. In certain embodiments, the method of treatment is effective in obtaining a reduced tumor burden in greater than 91% of the subjects. In certain embodiments, the method of treatment is effective in obtaining a reduced tumor burden in greater than 92% of the subjects. In certain embodiments, the method of treatment is effective in obtaining a reduced tumor burden in greater than 93% of the subjects. In certain embodiments, the method of treatment is effective in obtaining a reduced tumor burden in greater than 94% of the subjects. In certain embodiments, the method of treatment is effective in obtaining a reduced tumor burden in greater than 95% of the subjects. In certain embodiments, the method of treatment is effective in obtaining a reduced tumor burden in greater than 96% of the subjects. In certain embodiments, the method of treatment is effective in obtaining a reduced tumor burden in greater than 97% of the subjects. In certain embodiments, the method of treatment is effective in obtaining a reduced tumor burden in greater than 98% of the subjects. In certain embodiments, the method of treatment is effective in obtaining a reduced tumor burden in greater than 99% of the subjects. In some embodiments, the method of treatment is effective in obtaining a reduced tumor burden in 100% of the subjects.
[0227] In certain embodiments, the treatment method effectively obtains a minimal residual disease (MRD) negative state or maintains the minimal residual disease (MRD) state in the subject. In certain embodiments, the treatment method effectively obtains a minimal residual disease (MRD) negative state in the subject. In certain embodiments, the treatment method effectively obtains a minimal residual disease (MRD) negative state in the subject at a sensitivity level of 10-6. In certain embodiments, the treatment method effectively obtains a minimal residual disease (MRD) negative state in the subject at a sensitivity level of 10-5. In certain embodiments, the treatment method effectively obtains a minimal residual disease (MRD) negative state in the subject at a sensitivity level of 10-4. In certain embodiments, the treatment method effectively obtains a minimal residual disease (MRD) negative state in the subject at a sensitivity level of 10-3. In certain embodiments, when assessed in the bone marrow, the treatment method effectively obtains an MRD negative state. In certain embodiments, when assessed using an evaluable bone marrow sample, the treatment method effectively maintains an MRD negative state. In certain embodiments, when assessed using bone marrow DNA, the treatment method effectively obtains an MRD negative state. In certain embodiments, the method of treatment is effective to obtain an MRD-negative state when assessed at a follow-up time of greater than or equal to 28 days after administration of the CAR-T cells. In certain embodiments, the method of treatment is effective to obtain an MRD-negative state when assessed at a follow-up time of greater than or equal to 1 month after administration of the CAR-T cells. In certain embodiments, the method of treatment is effective to obtain an MRD-negative state when assessed at a follow-up time of greater than or equal to 3 months after administration of the CAR-T cells. In certain embodiments, the method of treatment is effective to obtain an MRD-negative state when assessed at a follow-up time of greater than or equal to 6 months after administration of the CAR-T cells. In certain embodiments, the method of treatment is effective to obtain an MRD-negative state when assessed at a follow-up time of greater than or equal to 9 months after administration of the CAR-T cells. In certain embodiments, the method of treatment is effective to obtain an MRD-negative state when assessed at a follow-up time of greater than or equal to 12 months after administration of the CAR-T cells.
[0228] In certain embodiments, the treatment method effectively maintains the first obtained minimal residual disease (MRD) negative state in the subject. In certain embodiments, the treatment method effectively maintains the MRD negative state at a sensitivity level of 10-5. In certain embodiments, the treatment method effectively obtains a minimal residual disease (MRD) negative state in the subject at a sensitivity level of 10-6. In certain embodiments, the treatment method effectively maintains the MRD negative state at a sensitivity level of 10-4. In certain embodiments, the treatment method effectively maintains the MRD negative state at a sensitivity level of 10-3. In certain embodiments, when a bone marrow sample is used for evaluation, the treatment method effectively maintains the MRD negative state. In certain embodiments, when an assessable bone marrow sample is used for evaluation, the treatment method effectively maintains the MRD negative state. In certain embodiments, when bone marrow DNA is used for evaluation, the treatment method effectively maintains the MRD negative state. In certain embodiments, when the follow-up time is greater than or equal to 1 month after the administration of CAR-T cells, the treatment method effectively maintains the MRD negative state. In certain embodiments, when the follow-up time is greater than or equal to 3 months after the administration of CAR-T cells, the treatment method effectively maintains the MRD negative state. In certain embodiments, the method of treatment is effective in maintaining MRD-negative status when assessed at a follow-up time greater than or equal to 6 months after administration of the CAR-T cells. In certain embodiments, the method of treatment is effective in maintaining MRD-negative status when assessed at a follow-up time greater than or equal to 9 months after administration of the CAR-T cells. In certain embodiments, the method of treatment is effective in maintaining MRD-negative status when assessed at a follow-up time greater than or equal to 12 months after administration of the CAR-T cells.
[0229] In certain embodiments, the efficacy of the treatment method is evaluated by evaluating the proportion of subjects with MRD-negative status. In certain embodiments, the efficacy of the treatment method is evaluated by evaluating the proportion of subjects with MRD-negative status at a sensitivity level of 10-6. In certain embodiments, the efficacy of the treatment method is evaluated by evaluating the proportion of subjects with MRD-negative status at a sensitivity level of 10-5. In certain embodiments, the efficacy of the treatment method is evaluated by evaluating the proportion of subjects with MRD-negative status at a sensitivity level of 10-4. In certain embodiments, the efficacy of the treatment method is evaluated by evaluating the proportion of subjects with MRD-negative status at a sensitivity level of 10-3. In certain embodiments, the efficacy of the treatment method is evaluated by evaluating the proportion of subjects with MRD-negative status at a median follow-up time of greater than or equal to 28 days after administration of CAR-T cells. In certain embodiments, the efficacy of the treatment method is evaluated by evaluating the proportion of subjects with MRD-negative status at a median follow-up time of greater than or equal to 1 month after administration of CAR-T cells. In certain embodiments, the efficacy of the treatment method is evaluated by evaluating the proportion of subjects with MRD-negative status at a median follow-up time of greater than or equal to 3 months after administration of CAR-T cells. In certain embodiments, the efficacy of the treatment method is evaluated by evaluating the proportion of subjects with MRD-negative status at a median follow-up time of greater than or equal to 6 months after administration of CAR-T cells. In certain embodiments, the efficacy of the treatment method is evaluated by evaluating the proportion of subjects with MRD-negative status at a median follow-up time of greater than or equal to 9 months after administration of CAR-T cells. In certain embodiments, the efficacy of the treatment method is evaluated by evaluating the proportion of subjects with MRD-negative status at a median follow-up time of greater than or equal to 12 months after administration of CAR-T cells.
[0230] In certain embodiments, the efficacy of the treatment method is evaluated by evaluating the proportion of subjects with evaluable bone marrow and MRD-negative status. In certain embodiments, the efficacy of the treatment method is evaluated by evaluating the proportion of subjects with evaluable bone marrow and MRD-negative status at a sensitivity level of 10-6. In certain embodiments, the efficacy of the treatment method is evaluated by evaluating the proportion of subjects with evaluable bone marrow and MRD-negative status at a sensitivity level of 10-5. In certain embodiments, the efficacy of the treatment method is evaluated by evaluating the proportion of subjects with evaluable bone marrow and MRD-negative status at a sensitivity level of 10-4. In certain embodiments, the efficacy of the treatment method is evaluated by evaluating the proportion of subjects with evaluable bone marrow and MRD-negative status at a sensitivity level of 10-3. In certain embodiments, the efficacy of the treatment method is evaluated by evaluating the proportion of subjects with evaluable bone marrow and MRD-negative status at a median follow-up time of greater than or equal to 28 days after administration of CAR-T cells. In certain embodiments, the efficacy of the treatment method is evaluated by evaluating the proportion of subjects with evaluable bone marrow and MRD-negative status at a median follow-up time of greater than or equal to 1 month after administration of CAR-T cells. In certain embodiments, the efficacy of the treatment method is evaluated by evaluating the proportion of subjects with evaluable bone marrow and MRD-negative status at a median follow-up time of greater than or equal to 3 months after administration of CAR-T cells. In certain embodiments, the efficacy of the treatment method is evaluated by evaluating the proportion of subjects with evaluable bone marrow and MRD-negative status at a median follow-up time of greater than or equal to 6 months after administration of CAR-T cells. In certain embodiments, the efficacy of the treatment method is evaluated by evaluating the proportion of subjects with evaluable bone marrow and MRD-negative status at a median follow-up time of greater than or equal to 9 months after administration of CAR-T cells. In certain embodiments, the efficacy of the treatment method is evaluated by evaluating the proportion of subjects with evaluable bone marrow and MRD-negative status at a median follow-up time of greater than or equal to 12 months after administration of CAR-T cells.
[0231] In certain embodiments, the efficacy of a treatment method is evaluated by evaluating the proportion of subjects with a stringent complete response. In certain embodiments, the efficacy of a treatment method is evaluated by evaluating the proportion of subjects with a complete response or better. In certain embodiments, the efficacy of a treatment method is evaluated by evaluating the proportion of subjects with a very good partial response or better. In certain embodiments, the efficacy of a treatment method is evaluated by evaluating the proportion of subjects with a partial response or better. In certain embodiments, the efficacy of a treatment method is evaluated using the overall response rate. In some embodiments, the overall response rate is the proportion of subjects with a partial response or better.
[0232] In certain embodiments, the method is effective to obtain a minimal residual disease (MRD) negative rate greater than 39% at a sensitivity threshold level of 10-5. In certain embodiments, the method is effective to obtain a minimal residual disease (MRD) negative rate greater than 44% at a sensitivity threshold level of 10-5. In certain embodiments, the method is effective to obtain a minimal residual disease (MRD) negative rate greater than 49% at a sensitivity threshold level of 10-5. In certain embodiments, the method is effective to obtain a minimal residual disease (MRD) negative rate greater than 54% at a sensitivity threshold level of 10-5. In certain embodiments, the method is effective to obtain a minimal residual disease (MRD) negative rate greater than 59% at a sensitivity threshold level of 10-5. In certain embodiments, the method is effective to obtain a minimal residual disease (MRD) negative rate greater than 64% at a sensitivity threshold level of 10-5. In certain embodiments, the method is effective to obtain a minimal residual disease (MRD) negative rate greater than 69% at a sensitivity threshold level of 10-5. In certain embodiments, the method is effective to obtain a minimal residual disease (MRD) negative rate of greater than 74% at a sensitivity threshold level of 10-5. In certain embodiments, the method is effective to obtain a minimal residual disease (MRD) negative rate of greater than 70% at a sensitivity threshold level of 10-5. In certain embodiments, the method is effective to obtain a minimal residual disease (MRD) negative rate of greater than 75% at a sensitivity threshold level of 10-5 in the evaluable bone marrow. In certain embodiments, the method is effective to obtain a minimal residual disease (MRD) negative rate of greater than 80% at a sensitivity threshold level of 10-5 in the evaluable bone marrow. In certain embodiments, the method is effective to obtain a minimal residual disease (MRD) negative rate of greater than 85% at a sensitivity threshold level of 10-5 in the evaluable bone marrow. In certain embodiments, the method is effective to obtain a minimal residual disease (MRD) negative rate of greater than 90% at a sensitivity threshold level of 10-5 in the evaluable bone marrow. In certain embodiments, the method is effective in obtaining a minimal residual disease (MRD) negative rate of greater than 95% at a sensitivity threshold level of 10-5 in evaluable bone marrow. In certain embodiments, the method is effective in obtaining a minimal residual disease (MRD) negative rate of 100% at a sensitivity threshold level of 10-5 in evaluable bone marrow.
[0233] In certain embodiments, the treatment method is effective to obtain an overall response rate of greater than 90%. In certain embodiments, the treatment method is effective to obtain an overall response rate of greater than 91%. In certain embodiments, the method is effective to obtain an overall response rate of greater than 93%. In certain embodiments, the method is effective to obtain an overall response rate of greater than 95%. In certain embodiments, the method is effective to obtain an overall response rate of greater than 97%. In certain embodiments, the method is effective to obtain an overall response rate of greater than 99%. In some embodiments, the method is effective to obtain an overall response rate of 100%. In certain embodiments, the overall response rate is evaluated at a median follow-up time of at least 6 months after the infusion of the CAR-T cells. In certain embodiments, the overall response rate is evaluated at a median follow-up time of at least 12 months after the infusion of the CAR-T cells.
[0234] In certain embodiments, more than 70% of the subjects respond to the treatment method at 9 months after the administration of the CAR-T cells. In certain embodiments, more than 72% of the subjects respond to the treatment method at 9 months after the administration of the CAR-T cells. In certain embodiments, more than 74% of the subjects respond to the treatment method at 9 months after the administration of the CAR-T cells. In certain embodiments, more than 76% of the subjects respond to the treatment method at 9 months after the administration of the CAR-T cells. In certain embodiments, more than 78% of the subjects respond to the treatment method at 9 months after the administration of the CAR-T cells. In certain embodiments, more than 80% of the subjects respond to the treatment method at 9 months after the administration of the CAR-T cells. In certain embodiments, more than 82% of the subjects respond to the treatment method at 9 months after the administration of the CAR-T cells. In certain embodiments, more than 84% of the subjects respond to the treatment method at 9 months after the administration of the CAR-T cells. In certain embodiments, more than 86% of the subjects respond to the treatment method at 9 months after the administration of the CAR-T cells.
[0235] In certain embodiments, more than 54% of responding subjects respond to the treatment method at 12 months after administration of the CAR-T cells. In certain embodiments, more than 58% of responding subjects respond to the treatment method at 12 months after administration of the CAR-T cells. In certain embodiments, more than 62% of responding subjects respond to the treatment method at 12 months after administration of the CAR-T cells. In certain embodiments, more than 66% of responding subjects respond to the treatment method at 12 months after administration of the CAR-T cells. In certain embodiments, more than 70% of responding subjects respond to the treatment method at 12 months after administration of the CAR-T cells. In certain embodiments, more than 74% of responding subjects respond to the treatment method at 12 months after administration of the CAR-T cells. In certain embodiments, more than 78% of responding subjects respond to the treatment method at 12 months after administration of the CAR-T cells.
[0236] In certain embodiments, the treatment method is effective to obtain a duration of response of greater than 9 months, 10 months, 11 months, 12 months, 13 months, 14 months, or 15 months. In certain embodiments, the treatment method is effective to obtain a duration of response of greater than 12.4 months. In certain embodiments, the treatment method is effective to obtain a duration of response of greater than 15.9 months.
[0237] In certain embodiments, the treatment method is effective to obtain a median duration of response of greater than 9 months, 10 months, 11 months, 12 months, 13 months, 14 months, or 15 months. In certain embodiments, the treatment method is effective to obtain a median duration of response of greater than 12.4 months. In certain embodiments, the treatment method is effective to obtain a median duration of response of greater than 15.9 months.
[0238] In certain embodiments, the treatment method is effective in obtaining a complete response or better in greater than 60% of the subjects. In certain embodiments, the treatment method is effective in obtaining a complete response or better in greater than 61% of the subjects. In certain embodiments, the treatment method is effective in obtaining a complete response or better in greater than 62% of the subjects. In certain embodiments, the treatment method is effective in obtaining a complete response or better in greater than 63% of the subjects. In certain embodiments, the treatment method is effective in obtaining a complete response or better in greater than 64% of the subjects. In certain embodiments, the treatment method is effective in obtaining a complete response or better in greater than 65% of the subjects. In certain embodiments, the treatment method is effective in obtaining a complete response or better in greater than 66% of the subjects. In certain embodiments, the treatment method is effective in obtaining a complete response or better in greater than 67% of the subjects. In certain embodiments, a complete response or better is assessed less than 1 month after administration of the CAR-T cells. In certain embodiments, a complete response or better is assessed less than 3 months after administration of the CAR-T cells. In certain embodiments, a complete response or better is assessed less than 6 months after administration of the CAR-T cells. In certain embodiments, a complete response or better is assessed less than 9 months after administration of the CAR-T cells. In certain embodiments, a complete response or better is assessed less than 12 months after administration of the CAR-T cells. In certain embodiments, a complete response or better is assessed less than 15 months after administration of the CAR-T cells. In certain embodiments, a complete response or better is assessed more than 15 months after administration of the CAR-T cells.
[0239] In certain embodiments, the treatment method is effective in obtaining a very good partial response or better in greater than 85% of the subjects. In certain embodiments, the treatment method is effective in obtaining a very good partial response or better in greater than 86% of the subjects. In certain embodiments, the treatment method is effective in obtaining a very good partial response or better in greater than 87% of the subjects. In certain embodiments, the treatment method is effective in obtaining a very good partial response or better in greater than 88% of the subjects. In certain embodiments, the treatment method is effective in obtaining a very good partial response or better in greater than 89% of the subjects. In certain embodiments, the treatment method is effective in obtaining a very good partial response or better in greater than 90% of the subjects. In certain embodiments, the treatment method is effective in obtaining a very good partial response or better in greater than 91% of the subjects. In certain embodiments, the treatment method is effective in obtaining a very good partial response or better in greater than 92% of the subjects. In certain embodiments, a very good partial response or better is assessed less than 1 month after administration of the CAR-T cells. In certain embodiments, a very good partial response or better is assessed less than 3 months after administration of the CAR-T cells. In certain embodiments, a very good partial response or better is assessed less than 6 months after administration of the CAR-T cells. In certain embodiments, a very good partial response or better is assessed less than 9 months after administration of the CAR-T cells. In certain embodiments, a very good partial response or better is assessed less than 12 months after administration of the CAR-T cells. In certain embodiments, a very good partial response or better is assessed less than 15 months after administration of the CAR-T cells. In certain embodiments, a very good partial response or better is assessed more than 15 months after administration of the CAR-T cells.
[0240] In certain embodiments, the treatment methods are effective to achieve a median time to first response of less than 1.15 months. In certain embodiments, the treatment methods are effective to achieve a median time to first response of less than 1.10 months. In certain embodiments, the treatment methods are effective to achieve a median time to first response of less than 1.05 months. In certain embodiments, the treatment methods are effective to achieve a median time to first response of less than 1.00 months. In certain embodiments, the treatment methods are effective to achieve a median time to first response of less than 0.95 months.
[0241] In certain embodiments, the treatment methods are effective to achieve a median time to best response of less than 2.96 months. In certain embodiments, the treatment methods are effective to achieve a median time to best response of less than 2.86 months. In certain embodiments, the treatment methods are effective to achieve a median time to best response of less than 2.76 months. In certain embodiments, the treatment methods are effective to achieve a median time to best response of less than 2.66 months. In certain embodiments, the treatment methods are effective to achieve a median time to best response of less than 2.56 months.
[0242] In certain embodiments, the method is effective to obtain an overall survival rate of greater than 80% at 9 months after administration of the CAR-T cells. In certain embodiments, the method is effective to obtain an overall survival rate of greater than 82% at 9 months after administration of the CAR-T cells. In certain embodiments, the method is effective to obtain an overall survival rate of greater than 85% at 9 months after administration of the CAR-T cells. In certain embodiments, the method is effective to obtain an overall survival rate of greater than 87% at 9 months after administration of the CAR-T cells. In certain embodiments, the method is effective to obtain an overall survival rate of greater than 90% at 9 months after administration of the CAR-T cells. In certain embodiments, the method is effective to obtain an overall survival rate of greater than 92% at 9 months after administration of the CAR-T cells. In certain embodiments, the method is effective to obtain an overall survival rate of greater than 95% at 9 months after administration of the CAR-T cells.
[0243] In certain embodiments, the method is effective to obtain an overall survival rate of greater than 80% at 12 months after administration of the CAR-T cells. In certain embodiments, the method is effective to obtain an overall survival rate of greater than 83% at 12 months after administration of the CAR-T cells. In certain embodiments, the method is effective to obtain an overall survival rate of greater than 86% at 12 months after administration of the CAR-T cells. In certain embodiments, the method is effective to obtain an overall survival rate of greater than 89% at 12 months after administration of the CAR-T cells. In certain embodiments, the method is effective to obtain an overall survival rate of greater than 92% at 12 months after administration of the CAR-T cells. In certain embodiments, the method is effective to obtain an overall survival rate of greater than 93% at 12 months after administration of the CAR-T cells.
[0244] In certain embodiments, the method is effective to obtain a progression-free survival rate of greater than 70% at 9 months after the administration of the CAR-T cells. In certain embodiments, the method is effective to obtain a progression-free survival rate of greater than 72% at 9 months after the administration of the CAR-T cells. In certain embodiments, the method is effective to obtain a progression-free survival rate of greater than 75% at 9 months after the administration of the CAR-T cells. In certain embodiments, the method is effective to obtain a progression-free survival rate of greater than 77% at 9 months after the administration of the CAR-T cells. In certain embodiments, the method is effective to obtain a progression-free survival rate of greater than 80% at 9 months after the administration of the CAR-T cells. In certain embodiments, the method is effective to obtain a progression-free survival rate of greater than 82% at 9 months after the administration of the CAR-T cells. In certain embodiments, the method is effective to obtain a progression-free survival rate of greater than 85% at 9 months after the administration of the CAR-T cells. In certain embodiments, the method is effective to obtain a progression-free survival rate of greater than or equal to 87% at 9 months after the administration of the CAR-T cells.
[0245] In certain embodiments, the method is effective to obtain a progression-free survival rate of greater than 66% at 12 months after the administration of the CAR-T cells. In certain embodiments, the method is effective to obtain a progression-free survival rate of greater than 69% at 12 months after the administration of the CAR-T cells. In certain embodiments, the method is effective to obtain a progression-free survival rate of greater than 72% at 12 months after the administration of the CAR-T cells. In certain embodiments, the method is effective to obtain a progression-free survival rate of greater than 76% at 12 months after the administration of the CAR-T cells. In certain embodiments, the method is effective to obtain a progression-free survival rate of greater than 80% at 12 months after the administration of the CAR-T cells. In certain embodiments, the method is effective to obtain a progression-free survival rate of greater than 84% at 12 months after the administration of the CAR-T cells.
[0246] In certain embodiments, the treatment method is effective in obtaining greater than 86% of subjects recovering from cytokine release syndrome. In certain embodiments, the treatment method is effective in obtaining greater than 88% of subjects recovering from cytokine release syndrome. In certain embodiments, the treatment method is effective in obtaining greater than 90% of subjects recovering from cytokine release syndrome. In certain embodiments, the treatment method is effective in obtaining greater than 92% of subjects recovering from cytokine release syndrome. In certain embodiments, the treatment method is effective in obtaining greater than 94% of subjects recovering from cytokine release syndrome. In certain embodiments, the treatment method is effective in obtaining greater than 96% of subjects recovering from cytokine release syndrome. In certain embodiments, the treatment method is effective in obtaining greater than 98% of subjects recovering from cytokine release syndrome. In certain embodiments, the treatment method is effective in obtaining greater than 99% of subjects recovering from cytokine release syndrome. In certain embodiments, the treatment method is effective in obtaining 100% of subjects recovering from cytokine release syndrome.
[0247] In certain embodiments, the method of treatment is effective to obtain greater than 90% of the subjects recovered from the neurotoxicity associated with immune effector cells (if any). In certain embodiments, the method of treatment is effective to obtain greater than 92% of the subjects recovered from the neurotoxicity associated with immune effector cells (if any). In certain embodiments, the method of treatment is effective to obtain greater than 94% of the subjects recovered from the neurotoxicity associated with immune effector cells (if any). In certain embodiments, the method of treatment is effective to obtain greater than 96% of the subjects recovered from the neurotoxicity associated with immune effector cells (if any). In certain embodiments, the method of treatment is effective to obtain greater than 98% of the subjects recovered from the neurotoxicity associated with immune effector cells (if any). In certain embodiments, the method of treatment is effective to obtain 100% of the subjects recovered from the neurotoxicity associated with immune effector cells (if any).
[0248] In some embodiments, the method further comprises diagnosing cytopenia in the subject. In some embodiments, cytopenia includes one or more or all of lymphopenia, neutropenia, and thrombocytopenia. Without being bound by theory, grade 3 or 4 but not grade 2 or lower lymphopenia is characterized by a lymphocyte count of less than 0.5×109 cells / liter of subject blood sample, grade 3 or 4 but not grade 2 or lower neutropenia is characterized by a neutrophil count of less than 1000 cells / microliter of subject blood sample, and grade 3 or 4 but not grade 2 or lower thrombocytopenia is characterized by a platelet count of less than 50,000 cells / microliter of subject blood sample. In some embodiments, more than 75% of subjects with grade 3 or 4 lymphopenia after CAR-T cell administration recover to grade 2 or lower lymphopenia 60 days after CAR-T cell administration. In some embodiments, more than 80% of subjects with grade 3 or 4 lymphopenia after CAR-T cell administration recover to grade 2 or lower lymphopenia 60 days after CAR-T cell administration. In some embodiments, more than 85% of subjects with grade 3 or 4 lymphopenia after CAR-T cell administration recover to grade 2 or lower lymphopenia 60 days after CAR-T cell administration. In some embodiments, more than 90% of subjects with grade 3 or 4 lymphopenia after CAR-T cell administration recover to grade 2 or lower lymphopenia 60 days after CAR-T cell administration. In some embodiments, more than 70% of subjects with grade 3 or 4 neutropenia after CAR-T cell administration recover to grade 2 or lower neutropenia 60 days after CAR-T cell administration. In some embodiments, more than 75% of subjects with grade 3 or 4 neutropenia after CAR-T cell administration recover to grade 2 or lower neutropenia 60 days after CAR-T cell administration. In some embodiments, more than 80% of subjects with Grade 3 or 4 neutropenia after CAR-T cell administration recover to Grade 2 or lower neutropenia 60 days after CAR-T cell administration. In some embodiments, more than 85% of subjects with Grade 3 or 4 neutropenia after CAR-T cell administration recover to Grade 2 or lower neutropenia 60 days after CAR-T cell administration. In some embodiments, more than 30% of subjects with Grade 3 or 4 thrombocytopenia after CAR-T cell administration recover to Grade 2 or lower thrombocytopenia 60 days after CAR-T cell administration. In some embodiments, more than 34% of subjects with Grade 3 or 4 thrombocytopenia after CAR-T cell administration recover to Grade 2 or lower thrombocytopenia 60 days after CAR-T cell administration.In some embodiments, more than 38% of subjects with grade 3 or 4 thrombocytopenia after CAR-T cell administration recover to grade 2 or lower thrombocytopenia 60 days after CAR-T cell administration. In some embodiments, more than 42% of subjects with grade 3 or 4 thrombocytopenia after CAR-T cell administration recover to grade 2 or lower thrombocytopenia 60 days after CAR-T cell administration.
[0249] In certain embodiments, the subject is treated again by administration of a second intravenous infusion of a second dose of CAR-T cells. In certain embodiments, the retreatment dose comprises 1.0×105 to 5.0×106 CAR-T cells / kg of subject mass. In certain embodiments, the retreatment dose comprises about 0.75×105 CAR-T cells / kg of subject mass. In certain embodiments, the subject is retreated when disease progression is exhibited after the best response of a minimal response or a better response after the first infusion of CAR-T cells. In certain embodiments, the time between the first infusion of CAR-T cells and the detection of disease progression comprises at least six months.
[0250] Kits and products
[0251] Any composition described herein may be included in a kit. In some embodiments, engineered immortalized CAR-T cells are provided in a kit, which may also include reagents suitable for expanding the cells, such as culture medium.
[0252] In non-limiting examples, a chimeric receptor expression construct, one or more reagents for producing a chimeric receptor expression construct, cells for transfecting the expression construct, and / or one or more instruments for obtaining immortalized T cells for transfecting the expression construct (such instruments may be syringes, pipettes, forceps and / or any such medically approved device).
[0253] In some aspects, the kit comprises reagents or devices for electroporation of cells.
[0254] In some embodiments, the kit comprises artificial antigen presenting cells.
[0255] The kit may include one or more appropriately aliquoted compositions of the present disclosure or reagents for producing the compositions of the present disclosure. The components of the kit may be packaged in aqueous media or lyophilized form. The container device of the kit may include at least one vial, test tube, flask, bottle, syringe or other container device (components can be placed and preferably appropriately aliquoted therein). In the case where there is more than one component in the kit, the kit will generally also contain a second, third or other additional container, in which the additional components can be placed separately. However, various combinations of components may be included in vials. The kit of the present disclosure will generally also include a device for containing chimeric receptor constructs and any other reagent containers in closed restrictions for commercial sale. Such containers may include, for example, injection or blow-molded plastic containers in which desired vials are retained.
[0256] Approved drug products
[0257] The present disclosure also provides a method for treating an adult patient with relapsed or refractory multiple myeloma, comprising administering to the patient an approved drug product comprising a suspension of cedakinumab in the amount and manner described in the drug product labeling of the approved drug product and / or in the administration and / or treatment regimen described herein.
[0258] The present disclosure further relates to a drug product comprising a cedakinumab suspension, wherein the drug product is packaged, and wherein the package includes a label identifying the cedakinumab suspension as an approved drug product for treating adult patients with relapsed or refractory multiple myeloma after receiving four or more prior lines of therapy comprising a proteasome inhibitor, an immunomodulator, and an anti-CD38 monoclonal antibody.
[0259] The present disclosure also provides a method of marketing an approved drug product comprising a cedakinumab suspension, the method comprising marketing the approved drug product, wherein the drug product labeling of a reference product of the approved drug product comprises instructions for use in treating patients with relapsed or refractory multiple myeloma after receiving four or more prior lines of therapy comprising a proteasome inhibitor, an immunomodulator, and an anti-CD38 monoclonal antibody.
[0260] In some embodiments, a method of marketing includes a method of marketing a biosimilar to an approved drug product comprising cedakinumab suspension, the method comprising marketing the biosimilar, wherein the drug product labeling of the reference product of the biosimilar includes instructions for use in treating patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy comprising a proteasome inhibitor, an immunomodulator, and an anti-CD38 monoclonal antibody.
[0261] The present disclosure also provides a method of offering for sale a drug product comprising a cedakinumab suspension, the method comprising offering for sale such a drug product, wherein the drug product labeling of a reference product for such a drug product comprises instructions for treating patients with relapsed or refractory multiple myeloma after receiving four or more prior lines of therapy comprising a proteasome inhibitor, an immunomodulator, and an anti-CD38 monoclonal antibody.
[0262] In some embodiments, a method of offering for sale comprises a method of offering for sale a biosimilar of an approved drug comprising cedakinumab suspension, the method comprising offering for sale the biosimilar, wherein the drug product labeling of the reference product of the biosimilar comprises instructions for treating patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy comprising a proteasome inhibitor, an immunomodulator, and an anti-CD38 monoclonal antibody.
[0263] As used herein, the terms "sale" or "sale" refer to the transfer of a pharmaceutical product, such as a pharmaceutical composition or dosage form, from a seller to a buyer.
[0264] As used herein, the term "offer to sell" refers to an offer by a seller to sell a pharmaceutical product, such as a pharmaceutical composition or dosage form, to a buyer. These methods include offering to sell a pharmaceutical product.
[0265] The term "drug product" means a product containing an active pharmaceutical ingredient that has been approved for marketing by a governmental authority, such as the Food and Drug Administration or similar authorities in other countries.
[0266] "Label" or "drug product labeling" refers to information provided to patients that provides relevant information about a drug product. Such information includes, but is not limited to, one or more of the following: description of the drug product, clinical pharmacology, indications (uses of the drug product), contraindications (who should not take the drug product), warnings, precautions, adverse events (side effects), drug abuse and dependence, dosage and administration, use during pregnancy, use by nursing mothers, use by children and elderly patients, how the drug product is supplied, patient safety information, or any combination thereof. In certain embodiments, the label or drug product label provides instructions for use in patients in need of BCMA CAR T cells. In further embodiments, the label or drug product label identifies the cedakitolan suspension and provides instructions for use in patients in need of BCMA CAR T cells.
[0267] The term "reference product" means the FDA-approved biological product (approved drug product) to which the proposed biosimilar product is compared. The approval of the reference product is based on, among other things, a complete complement of safety and effectiveness data. The proposed biosimilar product is compared and evaluated to the reference product to ensure that the products are highly similar and do not have clinically meaningful differences.
[0268] A “biosimilar” is a biological product that is highly similar to an existing FDA-approved reference product (approved drug product) and has no clinically meaningful differences. A biosimilar can be shown to be highly similar to the reference product by extensively analyzing (i.e., characterizing) the structure and function of the reference product and the proposed biosimilar and comparing the product characteristics, such as purity, chemical identity, and biological activity. Minor differences between the reference product and the proposed biosimilar product in clinically inactive ingredients (e.g., minor differences in stabilizers or buffers compared to those used in the reference product) are acceptable. The FDA carefully evaluates any differences between the proposed biosimilar product and the reference product to ensure that the biosimilar meets the FDA’s high standards for approval. Minor differences (i.e., acceptable intra-product variation) are expected in the manufacturing process for biological products, regardless of whether the product is a biosimilar or a reference product. Manufacturers must also demonstrate that their proposed biosimilar product has no clinically meaningful differences from the reference product in terms of safety, purity, and potency (safety and effectiveness), which is typically demonstrated through human pharmacokinetic (exposure) and pharmacodynamic (response) studies, clinical immunogenicity assessments, and, if needed, additional clinical studies.
[0269] Manufacturers of proposed biosimilar products generate data comparing the proposed product to an FDA-approved reference product to demonstrate biosimilarity. Biosimilar product applications must include data demonstrating biosimilarity to the reference product, which includes data from:
[0270] - Analytical studies demonstrate that the biological product is highly similar to the reference product despite minor differences in clinically inactive ingredients;
[0271] -Animal studies, including toxicity assessments; and
[0272] - One or more clinical studies sufficient to demonstrate the safety, purity, and potency of the proposed biosimilar product in one or more of the indications for which the reference product is licensed, typically including assessments of immunogenicity, pharmacokinetics (PK), and, in some cases, pharmacodynamics (PD), and may include comparative clinical studies.
[0273] Rather than generating the same complete set of nonclinical and clinical data as for the reference product, a manufacturer that demonstrates that its proposed biosimilar is highly similar to, and has no clinically meaningful differences from, the FDA-approved reference product may rely in part on the FDA’s prior determination of safety and effectiveness for the reference product’s approval. As a result, the biosimilar manufacturer may not need to conduct as many clinical trials.
[0274] Also disclosed herein are methods of supplying, storing, and handling an approved drug product containing a suspension of cedakiorencil. The approved drug product containing a suspension of cedakiorencil is provided in an infusion bag containing a frozen suspension of cedakiorencil in 5% DMSO as: 70 mL suspension in an infusion bag and a metal box (NDC 57894-111-01) or 30 mL suspension in an infusion bag and a metal box (NDC 57894-111-02). Each infusion bag is individually packaged in an aluminum freezer box. The infusion bags are stored and transported below -120°C, for example, in a container for cryogenic storage in a liquid nitrogen vapor phase, and the approved drug product is stored in the original packaging containing the box that protects the infusion bag. In some embodiments, the time from leukocyte separation to product availability can be 27 to 66 days. In some embodiments, the time from leukocyte separation to product availability can be 32 days.
[0275] The following exemplary embodiments are intended to be purely exemplary of the present disclosure and, therefore, should not be construed as limiting the present disclosure in any way.
[0276] Exemplary Embodiments
[0277] 1. A method of treating a subject, the method comprising administering to the subject a single infusion of a dose of a composition comprising T cells containing a chimeric antigen receptor (CAR),
[0278] wherein the CAR comprises the amino acid sequence of SEQ ID NO: 17;
[0279] The dosage comprises 0.5×10 6 to 1.0×10 6 T cells / kg subject body weight; and
[0280] The method comprises administering the dose of T cells to the subject at a temperature of about 20°C to 25°C within about 2.5 hours.
[0281] 2. The method of embodiment 1, wherein the subject has relapsed or refractory multiple myeloma who has received multiple lines of prior therapy, and wherein optionally, the subject has received three or more lines of prior therapy.
[0282] 3. The method of embodiment 1 or 2, wherein the subject has received four or more prior lines of therapy.
[0283] 4. The method of embodiment 2 or 3, wherein the prior line of therapy comprises a proteasome inhibitor, an immunomodulator, and an anti-CD38 monoclonal antibody.
[0284] 5. The method of any one of embodiments 1-4, wherein the T cells are autologous T cells.
[0285] 6. The method of any one of embodiments 1-5, wherein the method further comprises administering a lymphodepleting chemotherapy regimen to the subject prior to administering the T cells to the subject.
[0286] 7. The method of embodiment 6, wherein the lymphodepleting chemotherapy regimen comprises administering cyclophosphamide and fludarabine to the subject.
[0287] 8. The method of embodiment 7, wherein the lymphodepleting chemotherapy regimen comprises intravenous administration of cyclophosphamide and fludarabine to the subject.
[0288] 9. The method of Example 8, wherein the lymphodepleting chemotherapy regimen comprises administering to the subject intravenously about 300 mg / m 2 Cyclophosphamide at a dose of 30 mg / m 2 dose of fludarabine.
[0289] 10. The method of any one of embodiments 6-9, wherein the lymphodepleting chemotherapy regimen is about 3 days.
[0290] 11. The method of any one of embodiments 6-10, wherein the method comprises administering the lymphodepleting chemotherapy regimen to the subject for at least about 2-4 days prior to administering the T cells to the subject.
[0291] 12. The method of any one of embodiments 1-11, wherein the method further comprises administering a premedication to the subject up to 60 minutes prior to administering the T cells to the subject, and wherein the premedication comprises an antipyretic and an antihistamine.
[0292] 13. The method of embodiment 12, wherein the method comprises administering the premedication to the subject about 30-60 minutes prior to administering the T cells to the subject.
[0293] 14. The method of embodiment 12 or 13, wherein the antipyretic comprises paracetamol or acetaminophen.
[0294] 15. The method of embodiment 14, wherein the antipyretic comprises acetaminophen in a dosage of about 650 mg to 1000 mg.
[0295] 16. The method of any one of embodiments 12-15, wherein the antihistamine comprises diphenhydramine.
[0296] 17. The method of embodiment 16, wherein the dose of diphenhydramine is about 25 mg to 50 mg or an equivalent amount.
[0297] 18. The method of any one of embodiments 12-17, wherein the premedication is administered orally or intravenously.
[0298] 19. The method of any one of embodiments 12-18, wherein the premedication does not comprise systemic corticosteroids.
[0299] 20. The method of any one of embodiments 1-19, wherein the method comprises thawing the dose of T cells prior to administration, wherein the thawing is completed in no more than about 15 minutes.
[0300] 21. The method of embodiment 20, wherein the dose of T cells is thawed at a temperature of about 37°C ± 2°C.
[0301] 22. The method of any one of embodiments 1-21, wherein the method further comprises treating cytokine release syndrome (CRS) in the subject after administering the dose of T cells.
[0302] 23. The method of embodiment 22, wherein CRS comprises fever, pyrexia, hypotension, elevated aspartate aminotransferase, chills, elevated alanine aminotransferase, sinus tachycardia, hyperbilirubinemia, hypoxia, respiratory failure, acute kidney injury, disseminated intravascular coagulation and bleeding (e.g., retroperitoneal, intracerebral, or gastrointestinal bleeding), hemophagocytic lymphohistiocytosis (HLH), macrophage activation syndrome (MAS), angina pectoris, supraventricular and ventricular tachycardia, malaise, myalgia, increased C-reactive protein, ferritin, blood alkaline phosphatase, gamma-glutamyl transferase, organ toxicity, or any combination thereof.
[0303] 24. The method of embodiment 22 or 23, wherein treating the subject for CRS comprises administering an anti-cytokine agent or a corticosteroid to the subject.
[0304] 25. The method of embodiment 24, wherein the anti-cytokine agent comprises a monoclonal antibody targeting a cytokine.
[0305] 26. The method of embodiment 25, wherein the monoclonal antibody targeting cytokine is an IL-6R inhibitor.
[0306] 27. The method of embodiment 26, wherein the IL-6R inhibitor is tocilizumab.
[0307] 28. The method of embodiment 27, wherein the method comprises administering tocilizumab intravenously at a dose of about 8 mg / kg over about 1 hour.
[0308] 29. The method of embodiment 28, wherein the dose of tocilizumab does not exceed about 800 mg.
[0309] 30. The method of embodiment 28 or 29, wherein the dose of tocilizumab does not exceed 3 doses within 24 hours.
[0310] 31. The method of any one of embodiments 28-30, wherein the dose of tocilizumab does not exceed 4 doses in total.
[0311] 32. The method of embodiment 24, wherein the anti-cytokine agent further comprises an anti-cytokine agent other than tocilizumab.
[0312] 33. The method of embodiment 24, wherein the anti-cytokine agent further comprises a monoclonal antibody targeting a cytokine other than tocilizumab.
[0313] 34. The method of any one of embodiments 24-33, wherein the corticosteroid comprises dexamethasone or methylprednisolone.
[0314] 35. The method of embodiment 34, wherein the corticosteroid is dexamethasone.
[0315] 36. The method of embodiment 35, wherein the method comprises administering to the subject intravenously a dose of about 10 mg of dexamethasone about every 12-24 hours.
[0316] 37. The method of embodiment 36, wherein the method comprises administering dexamethasone to the subject intravenously at a dose of about 10 mg about every 12 hours.
[0317] 38. The method of embodiment 35, wherein the method comprises administering to the subject intravenously a dose of about 20 mg of dexamethasone about every 6-12 hours.
[0318] 39. The method of embodiment 38, wherein the method comprises administering to the subject intravenously a dose of about 20 mg of dexamethasone about every 6 hours.
[0319] 40. The method of embodiment 34, wherein the corticosteroid is methylprednisolone.
[0320] 41. The method of embodiment 40, wherein the method comprises administering to the subject intravenously a dose of about 2 mg / kg of methylprednisolone about every 12 hours.
[0321] 42. The method of embodiment 40, wherein the method comprises administering to the subject intravenously a dose of about 1-2 g of methylprednisolone about every 24 hours.
[0322] 43. The method of embodiment 22 or 23, wherein the method comprises administering an immunosuppressant to the subject.
[0323] 44. The method of any one of embodiments 1-43, wherein the method further comprises treating neurotoxicity in the subject after administering the dose of the T cells.
[0324] 45. The method of embodiment 44, wherein the neurotoxicity comprises immune effector cell associated neurotoxicity syndrome (ICANS), Parkinson's disease, Guillain-Barré syndrome, immune-mediated myelitis, peripheral neuropathy, cranial nerve palsy, or any combination thereof.
[0325] 46. The method of embodiment 45, wherein the neurotoxicity comprises ICANS, and wherein the ICANS comprises encephalopathy, aphasia, headache, decreased level of consciousness, seizures, motor findings, increased intracranial pressure (ICP), cerebral edema, or any combination thereof.
[0326] 47. The method of embodiment 46, wherein the ICANS comprises focal or generalized seizures, nonconvulsive seizures on electroencephalogram (EEG), life-threatening prolonged seizures, recurrent clinical or electrical seizures, deep focal motor weakness, hemiparesis, paraparesis, focal or localized edema on neuroimaging, stupor, coma, diffuse cerebral edema on neuroimaging, decerebrate or decorticate spasticity, cranial nerve VI palsy, papilledema, Cushing's triad, or any combination thereof.
[0327] 48. The method of embodiment 46 or 47, wherein the method comprises administering to the subject intravenously a dose of about 10 mg of dexamethasone about every 12-24 hours for about 2-3 days.
[0328] 49. The method of embodiment 48, wherein the method comprises administering to the subject intravenously a dose of about 10 mg of dexamethasone about every 12 hours for about 2-3 days or longer.
[0329] 50. The method of embodiment 46 or 47, wherein the method comprises administering dexamethasone to the subject intravenously at a dose of about 10-20 mg about every 6 hours.
[0330] 51. The method of any one of embodiments 46-50, wherein the method comprises administering to the subject a dose of about 1-2 g / day of methylprednisolone about every 24 hours.
[0331] 52. The method of any one of embodiments 46-50, wherein the ICANS comprises cerebral edema.
[0332] 53. The method of embodiment 52, wherein the method comprises administering hyperventilation and hyperosmotic therapy to the subject.
[0333] 54. The method of any one of embodiments 46-53, wherein the method comprises administering a non-sedating anti-epileptic drug to the subject.
[0334] 55. The method of embodiment 54, wherein the non-sedating anti-epileptic drug is levetiracetam.
[0335] 56. The method of embodiment 45, wherein the neurotoxicity comprises Parkinson's disease.
[0336] 57. The method of embodiment 56, wherein the Parkinson's disease comprises Parkinson's symptoms or non-Parkinson's symptoms.
[0337] 58. The method of embodiment 57, wherein the Parkinson's symptoms or the non-Parkinson's symptoms comprise tremor, bradykinesia, involuntary movements, stereotypies, loss of spontaneous movements, masked face, apathy, dullness, fatigue, rigidity, psychomotor retardation, microscopic dysgraphia, dysgraphia, apraxia, listlessness, confusion, drowsiness, loss of consciousness, delayed reflexes, hyperreflexia, memory loss, dysphagia, fecal incontinence, falls, hunched posture, slow gait, muscle weakness and wasting, motor dysfunction, movement and sensory loss, akinetic mutism, frontal release signs, or any combination thereof.
[0338] 59. The method of any one of embodiments 56-58, wherein the method comprises administering to the subject a treatment to alleviate Parkinson's disease.
[0339] 60. The method of embodiment 45, wherein the neurotoxicity comprises Guillain-Barré syndrome.
[0340] 61. The method of embodiment 60, wherein Guillain-Barré syndrome comprises symptoms consistent with the Miller-Fisher variant of Guillain-Barré syndrome, encephalopathy, motor weakness, speech disorders, polyradiculoneuritis, or any combination thereof.
[0341] 62. The method of embodiment 61, wherein the method comprises administering to the subject a treatment to alleviate Guillain-Barré syndrome.
[0342] 63. The method of embodiment 45, wherein the neurotoxicity comprises immune-mediated myelitis.
[0343] 64. The method of embodiment 63, wherein the symptoms of immune-mediated myelitis include decreased sensation in the lower extremities or lower abdomen with impaired sphincter control.
[0344] 65. The method of embodiment 63 or 64, wherein the method comprises administering to the subject a treatment to reduce immune-mediated myelitis, wherein optionally, the treatment comprises a corticosteroid or an immunoglobulin, and wherein optionally, the method comprises administering the immunoglobulin intravenously.
[0345] 66. The method of embodiment 45, wherein the neurotoxicity comprises peripheral neuropathy.
[0346] 67. The method of embodiment 66, wherein the peripheral neuropathy comprises sensory neuropathy, motor neuropathy, sensorimotor neuropathy, or any combination thereof.
[0347] 68. The method of embodiment 66 or 67, wherein the method comprises administering to the subject a treatment to reduce peripheral neuropathy.
[0348] 69. The method of embodiment 45, wherein the neurotoxicity comprises cranial nerve palsy.
[0349] 70. The method of embodiment 69, wherein the cranial nerve palsy comprises 3rd cranial nerve palsy, 6th cranial nerve palsy, 7th cranial nerve palsy, or bilateral 7th cranial nerve palsy.
[0350] 71. The method of embodiment 69 or 70, wherein the method comprises administering to the subject a treatment to reduce cranial nerve palsy.
[0351] 72. A method as described in Example 23, wherein CRS comprises hemophagocytic lymphohistiocytosis (HLH) or macrophage activation syndrome (MAS), wherein symptoms of HLH or MAS include hypotension, hypoxia with diffuse alveolar damage, coagulopathy, cytopenias, multiple organ dysfunction including renal dysfunction, or any combination thereof.
[0352] 73. The method of embodiment 72, wherein the method comprises administering to the subject a treatment to alleviate HLH or MAS.
[0353] 74. A method as described in any of Examples 1-73, wherein the method further comprises treating the subject for long-term or recurrent cytopenias before administering CAR-containing T cells to the subject, after administering a lymphodepleting chemotherapy regimen to the subject, or after administering the dose of CAR-containing T cells.
[0354] 75. The method of embodiment 74, wherein the long-term recurrent cytopenia comprises long-term neutropenia, long-term thrombocytopenia, recurrent neutropenia, thrombocytopenia, lymphopenia, anemia, or any combination thereof.
[0355] 76. The method of embodiments 1-75, wherein the method further comprises treating an infection in the subject.
[0356] 77. The method of embodiment 76, wherein the infection is viral, bacterial, fungal or caused by an unspecified pathogen, wherein optionally, the infection comprises lung abscess, sepsis, pneumonia, bronchopulmonary aspergillosis, Pneumocystis jiroveci pneumonia, CMV colitis (with HSV-1 hepatitis), mycotic aneurysm, cerebral aspergillosis or COVID-19 infection.
[0357] 78. The method of embodiment 76, wherein the infection causes febrile neutropenia or subarachnoid hemorrhage.
[0358] 79. The method of any one of embodiments 76-78, wherein the method comprises administering an antimicrobial agent to the subject.
[0359] 80. The method of embodiment 79, wherein the antimicrobial agent is an antibiotic.
[0360] 81. The method of embodiment 80, wherein the antibiotic is a broad-spectrum antibiotic.
[0361] 82. The method of embodiment 77, wherein the infection is viral.
[0362] 83. The method of embodiment 82, wherein the method comprises administering an antiviral therapy or a vaccine to the subject.
[0363] 84. The method of embodiments 1-83, wherein the method further comprises treating the subject for hypogammaglobulinemia.
[0364] 85. The method of embodiment 84, wherein after administration of the dose of CAR-containing T cells, hypogammaglobulinemia comprises a laboratory IgG level of less than about 500 mg / dL.
[0365] 86. A method as described in Example 84 or 85, wherein the method comprises administering a dose of intravenous immunoglobulin (IVIG) to the subject after administering the dose of CAR-containing T cells.
[0366] 87. The method of any one of embodiments 1-86, wherein the method further comprises treating a hypersensitivity reaction in the subject.
[0367] 88. The method of embodiment 87, wherein the hypersensitivity reaction comprises flushing, chest discomfort, tachycardia, wheezing, tremor, burning sensation, anaphylaxis, or any combination thereof.
[0368] 89. The method of embodiment 87 or 88, wherein the method comprises administering to the subject a treatment to reduce the hypersensitivity reaction.
[0369] 90. The method of any one of embodiments 1-89, wherein the method further comprises treating a secondary malignancy in the subject.
[0370] 91. The method of any one of embodiments 1-90, wherein the composition further comprises an excipient selected from dimethyl sulfoxide or dextran-40.
[0371] 92. The method of embodiment 91, wherein the excipient is dimethyl sulfoxide.
[0372] 93. The method of embodiment 92, wherein the excipient is about 1%-10% dimethyl sulfoxide.
[0373] 94. The method of embodiment 93, wherein the excipient is about 5% dimethyl sulfoxide.
[0374] 95. A drug product comprising a cedakinumab suspension for intravenous infusion, wherein the drug product is packaged, and wherein the package includes a label identifying the cedakinumab suspension as an approved drug product for the treatment of adult patients with relapsed or refractory multiple myeloma after receiving four or more prior lines of therapy comprising a proteasome inhibitor, an immunomodulator, and an anti-CD38 monoclonal antibody.
[0375] 96. A method of treating relapsed or refractory multiple myeloma in an adult patient in need thereof, the method comprising administering an approved drug product comprising a cedakinumab suspension in the amount and manner described in the drug product labeling for the approved drug product.
[0376] 97. A method of marketing an approved drug product comprising cedakinumab suspension, the method comprising marketing such drug product, wherein the drug product labeling of a reference product for such drug product comprises instructions for use in treating adult patients with relapsed or refractory multiple myeloma after receiving four or more prior lines of therapy comprising a proteasome inhibitor, an immunomodulator, and an anti-CD38 monoclonal antibody.
[0377] 98. A method of offering for sale a drug product comprising a cedakinumab suspension, the method comprising offering for sale such a drug product, wherein the drug product labeling of a reference product for such drug product comprises instructions for use in treating adult patients with relapsed or refractory multiple myeloma after receiving four or more prior lines of therapy comprising a proteasome inhibitor, an immunomodulator, and an anti-CD38 monoclonal antibody.
[0378] Examples
[0379] The following examples are provided to further describe some embodiments disclosed herein. The examples are intended to illustrate, but not limit, the disclosed embodiments.
[0380] Example 1: Cedar Race
[0381] B cell maturation antigen (BCMA, also known as CD269 and TNFRSF17) is a 20 kilodalton type III membrane protein that is part of the tumor necrosis receptor superfamily. BCMA is a cell surface antigen expressed at high levels primarily in B lineage cells. Figure 1 Expression of BCMA on various immune-derived cells was shown. Comparative studies have shown that BCMA is absent in most normal tissues and is not expressed on CD34-positive hematopoietic stem cells. BCMA binds 2 ligands that induce B-cell proliferation and plays a key role in B-cell maturation and subsequent differentiation into plasma cells. Selective expression and biological importance for myeloma cell proliferation and survival make BCMA a promising target for CAR-T-based immunotherapy (Cedacion).
[0382] Cidacioren is an autologous chimeric antigen receptor T cell (CAR-T) therapy targeting BCMA. The Cidacioren chimeric antigen receptor (CAR) contains two VHH domains targeting B cell maturation antigen (BCMA) designed to confer avidity. A diagram of the construct is shown in Figure 2The sidaciolense comprises a VHH domain comprising the amino acid sequence set forth in SEQ ID NO:2 and a VHH domain comprising the amino acid sequence set forth in SEQ ID NO:4.
[0383] Example 2: Treatment Method of Cedarciolamine
[0384] Here, we describe a Phase 1b-2, open-label, multicenter study designed to evaluate the safety and efficacy of cedaciclib in adult subjects with relapsed or refractory multiple myeloma. In the Phase 1b portion of the study, the recommended Phase 2 dose (RP2D) of cedaciclib was confirmed. In Phase 2, subjects were treated at the RP2D established in Phase 1b. The Phase 2 portion of the study was designed to further establish the safety and efficacy of cedaciclib. Figure 3 A schematic overview of the study flow chart, which includes the lymphodepletion protocol prior to cedakinumab infusion, is depicted in .
[0385] The first analysis was conducted approximately 6 months after the last subject received his initial dose of cedakiolamine. This report was generated by the first analysis specified in the protocol. A summary of the subjects who participated in the study is listed in Table 1, where the percentages are calculated with the number of subjects in all participating analysis sets as the denominator. A total of 113 subjects (Phase 1b: 35; Phase 2: 78) were enrolled (single collection) in the United States, of which 101 subjects (Phase 1b: 30; Phase 2: 71) received the conditioning regimen and 97 subjects (Phase 1b: 29; Phase 2: 68) received cedakiolamine infusion and received the infusion at the RP2D targeted. These 97 subjects constituted the all-treatment analysis group, which is the basis for all efficacy and safety analyses presented below. At the time of clinical cutoff, the median follow-up duration for all treatment analysis groups was 12.4 months based on Kaplan-Meier product limit estimates. A summary of the follow-up times for this study is presented in Table 2, which lists the follow-up times relative to the date of the first Cedarsin infusion (Day 1).
[0386] The patient population was screened to include patients with relapsed or refractory multiple myeloma who were treated with 3 prior lines or were double refractory to a PI / IMiD, and who had prior exposure to a PI, IMiD, or anti-CD38, where the PI is a proteasome inhibitor and the IMiD is an immunomodulatory drug. Another possible agent is an alkylating agent (ALKY). Eligible patients were ≥18 years of age, diagnosed with MM according to the International Myeloma Working Group (IMWG) diagnostic criteria, had measurable disease at baseline, and an Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2. Demographics and disease characteristics of the patient population in the Phase 1b portion of the study were as follows: Figure 8 shown.
[0387] Eligible subjects underwent apheresis to collect peripheral blood mononuclear cells (PBMCs). Study enrollment was defined as the day of apheresis. The cedakirine drug product (DP) was produced from T cells selected from the apheresis. Subjects who failed apheresis or production were allowed to attempt apheresis again.
[0388] Bridging therapy (anti-plasma cell-directed therapy between apheresis and the first dose conditioning regimen) is allowed when clinically indicated (i.e., to maintain disease stability while awaiting the manufacture of cedabenzab). Additional cycles of bridging therapy are considered based on the subject's clinical status and the time of availability of the CAR-T product. Bridging therapy is defined as a short-term treatment that has previously produced at least a stable disease response in the subject.
[0389] After meeting the safety criteria for treatment, a conditioning regimen was administered to the subjects to help them achieve lymphodepletion and promote CAR-T cell expansion. The lymphodepletion regimen consisted of daily intravenous (IV) administration of cyclophosphamide 300 mg / m2 and fludarabine 30 mg / m2 for 3 days. Cyclophosphamide 300 mg / m2 and fludarabine 30 mg / m2 before infusion of Cidaciorensay are consistent with the lymphodepletion regimen used in the commercially available CAR-T products Kymriah and Yescarta.
[0390] 5 to 7 days after starting the conditioning regimen, if Figure 4 Cedarsel prepared from apheresis material by viral transduction was administered on the day defined as Day 1 as indicated. Subjects received premedication approximately 1 hour prior to Cedarsel infusion. No corticosteroids were used prior to infusion. Pre-infusion medications are listed in Table 5. Following treatment with pre-infusion medications, Cedarsel was administered at a total target dose of 0.75×106 CAR-positive live T cells / kg (range: 0.5-1.0×106 CAR-positive live T cells / kg) in a single infusion, with a maximum total dose of 1.0×108 CAR-positive live T cells.
[0391] 1 or 2 cryopreserved patient-designated infusion bags contain a dose of Cedarciolamine. Thaw Cedarciolamine at the time of infusion coordinated with the time of infusion. Confirm infusion time in advance and coordinate thawing start time so that Cedarciolamine is available for infusion when the patient is ready. If receiving more than one bag for therapeutic infusion, thaw one bag at a time. Wait to thaw / infuse the next bag until you are certain that the previous bag has been safely administered.
[0392] The post-infusion period began after the completion of the Cedarsin infusion on Day 1 and continued until Day 100. The post-treatment period began on Day 101 and continued until study completion (defined as 2 years after the last subject received his or her initial dose of Cedarsin). Fig.14The expansion and persistence of cedakinumab as measured by blood concentrations are summarized in .
[0393] Example 3: Evaluation of the efficacy of the cedaciclib treatment method
[0394] Using the IMWG-based response criteria summarized in Table 6, the study classified responses in order from best to worst as stringent complete response (sCR), complete response (CR), very good partial response (VGPR), partial response (PR), minimal response (MR), stable disease, or progressive disease. Progressive disease was consistently documented across clinical study sites. The tests performed to assess the IMWG-based response criteria were as follows:
[0395] Myeloma protein measurements in serum and urine: Myeloma protein (M protein) measurements were performed using the following tests from blood and 24-hour urine specimens: serum quantitative Ig, serum protein electrophoresis (SPEP), serum immunofixation electrophoresis, serum FLC assay (per disease assessment for subjects with suspected CR / sCR and for subjects with serum FLC disease only), 24-hour urine M protein electrophoresis quantitative (UPEP), urine immunofixation electrophoresis, serum β2-microglobulin. Disease progression based on only one laboratory test was confirmed by at least one repeat study. Disease evaluation continued after relapse from CR until disease progression was confirmed. Serum and urine immunofixation and serum free light chain (FLC) assays were performed at screening and thereafter when CR was suspected (when serum or 24-hour urine M protein electrophoresis [by SPEP or UPEP] was 0 or not quantifiable). For subjects with light chain multiple myeloma, serum and urine immunofixation tests were routinely performed.
[0396] Serum calcium corrected for albumin: Blood samples for calculation of serum calcium corrected for albumin are collected and analyzed until development of documented disease progression; development of hypercalcemia (corrected serum calcium >11.5 mg / dL [>2.9 mmol / L]) may indicate disease progression or relapse if not attributable to any other cause. Calcium binds to albumin, and only unbound (free) calcium is biologically active; therefore, serum calcium levels must be adjusted for abnormal albumin levels ("corrected serum calcium").
[0397] Bone marrow examination: Bone marrow aspiration or biopsy is performed for clinical evaluation. Bone marrow aspiration is performed for biomarker evaluation. Clinical staging (morphology, cytogenetics and immunohistochemistry or immunofluorescence or flow cytometry) is performed. Immunophenotyping is performed on a portion of the bone marrow aspirate and BCMA, checkpoint ligand expression in CD138-positive multiple myeloma cells and checkpoint expression on T cells are monitored. If feasible, a bone marrow aspiration is also performed to confirm CR and sCR and disease progression. In addition, since minimal residual disease (MRD) negativity is evaluated as a potential surrogate for PFS and OS in the treatment of multiple myeloma, next-generation sequencing (NGS) is used for bone marrow aspirate DNA to monitor MRD in subjects. Baseline bone marrow aspirates are used to define myeloma clones, and post-treatment samples are used to evaluate MRD negativity. Fresh bone marrow aspirates are collected before the first dose of the conditioning regimen (≤7 days).
[0398] Skeletal Survey: A skeletal survey (including the skull, entire spine, pelvis, thorax, humerus, femur, and any other bones suspected by the investigator to be involved in disease) will be performed during the Screening Period and evaluated by radiography ("X-ray") or low-dose computed tomography (CT) scan without IV contrast. If a CT scan is used, it will be of diagnostic quality. After infusion of Cedars-Sinai and prior to confirmation of disease progression, local X-rays or CT scans will be performed to document response or progression, regardless of symptom-based clinical indication. Magnetic resonance imaging (MRI) is an acceptable method for evaluating bone disease and is included as appropriate; however, it does not replace the skeletal survey. If a radionuclide bone scan is used at Screening in addition to a complete skeletal survey, both methods are used to document disease status. These tests are performed simultaneously. A radionuclide bone scan may not replace a complete skeletal survey. If a subject has disease progression manifested by painful symptoms due to bone changes, disease progression will be documented by skeletal survey or other radiography, depending on the symptoms experienced by the subject. If the radiological investigation leads to a clear diagnosis of disease progression, repeat confirmatory X-rays are not considered necessary. If changes are unclear, repeat X-rays are performed within 1 to 3 weeks.
[0399] Documentation of Extramedullary Plasmacytoma: Document known sites of extramedullary plasmacytoma ≤ 14 days prior to the first dose of the conditioning regimen. Document extramedullary sites of disease using clinical examination or MRI. CT scan evaluation is considered an acceptable alternative if there are no contraindications to the use of IV contrast. Documentation of the size of extramedullary plasmacytoma by positron emission tomography scan or ultrasound testing is not acceptable. However, PET / CT fusion scans are optionally used to document extramedullary plasmacytoma if the CT portion of the PET / CT fusion scan is of adequate diagnostic quality. Evaluate extramedullary plasmacytoma by clinical examination or radiologic imaging for all subjects with a history of plasmacytoma or if clinically indicated ≤ 14 days prior to the first dose of the conditioning regimen. For subjects with a history of plasmacytoma or other subjects during treatment as clinically indicated, perform local assessment, measurement, or evaluation of measurable sites of extramedullary disease every 4 weeks (for physical examination) until development of a confirmed CR or confirmed disease progression. If only radiologic assessment can be performed, evaluation of extramedullary plasmacytoma is performed every 12 weeks. Irradiated or resected lesions are considered non-measurable and monitored only for disease progression. To qualify for VGPR or PR / minimal response (MR), the sum of the products of the perpendicular diameters of existing extramedullary plasmacytomas must have decreased by more than 90% or by at least 50%, respectively, and no new plasmacytomas must have developed. To qualify for disease progression, the sum of the products of the perpendicular diameters of existing extramedullary plasmacytomas must have increased by at least 50%, or the longest diameter of a prior lesion >1 cm in the short axis must have increased by at least 50%, or a new plasmacytoma must have developed. Disease progression criteria are met when not all existing extramedullary plasmacytomas are reported, but the sum of the products of the perpendicular diameters of the reported plasmacytomas has increased by at least 50%.
[0400] If study treatment was determined to interfere with the immunofixation assay, CR was defined as the disappearance of the original M-protein associated with multiple myeloma on immunofixation, and the determination of CR was not affected by unrelated M-protein secondary to study treatment.
[0401] The study endpoints (as assessed by the Independent Review Committee (IRC)) were as follows:
[0402] MRD was assessed in patients at baseline, day 28, and at 6, 12, 18, and 24 months follow-up in suspected complete response using next-generation sequencing (clonoSEQ version 2.0) (Adaptive Biotechnologies, Seattle, WA, USA), and then every 12 months until disease progression in patients remaining on study. MRD negativity was assessed in samples that passed calibration or quality control and included samples used for 10 -5Sufficient cells were assessed at the test threshold. The durability of MRD-negative status was assessed by estimating the MRD-negative rate at 6 and 12 months of follow-up.
[0403] Clinical benefit rate (CBR) was defined as the proportion of subjects who achieved MR or better response (sCR+CR+VGPR+PR+MR) according to IMWG criteria.
[0404] Overall response rate (ORR) was defined as the proportion of subjects who achieved PR or better response (sCR+CR+VGPR+PR) according to IMWG criteria.
[0405] The response rate of VGPR or better was defined as the proportion of subjects who achieved a VGPR or better response (sCR+CR+VGPR) according to IMWG criteria.
[0406] Duration of response (DOR) was calculated in responders (with a PR or better response) from the date of initial documentation of response (PR or better response) to the date of first documented evidence of progressive disease (as defined in the IMWG criteria). Relapse from a CR by positive immunofixation or trace M protein was not considered progressive disease. Disease evaluation continued after relapse from a CR until progressive disease was confirmed.
[0407] Time to response (TTR) was defined as the time between the initial infusion date of Cedaxacillin and the first efficacy evaluation in which a subject met all criteria for a PR or better response.
[0408] Progression-free survival (PFS) was defined as the time from the initial infusion date of Cedars-Sinai to the first documented date of disease progression (as defined in the IMWG criteria), or death from any cause, whichever occurred first.
[0409] Overall survival (OS) was measured from the date of initial infusion of Cedars-Sinai to the date of death of the subject.
[0410] For ORR, the response rate and its 95% exact confidence interval (CI) are calculated based on the binomial distribution, and the null hypothesis is rejected if the lower limit of the confidence interval exceeds 30%. The analysis of the response rate, DOR, PFS and OS of VGPR or better response is performed at the same cutoff value as ORR. The Kaplan-Meier method is used to estimate the event time efficacy endpoints (DOR, PFS and OS). The distribution (median and Kaplan-Meier curve) of DOR is provided using Kaplan-Meier estimates. Similar analyses were performed for OS, PFS and TTR.
[0411] Example 4: Safety evaluation of the treatment method of Cidaciolense
[0412] Adverse events were followed, reported, and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE version 5.0), with the exception of CRS and CAR-T cell-related neurotoxicity (such as ICANS). CRS was assessed according to the ASTCT consensus grade, summarized in Table 7. Subjects were hospitalized immediately for evaluation at the first sign of CRS (such as fever). Tocilizumab intervention was used as appropriate to treat subjects with fever symptoms when other sources of fever had been eliminated. Tocilizumab was used as appropriate for early treatment of subjects at high risk for severe CRS (e.g., high baseline tumor burden, early onset of fever, or persistent fever after 24 hours of symptomatic treatment). Other monoclonal antibodies targeting cytokines (e.g., anti-IL1 and / or anti-TNFα) are optionally used, especially for CRS that does not respond to tocilizumab.
[0413] CAR-T cell-related neurotoxicity (e.g., ICANS) was graded using the ASTCT consensus grade, summarized in Table 8. In addition, all individual symptoms of CRS (e.g., fever, hypotension) and ICANS (e.g., decreased level of consciousness, seizures) were captured as individual adverse events and graded according to CTCAE criteria. Neurotoxicity that was not temporarily associated with CRS, or any other neurological adverse event that did not meet ICANS, was graded according to CTCAE criteria. Any adverse event or serious adverse event not listed in the NCI CTCAE version 5.0 was graded using the following standard grades based on the investigator's clinical judgment:
[0414] Grade 1: Mild; asymptomatic or mildly symptomatic; clinical or diagnostic observation only; no intervention indicated.
[0415] Grade 2: Moderate; minimal, local, or noninvasive intervention indicated; limitation to age-appropriate instrumental activities of daily living.
[0416] Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolonged hospitalization indicated; disability; limiting self-care activities of daily living.
[0417] Level 4: Life-threatening consequences; urgent intervention indicated.
[0418] Grade 5: Death related to adverse events.
[0419] According to the independent review committee (IRC) assessment, at a median follow-up of 12.4 months, the responses and duration of responses of responders in all treatment analysis sets are shown in Figure 5. Table 9 summarizes the overall best response of subjects in all treatment analysis sets. In all treatment analysis groups, based on IRC assessment, 94 subjects (96.9%) achieved a response of PR or better response, 65 subjects (67.0%) achieved a complete response (CR) or better response, and the CBR was 96.9%. The following shows the deep and durable responses induced by Cedars-Sinai: the rate of VGPR or better response was 92.8% and the rate of CR or better response was 67.0%, and the median DOR was not reached at a median follow-up time of 12.4 months at the clinical cutoff time. The indicators used to evaluate the efficacy of Cedars-Sinai are summarized below:
[0420] Tumor burden reduction: 100% of subjects had a reduction in tumor burden. Fig.10 A graph showing the reduction in tumor burden in patients in the Phase 1b-2 study is shown in .
[0421] Overall Response Rate (ORR): 96.9% of subjects had an overall response, with 95% exact CI (91.2%, 99.4%). Fig.11 A summary of the ORR for patients in the Phase 1b-2 study is given in.
[0422] VGPR or better response: 90 subjects (92.8% of subjects) achieved a VGPR (very good partial response) or better response.
[0423] Duration of response (DOR): The median DOR was not reached with a 95% CI (15.9, NE) months; the probability of responders maintaining a response at 9 and 12 months was 80.2% (95% CI: 70.4%, 87.0%) and 68.2% (95% CI: 54.4%, 78.6%), respectively. Figure 6 Kaplan-Meier plots of the DOR for all responders in the all-treatment analysis set are given in and the DOR for all responders in the all-treatment analysis set is summarized in Table 10. Fig.13 A graph of the DOR for patients in the Phase 1b-2 study is given in .
[0424] Time to response (TTR): The median time to first response (PR or better) and the median time to best response were 0.95 and 2.56 months, respectively.
[0425] Progression-free survival (PFS): Median PFS was not reached with 95% CI (16.79, NE) months; 9-month and 12-month PFS rates (95% CI) were 80.3% (70.9%, 87.0%) and 76.6% (66.0%, 84.3%), respectively. A summary of PFS in all treatment analysis groups is presented in Table 11.
[0426] Overall survival (OS): At the clinical cutoff time, 14 subjects (14.4%) had died. The 9-month and 12-month overall survival rates (95% CI) were 90.7% (82.8%, 95.0%) and 88.5% (80.2%, 93.5%), respectively. Figure 7 Kaplan-Meier plots of OS based on all treatment analysis sets are given in and OS based on all treatment analysis sets are summarized in Table 12.
[0427] Mean residual disease (MRD) negative rate (in 10 -5 At the sensitivity level of 50%, the MRD-negative rate was 54.6% (95% CI: 44.2%, 64.8%), and 33 subjects (34.0%) achieved MRD-negative CR / sCR. Table 13 presents the 10 mRNA expression in the bone marrow of all subjects in all treatment analysis groups. -5 A summary of the overall MDR-negative rates under 10-year follow-up is presented in Table 14 for all treatment analysis groups. -5 The overall MDR-negative rates for subjects with evaluable samples are summarized below. Evaluable samples are samples that passed calibration and quality control and included sufficient cells for evaluation at the respective test threshold. Fig.12 and Fig.15 A summary of the MRD of patients in the Phase 1b-2 study is given in.
[0428] Cedars-Sinai was determined to have a safety profile consistent with the mechanism of action of CAR-T therapy. Fig. 9 A summary of adverse events in the Phase 1b-2 trials is shown in .
[0429] CRS: CAR-T cell-related adverse events of CRS were common (94.8%), but most were low grade. CRS of all grades was reported in 92 subjects (94.8%) as assessed by the ASTCT consensus grading system. All CRS events recovered except for 1 fatal event (1.1%) from a subject with CRS duration of 97 days. Table 15 and Fig.16 A summary of treatment-emergent CRS events in all treatment analysis sets is given in. Figure 17-19 A graph and summary of the various CRS protein markers observed in all patients are given.
[0430] Immune effector cell-associated neurotoxicity (ICANS): ICANS of all grades were reported in 16 (16.5%) subjects, as assessed by the ASTCT consensus grading system. All events recovered. A summary of ICANS occurring after infusion of cedakiol in all treatment analysis groups is presented in Table 16.
[0431] Cytopenias: Grade 3 or 4 cytopenias were common in the post-infusion period and included lymphopenia, neutropenia, thrombocytopenia, but most of these events recovered by Day 60. In the first 100 days after infusion of Cedars-Sinai, 96 (99.0%), 95 (97.9%), and 60 (61.9%) subjects had Grade 3 or 4 lymphopenia, neutropenia, and thrombocytopenia, respectively. By Day 60, 88 (90.7%), 85 (87.6%), and 41 (42.3%) subjects had their initial Grade 3 or 4 events for lymphopenia, neutropenia, and thrombocytopenia recovered to Grade 2 or less, respectively. A summary of cytopenias following treatment with Cedars-Sinai in all treatment analysis groups is presented in Table 17.
[0432] In conclusion, single-agent and one-time infusion of cedacion demonstrated unprecedented clinical activity in a heavily pretreated patient population, including an ORR of 96.9% and a rapid onset of response in less than 1 month.
[0433] Example 5: Evaluation results of the Cedarciolamine treatment method with a median follow-up time of 18 months
[0434] As of this analysis, 97 patients received infusions of cedaciolencel (median administered dose, 0.71×106; range, 0.51×106-0.95×106 CAR-positive viable T cells / kg). Of the 91 patients with baseline cytogenetic data, 23 patients (23.7%) had high-risk cytogenetic features based on the presence of at least one chromosomal abnormality, including del17p (19.6%), t(4;14) (3.1%) and / or t(14;16) (2.1%). Of the 96 patients with evaluable bone marrow biopsy and / or aspirate samples, more than half of the patients (60.4%) had a low disease burden (≤30 plasma cells), 21.9% had a high disease burden (≥60 plasma cells), and 17.7% had a moderate disease burden (>30 to <60 plasma cells). Plasma cell tumors were detected in 19.6% of patients at screening.
[0435] Table 18-26 and Figure 20-23 Various safety / efficacy parameters with a median follow-up of 18 months were detailed and are also summarized below.
[0436] effect
[0437] At a median follow-up of 18 months, the ORR was 97.9% (95% CI, 92.7-99.7), the sCR rate was 80.4%, the VGPR rate was 14.4%, and the PR rate was 3.1% (Table 1).
[0438] The median time to first response was 1 month (range, 0.9-10.7), the median time to best response was 2.6 months (range, 0.9-15.2), and the median time to CR or better was 2.6 months (range, 0.9-15.2).
[0439] • The median DOR for the overall population was 21.8 months (95% CI, 21.8-not estimable), which was not reached in sCR patients.
[0440] The median PFS for all patients was 22.8 months (95% CI, 22.8-not estimable) and was not reached in patients with sCR ( Fig. 20 The 18-month PFS rates in all patients and sCR patients were 66.0% (95% CI, 54.9-75.0) and 75.9% (95% CI, 63.6-84.5), respectively.
[0441] The 18-month OS rate among all patients was 80.9% (95% CI, 71.4-87.6) ( Fig. 20 ).
[0442] Among the 61 patients evaluable for MRD, 91.8% were within 10 -5 MRD negativity was achieved below the threshold. 44.3% (27 / 61) of patients had MRD negativity for ≥6 months, and 18% (11 / 61) of patients had MRD negativity for ≥12 months.
[0443] o The 18-month PFS rates were 96.3% (95% CI, 76.5-99.5) and 100% in patients with persistent MRD ≥6 months and ≥12 months, respectively.
[0444] ORRs were consistently high across all subgroups (range, 95.1%-100%), including patients treated with 3 prior lines of therapy (100% [95% CI, 80.5-100]), patients with high-risk cytogenetic features (100% [95% CI, 85.2-100]), patients with high disease burden (≥60% bone marrow plasma cells; 95.2% [95% CI, 76.2-99.9]), and patients with plasmacytomas (100.0% [95% CI, 82.4-100]) (Table 2). MRD-negative rates (threshold, 10 -5) is 80%-100%.
[0445] Although ORR and MRD-negative benefit were consistent, other efficacy results were not maintained in specific subgroups.
[0446] Patients with ISS stage III had lower median DOR (13.8 months [95% CI, 5.1-not estimable]), 18-month PFS rate (34.3% [95% CI, 9.4-61.6]), and 18-month OS rate (48.2% [95% CI, 20.8-71.2]), while patients with plasmacytomas at baseline had lower median DOR (6.8 months [4.0-not estimable]), 18-month PFS rate (46.8% [95% CI, 23.7-67.0]), and 18-month OS rate (64.5% [95% CI, 35.6-83.0]).
[0447] Patients with high tumor burden (≥60% bone marrow plasma cells) had lower 18-month PFS rates (50.6% [95% CI, 27.5-69.9]) and 18-month OS rates (71.4% [95% CI, 47.2-86.0]).
[0448] Security
[0449] No new safety signals were observed at a longer follow-up duration in patients treated with cedakitoplamine.
[0450] The most common (≥25%) grade 3 / 4 treatment-emergent AEs (TEAEs) were neutropenia (94.8%), anemia (68.0%), leukopenia (60.8%), thrombocytopenia (59.8%), and lymphopenia (49.5%) (Table 3).
[0451] The most common grade 3 / 4 non-hematologic TEAEs were hypophosphatemia (7.2%), fatigue (5.2%), and increased aspartate aminotransferase (AST) (5.2%) (Table 3).
[0452] CRS was reported in 94.8% (n=92) of patients (94.6% grade 1 / 2), with a median onset of 7 days (range: 1-12) and a median duration of 4 days (range: 1-97). 91 of 92 patients had CRS resolved within 14 days; one patient with grade 5 CRS and hemophagocytic lymphohistiocytosis died on day 99 after sequelae of prolonged grade 4 CRS.
[0453] No new neurotoxicity events were reported during extended follow-up compared with the primary analysis, and no new cases of neurocognitive TEAEs were identified.
[0454] One patient with progressive disease was retreated with cedakinumab; the patient's disease remained stable after retreatment (according to the computer algorithm) with no treatment-related neurotoxicity.
[0455] This extended follow-up of the Cedacioline trial described herein showed that Cedacioline maintained clinical benefit for 18 months in RRMM patients undergoing a median of 6 prior lines of therapy, and that such patients experienced manageable side effect profiles with no new safety signals. During an additional 6-month follow-up, a high ORR (97.9%) was maintained. Deep and durable responses were observed, with 80.4% of patients showing sCR. MRD negativity was also maintained in 91.8% of evaluable patients and lasted for 6-12 months. Given that there is evidence that MRD negativity has prognostic value for improving long-term survival outcomes across a variety of disease backgrounds, including patients exposed to several prior lines of therapy, it is particularly interesting to evaluate the persistence of MRD-negative status.
[0456] After 18 months of follow-up for cedaxolamine, no new safety signals were identified. The most frequently reported TEAEs were consistent with the side effect profile reported for cedaxolamine in the primary analysis. No new neurotoxicity events were reported, and no new cases of motor and neurocognitive TEAEs were observed.
[0457] In conclusion, the data from the Cedaciclib trial with longer follow-up described here confirm the significant clinical benefit of Cedaciclib in patients with RRMM across the three exposure categories.
[0458] Example 6: Results of the evaluation of the treatment with Cedars-Sinai in patient subgroups
[0459] Next, we evaluated the efficacy and safety of cedaciclib in different patient subgroups in a phase 1b-2 cedaciclib clinical trial. Eligible patients had multiple myeloma (MM) and had received at least 3 prior regimens or were double refractory to a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD) and had received a PI, IMiD, and anti-CD38 antibody. After apheresis, bridging therapy was allowed. Patients received a single cedaciclib infusion (target dose: 0.75×106 CAR+ viable T cells / kg; range 0.5-1.0×106) 5-7 days after lymphodepletion (300 mg / m2 cyclophosphamide, 30 mg / m2 fludarabine, daily for 3 days). The primary objectives were to characterize the safety of cedaciclib, confirm the recommended phase 2 dose (phase 1b), and evaluate efficacy (phase 2). Lee et al (Blood 2014) graded cytokine release syndrome (CRS) and neurotoxicity according to Common Terminology Criteria for Adverse Events (CTCAE) v5.0 (Phase 1b). CRS and immune effector cell-associated neurotoxicity (ICANS) were graded according to the American Society for Transplantation and Cellular Therapy (ASTCT) criteria (Phase 2). Herein, Lee et al and CTCAE v5.0 were mapped to ASTCT for CRS and ICANS, respectively. Efficacy and safety were evaluated in the following subgroups according to baseline (BL) characteristics: age ≥65 years, black / African American, 3 prior lines of therapy (LOT), ≥4 prior LOT, refractory to three classes, refractory to five classes of drugs, standard and high-risk cytogenetics, International Staging System stage III, bone marrow plasma cells (≤30%, >30 to <60%, and ≥60%), BCMA tumor expression (< median, ≥ median), and the presence of plasmacytoma (bone and extramedullary based).
[0460] Tables 28-32 and Figures 24-27 detail the various safety / efficacy parameters for the different subgroups analyzed at a median follow-up of 18 months. These parameters are also summarized below.
[0461] As of this subgroup analysis, at a median follow-up of 18 months, 97 patients in the overall population (58.8% male; median age, 61 years [range, 43-78]; median time from diagnosis to enrollment, 5.9 years [1.6-18.2]) received cedacion. Efficacy results were comparable to the overall population, with consistently high ORRs across all evaluated subgroups (range, 95.1%-100%; table), including those with high-risk cytogenetics, ISS stage III MM, BL bone marrow cells ≥60%, and BL plasmacytoma. The median DOR and median PFS were consistent with the overall population or not reached in most subgroups, while they were lower in patients with high-risk diseases such as ISS stage III and BL plasmacytoma (table). In all subgroups, the majority of patients (80%-100%) who could assess MRD at a threshold of 10-5 achieved MRD negativity. The 18-month PFS and OS rates were consistent with the overall population in most subgroups. These improvements were also achieved in patients with high-risk disease, albeit at a lower rate (Table). The incidence of CRS, ICANS, and other CAR T-cell neurotoxicities (events not reported as ICANS [ie, onset some time after recovery from CRS and ICANS]) in the different subgroups was consistent with that in the overall population, with no new safety signals.
[0462] At a median follow-up of 18 months, a single infusion of cedaciclib produced deep and durable responses in all evaluated high-risk patient subgroups with poor prognosis described herein. Across different subgroups, 90%-100% of patients achieved ORR, including patients with high-risk cytogenetics, ISS stage III MM, BL bone marrow cells ≥ 60%, and BL plasmacytoma. The safety profile of cedaciclib across subgroups was consistent with the overall population, with no new safety signals.
[0463] Example 7: Comparison of the Cedarsin Treatment Method with the Physician's Choice Treatment
[0464] As described in Examples 2-4 (supra), cedacib is effective and safe in patients with relapsed or refractory multiple myeloma ("RRMM") who are triple-exposure (exposure to immunomodulatory drugs, proteasome inhibitors, and anti-CD38 monoclonal antibodies). Because there is no clear standard of care for this indication, and because of the lack of direct head-to-head trials evaluating cedacib and other related treatments, we performed an indirect treatment comparison (ITC) between cedacib and treatments currently used in clinical practice (i.e., physician's choice of treatment ("PCT")). In brief, a meta-analysis was performed to evaluate cedacib versus PCT in patients with triple-exposure RRMM by combining ITCs to derive a single summary effect estimate for overall survival ("OS") and progression-free survival ("PFS").
[0465] An ITC examining the comparative effectiveness of cedaciclib versus PCT on OS and PFS was included. Fig.28 The selection of the comparator groups for the ITC analysis is summarized in . Data on PCT were obtained from the following sources: (i) the Flatiron database, a predominantly US community-based multiple myeloma registry, (ii) long-term follow-up results of 3 global randomized clinical trials of daratumumab in RRMM (POLLUX [NCT02076009], CASTOR [NCT02136134], and EQUULEUS [NCT01998971]), (iii) the US-based retrospective MAMMOTH study, (iv) a representative German patient registry maintained by the Oncology Information Service (OIs), and (v) the LocoMMotion study [NCT04035226], a prospective, noninterventional, multinational study of the efficacy and safety of real-life standard of care in patients with RRMM who have received at least three prior lines of therapy, including at least one PI, IMiD, and anti-CD38 antibody. In each ITC, the PCT group consisted of patients who met the key eligibility criteria of the Phase 1b-2 clinical trial of Cedars-Sinai described in Examples 2-4 (the "Cedars-Sinai Trial") and was weighted using inverse probability of treatment to make it comparable to the Cedars-Sinai Trial. Therefore, the ITCs were considered suitable for meta-analysis. The meta-analysis used a robust variance estimator to account for the use of the Cedars-Sinai Trial in each paired ITC.
[0466] We performed meta-analyses using two populations: (1) the “ITT” (intention-to-treat) population, which included all enrolled (apheresis) participants in the Cedaciolinsel study and all eligible patients in the PCT group; and (2) the “mITT” (modified intention-to-treat) population, which included all participants who received an infusion of Cedaciolinsel in the Cedaciolinsel study and all eligible patients in the PCT group who did not progress or die within 47 days (52 days for OIs and LocoMMotion) after starting treatment; the median (mean) time between apheresis and infusion in the Cedaciolinsel study. The meta-analysis was performed in two formats:
[0467] 1. The primary meta-analysis considered all index dates for all participants treated with cedarioxaban in the cedarioxaban trial compared with PCT using the modified intention-to-treat (“mITT”) and intention-to-treat (“ITT”) populations. For these meta-analyses, the start of each eligible LOT was used as the index date. Eligible patients in the PCT group who received multiple subsequent therapies contributed multiple LOTs to the analysis (as independent observations) if they remained eligible at the start of each LOT. ITCs with all index dates were not available for MAMMOTH and LocoMMotion.
[0468] 2. Additional analyses of ITC were performed using the first index date for both the mITT and ITT populations. For these meta-analyses, the start of the first eligible LOT was used as the index date, and each patient in the PCT group contributed only their first eligible LOT to the analysis.
[0469] Sensitivity analyses considered ITC effect estimates based on all enrolled participants in the Cedars-Sinai trial. Pooled summary effect estimates are presented as hazard ratios (HRs) with corresponding 95% confidence intervals (CIs).
[0470] Based on data availability, the primary meta-analysis included four ITCs for OS and three ITCs for PFS. Sensitivity analyses including all enrolled participants confirmed the results of the primary meta-analysis. Figures 29-32 show meta-analysis comparisons of overall survival (OS) or progression-free survival (PFS) for patients enrolled / treated in the Cedars-Sinai trial and those who received physician's choice of treatment using all index dates or the first index date.
[0471] Cedars-Sinai demonstrated significant superiority over PCT in terms of OS, PFS, TTNT, and ORR, highlighting its potential as an effective therapy for patients with RRMM in the three exposure categories. Conclusions were consistent across populations (mITT vs ITT) and available index dates.
[0472] In conclusion, the meta-analysis showed that cedaxel had a significant advantage over PCT in terms of OS and PFS, highlighting its potential as an effective therapy in patients with RRMM with three exposure categories. In the absence of a head-to-head comparison of cedaxel and treatments used in real-world clinical practice, this meta-analysis of ITCs showed that cedaxel provided a clinical benefit far greater than PCT for patients with RRMM with three exposure categories.
[0473]
[0474]
[0475]
[0476]
[0477]
[0478]
[0479]
[0480] Table 5: Pre-infusion medications
[0481]
[0482] Table 6: Criteria for response to treatment in multiple myeloma
[0483]
[0484]
[0485] a Criteria for interpretation of CR and VGPR for subjects whose disease can only be measured by serum FLC levels:
[0486] In addition to the CR criteria listed above, CR in such subjects indicates a normal FLC ratio of 0.26 to 1.65. Such subjects must have a ≥90% decrease in the difference between the VGPR, affected and unaffected FLC levels. For patients who achieve a very good partial response by other criteria, the sum of the maximum perpendicular diameters (SPD) of the soft tissue plasmacytomas must be reduced by more than 90% from baseline.
[0487] b. In some cases, it is possible that the original M protein light chain isotype is still detected by immunofixation, but the accompanying heavy chain component has disappeared; even if the heavy chain component is undetectable, this is not considered a CR because the clone may have evolved into a clone that secretes only light chains. Therefore, if the patient has an IgA lambda myeloma, then in order to qualify as a CR, no IgA should be detected in serum or urine immunofixation; if free lambda is detected in the absence of IgA, then it must be accompanied by a different heavy chain isotype (IgG, IgM, etc.).
[0488] c. Clarification on the interpretation of disease progression criteria: The bone marrow criteria for disease progression are used only in subjects whose disease is not measurable by M-protein and by FLC levels; the “25% increase” refers to M-protein and FLC, not to bone lesions or soft tissue plasmacytomas, and the “lowest response value” does not need to be a definitive value.
[0489] NOTE: All response categories (CR, sCR, VGPR, PR, MR, and progressive disease) require 2 consecutive assessments at any time prior to initiation of any new therapy; if radiographic studies are performed, the CR, sCR, VGPR, PR, MR, and stable disease categories must also have no known evidence of progressive or new bone lesions. The VGPR and CR categories must have serum and urine studies, regardless of whether the disease at baseline is measurable in serum, urine, both, or neither.
[0490] Radiologic studies are not required to meet these response requirements. Confirmatory bone marrow evaluation is not required. For progressive disease, an increase in serum M component of ≥1 g / dL is sufficient to define relapse if the nadir M component is ≥5 g / dL.
[0491] Table 7: ASTCT consensus grading system for cytokine release syndrome
[0492]
[0493] a Fever that cannot be attributed to any other cause. In patients who have CRS and then receive antipyretics or anticytokine therapy such as tocilizumab or steroids, fever is no longer required to grade the severity of subsequent CRS. In this setting, CRS grading is driven by hypotension and / or hypoxia.
[0494] b Low-flow nasal cannula was defined as oxygen delivery at ≤6 L / min or sparge oxygen delivery. High-flow nasal cannula was defined as oxygen delivery at >6 L / min.
[0495] c The CRS grade was determined by the more severe event: hypotension or hypoxia that could not be attributed to any other cause.
[0496] Note: Organ toxicity associated with CRS can be graded according to CTCAE v5.0 but does not affect the CRS grade.
[0497] Table 8: ASTCT consensus grading system for immune effector cell-associated neurotoxicity syndrome (ICANS) a,b
[0498]
[0499]
[0500] a: According to the toxicity classification of Lee et al. 2019
[0501] b: ICANS grade was determined by the most severe event (ICE score, level of consciousness, seizure, motor findings, increased ICP / cerebral edema) that could not be attributed to any other cause.
[0502] NOTE: All other neurologic adverse events (not related to ICANS) should continue to be graded using the CTCAE version 5.0 during both phases of the study.
[0503]
[0504]
[0505]
[0506]
[0507]
[0508]
[0509]
[0510]
[0511]
[0512]
[0513]
[0514]
[0515]
[0516]
[0517]
[0518]
[0519]
[0520]
[0521]
[0522]
[0523]
[0524]
[0525]
[0526]
[0527]
[0528]
[0529]
[0530]
[0531] Table 28: Efficacy Results by Patient Subgroup; All Treatment Analysis Groups with a Median Follow-up of 18 Months
[0532]
[0533]
[0534] *In MRD-evaluable patients; in all treated patients at day 28 and at months 6, 12, 18, and 24 by next-generation sequencing (clonoSEQ, Adaptive Biotechnologies). -5 MRD was assessed in evaluable samples at threshold values, regardless of disease status measured in blood or urine. Includes bone-based and extramedullary plasmacytomas.
[0535] DOR, duration of response; LOT, line of therapy, MRD, minimal residual disease; NE, not estimable; NR, not reached; ORR, overall response rate; OS, overall survival; PFS, progression-free survival.
[0536]
[0537]
[0538]
[0539]
[0540]
[0541]
[0542]
[0543]
[0544]
[0545]
[0546]
[0547] Example 8: Approved Drug Product Labeling Approved Drug Product Labeling:
[0548]
[0549]
[0550]
[0551] FULL PRESCRIBING INFORMATION WARNING: Cytokine release syndrome, neurotoxicity, HLH / MAS, and prolonged and recurrent cytopenias, including fatal or life-threatening reactions, have occurred in patients following CARVYKTI treatment. Do not administer CARVYKTI to patients with active infection or inflammatory disease. Treat severe or life-threatening CRS with tocilizumab or tocilizumab and corticosteroids [see Dosage and Administration (2.2, 2.3), Warnings and Precautions (5.1)].
[0552] Immune effector cell-associated neurotoxicity syndrome (ICANS), which may be fatal or life-threatening, has occurred following CARVYKTI treatment, including before the onset of CRS, concurrently with CRS, after resolution of CRS, or in the absence of CRS. Monitor for neurologic events following CARVYKTI treatment. Provide supportive care and / or corticosteroids as needed [see Dosage and Administration (2.2, 2.3), Warnings and Precautions (5.2)].
[0553] Parkinsonism and Guillain-Barré syndrome and their related complications, leading to fatal or life-threatening reactions, have occurred following treatment with CARVYKTI [see Warnings and Precautions (5.2)].
[0554] Hemophagocytic lymphohistiocytosis / macrophage activation syndrome (HLH / MAS), including fatal and life-threatening reactions, has occurred in patients following treatment with CARVYKTI. HLH / MAS may occur in conjunction with CRS or neurotoxicity [see Warnings and Precautions (5.3)].
[0555] Prolonged and / or recurrent cytopenias, associated with bleeding and infection, requiring stem cell transplantation to restore hematopoiesis, occurred following CARVYKTI treatment [see Warnings and Precautions (5.5)].
[0556] CARVYKTI is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS), known as the CARVYKTI REMS Program [see Warnings and Precautions (5.4)].
[0557] 1 Indications and Usage
[0558] CARVYKTI is a genetically modified autologous T cell immunotherapy directed against B-cell maturation antigen (BCMA) indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
[0559] 2 Dosage and administration
[0560] For autologous use only. For intravenous use only.
[0561] 2.1 Dosage
[0562] CARVYKTI is provided as a single-dose infusion containing a suspension of live chimeric antigen receptor (CAR)-positive T cells in one infusion bag.
[0563] The recommended dose range is 0.5-1.0×10 6 CAR-positive live T cells / kg body weight, with a maximum dose of 1×10 8 CAR-positive live T cells.
[0564] 2.2 Application
[0565] CARVYKTI is for autologous use only. The patient's identity must match the patient identifier on the CARVYKTI box and infusion bag. Do not infuse CARVYKTI if the information on the patient-specific label does not match the intended patient.
[0566] Preparing the patient for CARVYKTI infusion
[0567] Confirm availability of CARVYKTI prior to initiating a lymphodepleting chemotherapy regimen.
[0568] Preprocessing
[0569] Lymphodepleting chemotherapy: cyclophosphamide 300 mg / m daily 2 Intravenous (IV) and fludarabine 30 mg / m 2 IV for 3 days.
[0570] See the prescribing information for cyclophosphamide and fludarabine for information on dose adjustments for renal impairment.
[0571] The lymphodepleting regimen must be delayed if the patient has experienced severe adverse reactions from prior bridging therapy (including clinically significant active infection, cardiotoxicity, and pulmonary toxicity) or active graft-versus-host disease in patients who have received a prior allogeneic stem cell transplant. If CARVYKTI dosing is delayed for more than 14 days and the patient has recovered from toxicity from the first lymphodepleting regimen, consider repeating the lymphodepleting regimen.
[0572] Administer the CARVYKTI infusion 2 to 4 days after completion of the lymphodepleting chemotherapy regimen.
[0573] The CARVYKTI infusion should be delayed if the patient has any of the following:
[0574] Clinically significant active infection or inflammatory disorder.
[0575] Grade ≥3 non-hematologic toxicities with cyclophosphamide and fludarabine conditioning, excluding Grade 3 nausea, vomiting, diarrhea, or constipation. CARVYKTI infusion should be delayed until these events resolve to ≤ Grade 1.
[0576] Pre-medication
[0577] Administer the following pre-infusion medications to all patients 30-60 minutes prior to CARVYKTI infusion:
[0578] Antipyretics (acetaminophen 650 to 1000 mg orally or intravenously).
[0579] Antihistamines (diphenhydramine 25 to 50 mg orally or intravenously or equivalent).
[0580] Avoid prophylactic use of systemic corticosteroids as their use may interfere with the activity of CARVYKTI.
[0581] CARVYKTI’S ACCEPTANCE
[0582] All sites approved for infusion will support the required storage conditions for the liquid nitrogen vapor phase.
[0583] CARVYKTI is shipped in a liquid nitrogen vapor phase shipping box directly to the cell laboratory or clinical pharmacy associated with the infusion center.
[0584] ·Confirm patient identity using the patient identifier on the shipping box.
[0585] If the patient is not expected to be ready for same-day administration, transfer CARVYKTI to on-site liquid nitrogen vapor phase storage prior to expiration of the shipping container.
[0586] Preparation of CARVYKTI for infusion
[0587] Do not thaw the product until ready to use. Coordinate the timing of CARVYKTI thawing and infusion. Confirm the infusion schedule in advance and adjust the thawing start time so that CARVYKTI can be infused when the patient is ready. After thawing, CARVYKTI infusion must be completed within 2.5 hours at room / ambient temperature (20°C to 25°C).
[0588] Before thawing the product, confirm that tocilizumab and emergency equipment are available prior to infusion and during the recovery period.
[0589] 1. Confirm Patient Identity: Prior to preparing CARVYKTI, match the patient identity with the patient identifier on the CARVYKTI box. If the information on the patient-specific label does not match the intended patient, do not remove the CARVYKTI infusion bag from the box. If there is any discrepancy between the label and the patient identifier, contact Janssen Biotech, Inc. at 1-800-526-7736.
[0590] 2. After confirming the patient's identity, remove the CARVYKTI product bag from the box and check that the patient information on the box label matches the patient information on the bag label.
[0591] 3. Inspect product bags for any signs of damage to container integrity, such as cracks or tears, before thawing. If bag is damaged, do not apply and contact Janssen Biotech, Inc. at 1-800-526-7736.
[0592] 4. Place the infusion bag in a sealable plastic bag (preferably sterile) before thawing.
[0593] 5. Thaw CARVYKTI at 37°C ± 2°C using a water bath or dry thawing method until no ice is visible in the infusion bag. The total time from the start of thawing to completion of thawing should not exceed 15 minutes.
[0594] 6. Remove the infusion bag from the sealable plastic bag and wipe dry. Gently mix the contents of the bag to disperse clumps of cellular material. If clumps of cells are still visible, continue to gently mix the contents of the bag. Small clumps of cellular material should be dispersed by gentle manual mixing. Do not pre-filter CARVYKTI into a different container, wash, spin, or resuspend in new media prior to infusion.
[0595] 7. Do not refreeze or refrigerate thawed product.
[0596] Application
[0597] For autologous infusion only.
[0598] Do not use leukocyte removal filters.
[0599] Ensure that at least two doses of tocilizumab and emergency equipment are available before the infusion and during the recovery period.
[0600] Central venous access is available for infusion of CARVYKTI and is encouraged in patients with poor peripheral access.
[0601] 1. Confirm patient identity using the patient identifier on the infusion bag. Do not infuse CARVYKTI if the information on the patient-specific label does not match the intended patient.
[0602] 2. Fill the tubing of the infusion set with normal saline before infusion.
[0603] 3. After thawing, administer the entire contents of the CARVYKTI bag by intravenous infusion over 2.5 hours using an infusion set equipped with an inline filter.
[0604] 4. Gently mix the contents of the bag during CARVYKTI infusion to disperse cell clumps.
[0605] 5. After infusing the entire contents of the product bag, flush the administration line (including the in-line filter) with a volume of normal saline equal to or greater than the total holding volume of the primary administration set including the dropper to ensure that all product has been delivered.
[0606] CARVYKTI contains human blood cells that have been genetically modified with a replication-incompetent, self-inactivating lentiviral vector. Follow universal precautions and local biosafety guidelines for handling and disposal of CARVYKTI to avoid potential spread of infectious diseases.
[0607] Post-infusion monitoring
[0608] Administer CARVYKTI in a REMS-certified healthcare setting.
[0609] Monitor patients for signs and symptoms of cytokine release syndrome (CRS) and neurotoxicity at least daily for 10 days following the infusion of CARVYKTI at a certified healthcare facility. Monitor for signs and symptoms of delayed neurotoxicity regularly for 4 weeks.
[0610] Instruct patients to remain in the vicinity of a certified healthcare facility for at least 4 weeks following infusion.
[0611] Instruct patients to avoid driving or performing hazardous activities for at least 8 weeks after infusion.
[0612] 2.3 Management of serious adverse reactions
[0613] Cytokine Release Syndrome
[0614] Recognize CRS based on clinical presentation [see Warnings and Precautions (5.1)]. Evaluate and treat other causes of fever, hypoxia, and hypotension. Consider laboratory tests to monitor disseminated intravascular coagulation, hematologic parameters, and pulmonary, cardiac, renal, and hepatic function. If CRS is suspected, manage according to the recommendations in Table 1.
[0615] Patients who experience CRS should have their cardiac and other organ function closely monitored until symptoms resolve. Consider antiseizure prophylaxis with levetiracetam in patients who experience CRS.
[0616] Patients who experience Grade 2 or higher CRS (eg, hypotension unresponsive to fluids or hypoxia requiring supplemental oxygenation) should be monitored by continuous telemetry and pulse oximetry.
[0617] For severe or life-threatening CRS, consider intensive care unit-level monitoring and supportive care.
[0618] Consider alternative treatment options (i.e., higher corticosteroid doses, alternative anti-cytokine agents, such as anti-IL1 and / or anti-TNFα, anti-T-cell therapy) for CRS that is refractory to first-line interventions (e.g., tocilizumab or tocilizumab and corticosteroids). Refractory CRS is characterized by fever, end-organ toxicity (e.g., hypoxia, hypotension) that does not improve within 12 hours after first-line intervention, or the development of HLH / MAS.
[0619] If concurrent neurotoxicity is suspected during CRS, administer:
[0620] Corticosteroids according to more aggressive intervention based on the grade of CRS and neurotoxicity in Tables 1 and 2
[0621] Tocilizumab according to the CRS grade in Table 1
[0622] According to the neurotoxic antiepileptic drugs in Table 2
[0623] Table 1: CRS Levels and Management Guidelines
[0624]
[0625] Table 1: CRS Levels and Management Guidelines
[0626]
[0627] Table 1: CRS Levels and Management Guidelines
[0628]
[0629] a Based on the ASTCT 2019 grading system (Lee et al., 2019), modified to include organ toxicity.
[0630] b See the tocilizumab prescribing information for details.
[0631] cattributed to CRS. Fever may not always occur simultaneously with hypotension or hypoxia as it may be masked by interventions such as antipyretics or anti-cytokine therapy (e.g., tocilizumab or steroids). The absence of fever did not influence CRS management decisions. In this setting, CRS management was driven by hypotension and / or hypoxia and more severe symptoms not attributable to any other cause.
[0632] d Monoclonal antibodies targeting cytokines may be considered depending on institutional practice for unresponsive CRS.
[0633] e Low-flow nasal cannula ≤6L / min; high-flow nasal cannula >6L / min.
[0634] f Continue corticosteroids until the event is Grade 1 or less; taper steroids if total corticosteroid exposure is greater than 3 days.
[0635] g Organ toxicity was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0.
[0636] Neurotoxicity
[0637] Monitor patients for signs and symptoms of neurotoxicity (ICANS and other neurotoxicities) (Table 2). Exclude alternative etiologies for neurological signs or symptoms. Provide intensive care and supportive care for severe or life-threatening neurotoxicity. See section 5.2 for non-ICANS neurotoxicity. If ICANS is suspected, manage according to the recommendations in Table 2.
[0638] If CRS is suspected during a neurotoxic event, administer:
[0639] Corticosteroids according to more aggressive intervention based on the grade of CRS and neurotoxicity in Tables 1 and 2
[0640] Tocilizumab according to the CRS grade in Table 1
[0641] According to the neurotoxic antiepileptic drugs in Table 2
[0642] Table 2: ICANS Administration Guidelines
[0643]
[0644] Table 2: ICANS Administration Guidelines
[0645]
[0646] Note: ICANS classification and management are determined by the most severe event (ICE score, level of consciousness, seizure, motor findings, increased ICP / cerebral edema) that cannot be attributed to any other cause.
[0647] a ASTCT 2019 neurotoxicity grading criteria (Lee et al., 2019).
[0648] b If the patient can be aroused and is able to perform the immune effector cell-associated encephalopathy (ICE) assessment, the following will be assessed: orientation (oriented to year, month, city, hospital = 4 points); naming (naming 3 objects, e.g., pointing to clock, pen, button = 3 points); following commands (e.g., "show me 2 fingers" or "close your eyes and stick out your tongue" = 1 point); writing (ability to write a standard sentence = 1 point); and attention (counting backwards by tens from 100 = 1 point). If the patient cannot be aroused and is unable to perform the ICE assessment (4-level ICANS) = 0 points.
[0649] c All references to dexamethasone administration are to dexamethasone or equivalent.
[0650] d Intracranial hemorrhage with or without associated edema is not considered a neurotoxic feature and is excluded from the ICANS classification. It can be graded according to the NCI CTCAE v5.0.
[0651] e Tremor and myoclonus associated with immune effector cell therapy can be graded according to the NCI CTCAE v5.0, but they do not affect the ICANS grade.
[0652] 3 Dosage forms and strengths
[0653] CARVYKTI is a cell suspension for intravenous infusion.
[0654] A single dose of CARVYKTI contains 0.5-1.0 × 10 6 Cell suspension with a maximum of 1×10 CAR-positive live T cells / kg body weight 8 CAR-positive live T cells [see How to Supply / Storage and Handling (16)].
[0655] 4 Taboos
[0656] none.
[0657] 5 Warnings and Precautions
[0658] 5.1 Cytokine Release Syndrome
[0659] Cytokine release syndrome, including fatal or life-threatening reactions, occurred following treatment with CARVYKTI. CRS occurred in 95% (92 / 97) of patients receiving cedaciclib. Grade 3 or higher CRS occurred in 5% (5 / 97) of patients (2019 ASTCT grade) 1 , 1 patient reported Grade 5 CRS. The median duration of CRS onset was 7 days (range: 1 to 12 days). The median duration of CRS was 4 days (range: 1 to 40 days) for all patients, except for one patient whose CRS lasted 97 days and subsequently had a fatal outcome. Among patients who experienced CRS, the most common manifestations of CRS included fever (100%), hypotension (43%), increased aspartate aminotransferase (AST) (22%), chills (15%), increased alanine aminotransferase (14%), and sinus tachycardia (11%). Grade 3 or higher events associated with CRS included increased AST and ALT, hyperbilirubinemia, hypotension, pyrexia, hypoxia, respiratory failure, acute kidney injury, disseminated intravascular coagulation, HLH / MAS, angina, supraventricular and ventricular tachycardia, malaise, myalgia, increased C-reactive protein, ferritin, blood alkaline phosphatase, and gamma-glutamyl transferase [see Adverse Reactions (6.1)].
[0660] Identify CRS based on clinical presentation. Evaluate and treat other causes of fever, hypoxia, and hypotension. CRS has been reported to be associated with findings of HLH / MAS, and the physiology of the syndrome may overlap. HLH / MAS is a potentially life-threatening condition. Evaluate for evidence of HLH / MAS in patients who have progressive symptoms of CRS or who are refractory to treatment. See Section 5.3; Hemophagocytic Lymphohistiocytosis (HLH) / Macrophage Activation Syndrome (MAS).
[0661] Sixty-nine of 97 patients (71%) received tocilizumab and / or corticosteroids for CRS after infusion of cedakinumab. Forty-four patients (45%) received tocilizumab without corticosteroids, including 33 (34%) who received a single dose and 11 (11%) who received more than 1 dose; 24 patients (25%) received tocilizumab and corticosteroids, and 1 patient (1%) received corticosteroids alone.
[0662] Ensure that at least two doses of tocilizumab are available prior to the infusion of CARVYKTI.
[0663] Monitor patients for signs and symptoms of CRS at least daily for 10 days after CARVYKTI infusion at a REMS-certified healthcare facility. Monitor patients for signs or symptoms of CRS for at least 4 weeks after infusion. At the first sign of CRS, promptly initiate supportive care, tocilizumab, or tocilizumab and corticosteroids as outlined in Table 1 [see Dosing and Administration (2.3)].
[0664] If signs or symptoms of CRS occur at any time, advise patients to seek medical attention immediately [see Patient Counseling Information (17)].
[0665] 5.2 Neurotoxicity
[0666] Neurotoxicities occur following treatment with CARVYKTI and may be severe, life-threatening, or fatal. Neurotoxicities include ICANS, neurotoxicity with parkinsonian signs and symptoms, Guillain-Barré syndrome, peripheral neuropathy, and cranial nerve palsies. Counsel patients about the signs and symptoms of these neurotoxicities and the delayed onset nature of some of these toxicities. If any signs or symptoms of any of these neurotoxicities occur at any time, instruct patients to seek prompt medical attention for further evaluation and management [see Patient Counseling Information (17)].
[0667] Overall, 26% (25 / 97) of ...
Claims
1. A method of treating a subject, the method comprising administering to the subject a single infusion of a dose of a composition comprising T cells containing a chimeric antigen receptor (CAR), wherein the CAR comprises the amino acid sequence of SEQ ID NO: 17; The dosage comprises 0.5×10 6 to 1.0×10 6 T cells / kg subject body weight; and The method comprises administering the dose of T cells to the subject at a temperature of about 20°C to 25°C within about 2.5 hours.
2. The method of claim 1, wherein the subject has relapsed or refractory multiple myeloma, the subject has received multiple lines of prior therapy, and wherein optionally, the subject has received three or more lines of prior therapy.
3. The method of claim 1 or 2, wherein the subject has received four or more prior lines of therapy.
4. The method of claim 2 or 3, wherein the prior line of therapy comprises a proteasome inhibitor, an immunomodulator, and an anti-CD38 monoclonal antibody.
5. The method of any one of claims 1-4, wherein the T cells are autologous T cells.
6. The method of any one of claims 1 to 5, wherein the method further comprises: (1) administering a lymphodepleting chemotherapy regimen to the subject prior to administering the T cells to the subject, wherein optionally: (a) the lymphodepleting chemotherapy regimen comprises administering cyclophosphamide and fludarabine to the subject, (b) the lymphodepleting chemotherapy regimen comprises intravenous administration of cyclophosphamide and fludarabine to the subject, (c) the lymphodepleting chemotherapy regimen comprises administering to the subject intravenously about 300 mg / m 2 Cyclophosphamide at a dose of 30 mg / m 2 Doses of fludarabine, (d) the lymphodepleting chemotherapy regimen is about 3 days, (e) the method comprises administering the lymphodepleting chemotherapy regimen to the subject for at least about 2-4 days prior to administering the T cells to the subject; or (2) administering a premedication to the subject up to 60 minutes before administering the T cells to the subject, and wherein the premedication comprises an antipyretic and an antihistamine, wherein optionally: (a) the method comprises administering the premedication to the subject about 30-60 minutes before administering the T cells to the subject, (b) the antipyretic drug comprises paracetamol or acetaminophen, (c) the antipyretic drug comprises acetaminophen in a dosage of about 650 mg to 1000 mg, (d) the antihistamine comprises diphenhydramine, (e) the dosage of diphenhydramine is about 25 mg to 50 mg or an equivalent amount, (f) the premedication is administered orally or intravenously, or (g) The premedication does not include systemic corticosteroids.
7. The method of any one of claims 1-6, wherein the method comprises thawing the dose of T cells prior to administration, wherein the thawing is completed in no more than about 15 minutes, wherein optionally, the dose of T cells is thawed at a temperature of about 37°C ± 2°C.
8. The method of any one of claims 1-7, wherein the method further comprises treating cytokine release syndrome (CRS) in the subject after administering the dose of T cells, wherein optionally, treating the subject's CRS comprises administering an anti-cytokine agent or a corticosteroid to the subject, wherein optionally: (1) the anti-cytokine agent comprises a monoclonal antibody targeting a cytokine, wherein optionally the monoclonal antibody targeting a cytokine is an IL-6R inhibitor, wherein optionally the IL-6R inhibitor is tocilizumab, wherein optionally the method comprises administering tocilizumab intravenously at a dose of about 8 mg / kg within about 1 hour, wherein optionally the dose of tocilizumab does not exceed about 800 mg, wherein optionally the dose of tocilizumab does not exceed 3 doses within 24 hours or does not exceed 4 doses in total, wherein further optionally the anti-cytokine agent further comprises an anti-cytokine agent other than tocilizumab, wherein further optionally the anti-cytokine agent further comprises a monoclonal antibody targeting a cytokine other than tocilizumab; (2) the corticosteroid comprises dexamethasone or methylprednisolone, wherein optionally the corticosteroid is dexamethasone, wherein further optionally the method comprises administering to the subject intravenously a dose of about 10 mg of dexamethasone approximately every 12-24 hours, wherein further optionally the method comprises administering to the subject intravenously a dose of about 10 mg of dexamethasone approximately every 12 hours, wherein further optionally the method comprises administering to the subject intravenously a dose of about 20 mg of dexamethasone approximately every 6-12 hours, wherein further optionally the method comprises administering to the subject intravenously a dose of about 20 mg of dexamethasone approximately every 6 hours, wherein optionally the corticosteroid is methylprednisolone, wherein further optionally the method comprises administering to the subject intravenously a dose of about 2 mg / kg of methylprednisolone approximately every 12 hours, and wherein further optionally the method comprises administering to the subject intravenously a dose of about 1-2 g of methylprednisolone approximately every 24 hours; or (3) The method comprises administering an immunosuppressant to the subject.
9. The method of claim 8, wherein CRS comprises fever, pyrexia, hypotension, elevated aspartate aminotransferase, chills, elevated alanine aminotransferase, sinus tachycardia, hyperbilirubinemia, hypoxia, respiratory failure, acute kidney injury, disseminated intravascular coagulation and bleeding (e.g., retroperitoneal, intracerebral, or gastrointestinal bleeding), hemophagocytic lymphohistiocytosis (HLH), macrophage activation syndrome (MAS), angina, supraventricular and ventricular tachycardia, malaise, myalgia, increased C-reactive protein, ferritin, blood alkaline phosphatase, gamma-glutamyl transferase, organ toxicity, or any combination thereof.
10. The method of claim 9, wherein CRS comprises hemophagocytic lymphohistiocytosis (HLH) or macrophage activation syndrome (MAS), wherein symptoms of HLH or MAS comprise hypotension, hypoxia with diffuse alveolar damage, coagulopathy, cytopenias, multiple organ dysfunction including renal dysfunction, or any combination thereof, wherein optionally the method comprises administering to the subject a treatment to alleviate HLH or MAS.
11. The method of any one of claims 1-10, wherein the method further comprises treating neurotoxicity in the subject after administering the dose of the T cells.
12. The method of claim 11, wherein the neurotoxicity comprises immune effector cell associated neurotoxicity syndrome (ICANS), Parkinson's disease, Guillain-Barré syndrome, immune-mediated myelitis, peripheral neuropathy, cranial nerve palsy, or any combination thereof.
13. The method of claim 12, wherein the neurotoxicity comprises ICANS, and wherein the ICANS comprises encephalopathy, aphasia, headache, decreased level of consciousness, seizures, motor findings, increased intracranial pressure (ICP), cerebral edema, or any combination thereof, wherein optionally the ICANS comprises focal or generalized seizures, nonconvulsive seizures on electroencephalogram (EEG), life-threatening prolonged seizures, recurrent clinical or electrical seizures, deep focal motor weakness, hemiparesis, paraparesis, focal or localized edema on neuroimaging, stupor, coma, diffuse cerebral edema on neuroimaging, decerebrate or decorticate rigidity, cranial nerve VI palsy, papilledema, Cushing's triad, or any combination thereof, wherein optionally: (1) The method comprises administering to the subject intravenously a dose of about 10 mg of dexamethasone approximately every 12-24 hours for about 2-3 days, (2) The method comprises administering to the subject intravenously a dose of about 10 mg of dexamethasone about every 12 hours for about 2-3 days or longer, (3) the method comprises administering to the subject intravenously a dose of about 10-20 mg of dexamethasone about every 6 hours, or (4) The method comprises administering to the subject a dose of about 1-2 g / day of methylprednisolone approximately every 24 hours, Wherein further optionally the ICANS comprises cerebral edema, wherein further optionally the method comprises administering hyperventilation and hyperosmotic therapy to the subject, wherein further optionally the method comprises administering a non-sedating anti-epileptic drug to the subject, and wherein further optionally the non-sedating anti-epileptic drug is levetiracetam.
14. The method of claim 12, wherein the neurotoxicity comprises Parkinson's disease, wherein optionally the Parkinson's disease comprises Parkinson's symptoms or non-Parkinson's symptoms, wherein optionally the Parkinson's symptoms or the non-Parkinson's symptoms comprise tremor, bradykinesia, involuntary movements, stereotypies, loss of spontaneous movements, masked face, apathy, apathy, fatigue, rigidity, psychomotor retardation, microdysgraphia, dysgraphia, apraxia, listlessness, confusion, drowsiness, loss of consciousness, delayed reflexes, hyperreflexia, memory loss, dysphagia, fecal incontinence, falls, hunched posture, slow gait, muscle weakness and wasting, motor dysfunction, movement and sensory loss, akinetic mutism, frontal release signs, or any combination thereof, and wherein optionally the method comprises administering to the subject a treatment to reduce Parkinson's disease.
15. The method of claim 12, wherein the neurotoxicity comprises Guillain-Barré syndrome, wherein optionally the Guillain-Barré syndrome comprises symptoms consistent with the Miller-Fisher variant of Guillain-Barré syndrome, encephalopathy, motor weakness, speech disorders, polyradiculoneuritis, or any combination thereof, and wherein optionally the method comprises administering to the subject a treatment to alleviate the Guillain-Barré syndrome.
16. The method of claim 12, wherein the neurotoxicity comprises immune-mediated myelitis, wherein optionally symptoms of immune-mediated myelitis comprise decreased sensation in the lower extremities or lower abdomen with impaired sphincter control, wherein optionally the method comprises administering to the subject a treatment to reduce the immune-mediated myelitis, wherein optionally the treatment comprises corticosteroids or immunoglobulin, and wherein optionally the method comprises administering the immunoglobulin intravenously.
17. The method of claim 12, wherein the neurotoxicity comprises peripheral neuropathy, wherein optionally the peripheral neuropathy comprises sensory neuropathy, motor neuropathy, sensorimotor neuropathy, or any combination thereof, and wherein optionally the method comprises administering to the subject a treatment to reduce peripheral neuropathy.
18. The method of claim 12, wherein the neurotoxicity comprises cranial nerve palsy, wherein optionally the cranial nerve palsy comprises 3rd cranial nerve palsy, 6th cranial nerve palsy, 7th cranial nerve palsy, or bilateral 7th cranial nerve palsy, and wherein optionally the method comprises administering to the subject a treatment to alleviate the cranial nerve palsy.
19. The method of any one of claims 1-18, wherein the method further comprises treating the subject's long-term or recurrent cytopenias before administering CAR-containing T cells to the subject, after administering a lymphodepleting chemotherapy regimen to the subject, or after administering the dose of CAR-containing T cells, wherein optionally the long-term recurrent cytopenias comprise long-term neutropenia, long-term thrombocytopenia, recurrent neutropenia, thrombocytopenia, lymphopenia, anemia, or any combination thereof.
20. The method of any one of claims 1-19, wherein the method further comprises treating an infection in the subject, wherein optionally the infection is viral, bacterial, fungal, or caused by an unspecified pathogen, wherein optionally the infection comprises lung abscess, sepsis, pneumonia, bronchopulmonary aspergillosis, Pneumocystis jiroveci pneumonia, CMV colitis (with HSV-1 hepatitis), mycotic aneurysm, cerebral aspergillosis, or COVID-19 infection, wherein optionally the infection causes febrile neutropenia or subarachnoid hemorrhage, wherein optionally the method comprises administering an antimicrobial to the subject, wherein optionally the antimicrobial is an antibiotic, wherein further optionally the antibiotic is a broad-spectrum antibiotic, wherein optionally the infection is viral, and wherein further optionally the method comprises administering an antiviral therapy or a vaccine to the subject.
21. The method of any one of claims 1-20, wherein the method further comprises treating the subject for hypogammaglobulinemia, wherein optionally after administration of the dose of CAR-containing T cells, the hypogammaglobulinemia comprises a laboratory IgG level of less than about 500 mg / dL, and wherein optionally the method comprises administering a dose of intravenous immunoglobulin (IVIG) to the subject after administration of the dose of CAR-containing T cells.
22. The method of any one of claims 1-21, wherein the method further comprises treating a hypersensitivity reaction in the subject, wherein optionally the hypersensitivity reaction comprises flushing, chest discomfort, tachycardia, wheezing, tremor, burning sensation, anaphylaxis, or any combination thereof, and wherein optionally the method comprises administering a treatment to the subject to alleviate the hypersensitivity reaction.
23. The method of any one of claims 1-22, wherein the method further comprises treating a secondary malignancy in the subject.
24. The method of any one of claims 1-23, wherein the composition further comprises an excipient selected from dimethyl sulfoxide or dextran-40, wherein optionally the excipient is dimethyl sulfoxide, wherein optionally the excipient is about 1-10% dimethyl sulfoxide, and wherein further optionally the excipient is about 5% dimethyl sulfoxide.
25. A drug product comprising a cedakinumab suspension for intravenous infusion, wherein the drug product is packaged, and wherein the package includes a label identifying the cedakinumab suspension as an approved drug product for the treatment of adult patients with relapsed or refractory multiple myeloma after receiving four or more prior lines of therapy comprising a proteasome inhibitor, an immunomodulator, and an anti-CD38 monoclonal antibody.
26. A method of treating relapsed or refractory multiple myeloma in an adult patient in need thereof, the method comprising administering an approved drug product comprising a cedakinumab suspension in the amount and manner described in the drug product labeling for the approved drug product.
27. A method of marketing an approved drug product comprising cedakinumab suspension, the method comprising marketing such drug product, wherein the drug product labeling of a reference product for such drug product comprises instructions for use in treating adult patients with relapsed or refractory multiple myeloma after receiving four or more prior lines of therapy comprising a proteasome inhibitor, an immunomodulator, and an anti-CD38 monoclonal antibody.
28. A method of offering for sale a drug product comprising a cedakinumab suspension, the method comprising offering for sale such a drug product, wherein the drug product labeling of a reference product for such a drug product comprises instructions for use in treating adult patients with relapsed or refractory multiple myeloma after receiving four or more prior lines of therapy comprising a proteasome inhibitor, an immunomodulator, and an anti-CD38 monoclonal antibody.
